WO2012012776A1 - Methods and compounds for treating paramyxoviridae virus infections - Google Patents

Methods and compounds for treating paramyxoviridae virus infections Download PDF

Info

Publication number
WO2012012776A1
WO2012012776A1 PCT/US2011/045102 US2011045102W WO2012012776A1 WO 2012012776 A1 WO2012012776 A1 WO 2012012776A1 US 2011045102 W US2011045102 W US 2011045102W WO 2012012776 A1 WO2012012776 A1 WO 2012012776A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
substituted
independently
formula
Prior art date
Application number
PCT/US2011/045102
Other languages
French (fr)
Inventor
Richard L. Mackman
Jay P. Parrish
Adrian S. Ray
Dorothy Agnes Theodore
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44534635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012012776(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AP2013006680A priority Critical patent/AP3269A/en
Priority to CA2804840A priority patent/CA2804840C/en
Priority to AU2011280910A priority patent/AU2011280910B2/en
Priority to SG2012095683A priority patent/SG186830A1/en
Priority to BR112013001553-5A priority patent/BR112013001553B1/en
Priority to JP2013520895A priority patent/JP5969471B2/en
Priority to KR1020137004005A priority patent/KR101821680B1/en
Priority to NZ606156A priority patent/NZ606156A/en
Priority to SI201130275T priority patent/SI2595980T1/en
Priority to PL11743709T priority patent/PL2595980T3/en
Priority to CN201180035776.1A priority patent/CN103052631B/en
Priority to EA201390152A priority patent/EA025252B1/en
Priority to MEP-2014-148A priority patent/ME01924B/en
Priority to EP11743709.5A priority patent/EP2595980B1/en
Priority to CR20170278A priority patent/CR20170278A/en
Priority to KR1020187001641A priority patent/KR101924765B1/en
Priority to MX2013000744A priority patent/MX2013000744A/en
Priority to UAA201302207A priority patent/UA111163C2/en
Priority to MA35665A priority patent/MA34470B1/en
Priority to BR122020020745A priority patent/BR122020020745B8/en
Priority to ES11743709.5T priority patent/ES2524356T3/en
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of WO2012012776A1 publication Critical patent/WO2012012776A1/en
Priority to IL224043A priority patent/IL224043A/en
Priority to HK13110926.3A priority patent/HK1183487A1/en
Priority to IL245348A priority patent/IL245348B/en
Priority to NO2020047C priority patent/NO2020047I1/en
Priority to NL301084C priority patent/NL301084I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates generally to methods and compounds for treating
  • Paramyxoviridae virus infections particularly methods and nucleosides for treating respiratory syncytial virus infections and parainfluenza virus infections.
  • Paramyxoviruses of the Paramyxoviridae family are negative-sense, single-stranded, RNA viruses that are responsible for many prevalent human and animal diseases. These viruses comprise at least two major subfamilies, Paramyxovirinae and Pneumovirinae.
  • the subfamily Paramyxovirina includes the human parainfluenza viruses (HP IV), measles virus and mumps virus.
  • HPIVs can cause repeated infections throughout life including upper respiratory tract illness and even serious lower respiratory tract disease (e.g., pneumonia, bronchitis, and bronchiolitis), the latter being especially of concern among the elderly, and among patients with compromised immune systems (Sable, Infect. Dis. Clin. North Am. 1995, 9, 987-1003).
  • lower respiratory tract disease e.g., pneumonia, bronchitis, and bronchiolitis
  • HRSV Human respiratory syncytial virus
  • Ribosides of the nucleobases pyrrolo[l,2-fJ[l,2,4]triazine, imidazo[l,5- fj[l,2,4]triazine, imidazo[l,2-f][l ,2,4]triazine, and [l,2,4]triazolo[4,3- fj[l,2,4]triazine have been disclosed in Carbohydrate Research 2001, 331 (1), 77- 82; Nucleosides & Nucleotides (1996), 15(1-3), 793-807; Tetrahedron Letters (1994), 35(30), 5339-42; Heterocycles (1992), 34(3), 569-74; J. Chem. Soc.
  • Ribosides of pyrrolo[l,2-fJ[l,2,4]triazine nucleobases with antiviral, anti-HCV, and anti-RdRp activity have been disclosed by Babu (WO2008/089105 and WO2008/141079) and Francom(WO2010/002877).
  • a method for treating a Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I:
  • each R 1 is H or halogen
  • each R 2 , R 3 or R 5 is independently H, OR a , N(R a ) 2 , N 3 , CN, N0 2 , S(0) n R a , halogen, (Ci-Cg)alkyl, (C 4 -Cg)carbocyclylalkyl, (Ci-Cg)substituted alkyl,
  • each n is independently 0, 1, or 2;
  • each Y or Y 1 is, independently, O, S, NR, + N(0)(R), N(OR), + N(0)(OR), or N-NR 2 ;
  • W 1 and W 2 when taken together, are -Y 3 (C(R y ) 2 ) 3 Y 3 -; or one of W 1 or W 2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W 2 is Formula la; or W 1' and W 2 z are each, independently, a group of the Formula la:
  • each Y 2 is independently a bond, O, CR 2 , NR, + N(0)(R), N(OR),
  • each Y is independently O, S, or NR;
  • M2 is 0, 1 or 2;
  • each R x is independently R y or the formula:
  • each Mi a, Ml c, and Mid is independently 0 or 1 ;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • each R is independently H, (Q-C 8 ) alkyl, (Ci-C 8 ) substituted alkyl, (C 2 - C 8 )alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl, (C 2 -C 8 ) substituted alkynyl, C 6 -C 2 o aryl, C 6 -C 2 o substituted aryl, C 2 -C 2 o heterocyclyl, C 2 -C 20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
  • W 3 is W 4 or W 5 ;
  • W 4 is R, -0( ⁇ 3 ⁇ 4 -C ⁇ W 5 , -S0 2 R y , or -S0 2 W 5 ;
  • W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups;
  • each R n or R 12 is independently H, (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 - Cg)alkynyl, (C4-C 8 )carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -S(0) n (Ci-C 8 )alkyl or aryl(Ci-
  • each (C]-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -Cg)alkynyl or aryl(Ci- C 8 )alkyl of each R 2 , R 3 , R 5 , R 6 , R 11 or R 12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a ; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C 8 )alkyl may be optionally replaced with -0-, -S- or -NR a -.
  • the method comprises administering a
  • the method comprises treating a Paramyxovirina infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof.
  • the method comprises treating a parainfluenza, measles or mumps virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a
  • the method comprises treating a parainfluenza virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof.
  • the method comprises treating a Pneumovirinae infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof.
  • the method comprises treating a respiratory syncytial virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a
  • the method comprises administering a
  • a pharmaceutical composition comprising an effective amount of a Formula I compound, or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable diluent or carrier.
  • the method comprises administering a
  • a pharmaceutical composition comprising an effective amount of a Formula I compound, or a phannaceutically acceptable salt or ester thereof, in combination with at least one additional therapeutic agent.
  • the method comprises administering a
  • a) a first pharmaceutical composition comprising a compound of Formula I; or a pharmaceutically acceptable salt, solvate, or ester thereof; and b) a second pharmaceutical composition comprising at least one additional therapeutic agent active against infectious Paramyxoviridae viruses.
  • the present application provides for a method of inhibiting a Paramyxoviridae R A-dependent RNA polymerase, comprising contacting a cell infected with a Paramyxoviridae virus with an effective amount of a compound of Formula I; or a pharmaceutically acceptable salts, solvate, and/or ester thereof.
  • a compound of Formula I or a pharmaceutically acceptable salt, solvate, and/or ester thereof to treat a viral infection caused by a Paramyxoviridae virus.
  • the invention also provides processes and novel intermediates disclosed herein which are useful for preparing Formula I compounds of the invention.
  • novel methods for synthesis, analysis, separation, isolation, purification, characterization, and testing of the compounds of this invention are provided.
  • each R 1 is H or halogen
  • each R 2 is OR a or halogen
  • each R 3 or R 5 is independently H, OR a , N(R a ) 2 , N 3 , CN, N0 2 , S(0) n R a , halogen, (Ci-Cg)alkyl, (C 4 -Cg)carbocyclylalkyl, (Ci-C8)substituted alkyl, (C 2 -Cg)alkenyl, (C 2 -Cg)substituted alkenyl, (C 2 -Cg)alkynyl or (C 2 -Cg)substituted alkynyl;
  • each n is independently 0, 1, or 2;
  • each Y or Y is, independently, O, S, NR, N(0)(R), N(OR), + N(0)(OR), or N-NR 2 ;
  • W 1 and W 2 when taken together, are -Y 3 (C(R y ) 2 ) 3 Y 3 -; or one of W 1 or W 2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W 2 is Formula la; or W and W are each, ind endentl a group of the Formula la:
  • each Y 2 is independently a bond, O, CR 2 , NR, + N(0)(R), N(OR),
  • each Y is independently O, S, or NR;
  • M2 is 0, 1 or 2;
  • each R x is inde endently R y or the formula:
  • each Mia, Ml c, and Mid is independently 0 or 1 ;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
  • each R is independently H, (Ci-C ) alkyl, (Ci-Cg) substituted alkyl, (C 2 - C 8 )alkenyl, (C 2 -Cg) substituted alkenyl, (C 2 -C 8 ) alkynyl, (C 2 -C 8 ) substituted alkynyl, C 6 -C 2 o aryl, C 6 -C 2 o substituted aryl, C 2 -C 2 o heterocyclyl, C 2 -C 20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
  • W 3 is W 4 or W 5 ;
  • W 4 is R, -C(Y )R y , -QY ⁇ W 5 , -S0 2 R y , or -S0 2 W 5 ;
  • W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups;
  • each (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl or aryl(Ci- C 8 )alkyl of each R 3 , R 5 , R 6 , R n or R 12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R ) 2 or OR a ; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C 8 )al
  • R 1 of Formula II is H.
  • R 6 of Formula II is N 3 , CN, halogen, (Ci-C 8 )alkyl, (Ci-C8)substituted alkyl, (C 2 --C 8 )alkenyl, (C 2 -C 8 ) substituted alkenyl,
  • R 6 of Formula II is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R 6 of Formula II is CN. In another aspect of this embodiment, R 6 of Formula II is methyl. In another aspect of this embodiment, R 5 of Formula II is H. In another aspect of this embodiment, R 2 of Formula II is OR a . In another aspect of this embodiment, R of Formula II is OH. In another aspect of this embodiment, R 2 of Formula II is F. In another aspect of this embodiment, R 3 of Formula II is OR a .
  • R 8 of Formula II is NH 2 .
  • R of Formula II is OR .
  • R 8 of Formula II is OH.
  • R 9 of Formula II is H.
  • R 9 of Formula II is NR n R 12 .
  • R 9 of Formula II is NH 2 .
  • R 7 of Formula II another aspect of this embodiment, R 7 of Formula II is
  • Paramyxoviridae infection is caused by a Paramyxovirina virus.
  • the Paramyxovirina virus is a parainfluenza, measles or mumps vims.
  • the Paramyxovirina virus is a Respirovirus virus.
  • the Paramyxovirina virus is a type 1 or 3 Human parainfluenza virus.
  • Paramyxoviridae infection is caused by a Pneumovirinae virus.
  • the Pneumovirinae virus is a respiratory syncytial virus.
  • the Pneumovirinae virus is a Human respiratory syncytial virus.
  • each R 2 is OR a or F
  • each R 3 is OR a ;
  • n is independently 0, 1, or 2;
  • each Y or Y 1 is, independently, O, S, NR, + N(0)(R), N(OR), + N(0)(OR), or N-NR 2 ;
  • W 1 and W 2 when taken together, are -Y 3 (C(R y ) 2 ) 3 Y 3 -; or one of W 1 or W 2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W2 is Formula la; or
  • W 1 1 and W 2 are each, independently, a group of the Formula la:
  • each Y 2 is independently a bond, O, CR 2 , NR, + N(0)(R), N(OR),
  • each Y is independently O, S, or NR;
  • M2 is 0, 1 or 2;
  • each R x is independently R y or the formula:
  • each Mia, Ml c, and Mid is independently 0 or 1;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • each R is independently H, (Q-Cg) alkyl, (Ci-C 8 ) substituted alkyl, (C 2 - Cg)alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -Cg) alkynyl, (C 2 -Cg) substituted alkynyl, C 6 -C 2 o aryl, C 6 -C 2 o substituted aryl, C 2 -C 2 o heterocyclyl, C 2 -C 2 o substituted heterocyclyl, arylalkyl or substituted arylalkyl;
  • W 3 is W 4 or W 5 ;
  • W 4 is R, -0( ⁇ 3 ⁇ 4 -C(Y ] )W 5 , -S0 2 R y , or -S0 2 W 5 ;
  • W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups;
  • each (Ci-C )alkyl, (C 2 -C 8 )alkenyl, (C 2 -Cg)alkynyl or aryl(Ci- C 8 )alkyl of each R 6 , R 11 or R 12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a ; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C 8 )alkyl may be optionally replaced with -O-, -S- or -NR a -.
  • R 6 of Formula III is N 3 , CN, halogen, (d-C 8 )alkyl, (Ci-C 8 )substituted alkyl, (C 2 -C 8 )alkenyl,
  • R 6 of Formula III is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R 6 of Formula III is CN. In another aspect of this embodiment, R 6 of Formula III is methyl. In another aspect of this embodiment, R 2 of Formula III is OR a . In another aspect of this embodiment,
  • R 7 of Formula III is H.
  • R 7 of Formula III is
  • R 6 of Formula III is N 3 , CN, halogen, (C 1 -C 8 )alkyl, (Ci-Cg)substituted alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )substituted alkenyl, (C 2 -C 8 )alkynyl, or (C 2 -C 8 )substituted alkynyl and R 8 is NH 2 .
  • R 6 of Formula III is CN, methyl, ethenyl, or ethynyl.
  • R of Formula III is
  • R 6 of Formula III is CN, methyl, ethenyl, or ethynyl, R 8 is N3 ⁇ 4, and R 9 is H.
  • R 6 of Formula III is CN.
  • R 6 of Formula III is methyl.
  • R 2 of Formula III is OR a .
  • Formula III is OH.
  • R 2 of Formula III is F.
  • R 3 of Formula III is OH.
  • R 7 of Formula III is H.
  • R 7 of Formula III is
  • Paramyxoviridae infection is caused by a Paramyxovirina virus.
  • the Paramyxovirina virus is a parainfluenza, measles or mumps virus.
  • the Paramyxovirina virus is a Respirovirus virus.
  • the Paramyxovirina virus is a type 1 or 3 Human parainfluenza virus.
  • Paramyxoviridae infection is caused by a Pneumovirinae virus.
  • the Pneumovirinae virus is a respiratory syncytial virus.
  • the Pneumovirinae virus is a Human respiratory syncytial virus.
  • each R 1 is H or halogen
  • each R 3 or R 5 is independently H, OR a , N(R a ) 2 , N 3 , CN, N0 2 , S(0) n R a , halogen, (Ci-C 8 )alkyl, (C4-C )carbocyclylalkyl, (C 1 -C 8 )substituted alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )substituted alkenyl, (C2-Cg)alkynyl or (C 2 -C 8 )substituted alkynyl;
  • each n is independently 0, 1, or 2;
  • each Y or Y 1 is, independently, O, S, NR, + N(0)(R), N(OR), + N(0)(OR), or N-NR 2 ;
  • W 1 and W 2 when taken together, are -Y 3 (C(R y ) 2 ) 3 Y 3 -; or one of W 1 or W 2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W 2 is Fonnula la; or W 1 and W 2 are each, independently, a group of the Formula la:
  • each Y 2 is independently a bond, O, CR 2 , NR, + N(0)(R), N(OR), + N(0)(OR), N-NR 2 , S, S-S, S(O), or S(0) 2 ;
  • each Y is independently O, S, or NR;
  • M2 is 0, 1 or 2;
  • each R x is inde endently R y or the formula:
  • each Mia, Ml c, and Mid is independently 0 or 1 ;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
  • each R is independently H, (Ci-C 8 ) alkyl, (Ci-Cg) substituted alkyl, (C 2 - C 8 )alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl, (C 2 -C 8 ) substituted alkynyl, C 6 -C 2 o aryl, C 6 -C 2 o substituted aryl, C 2 -C 20 heterocyclyl, C 2 -C 2 o substituted heterocyclyl, arylalkyl or substituted arylalkyl;
  • W 3 is W 4 or W 5 ;
  • W 4 is R, -C(Y')R y , -CCY ⁇ W 5 , -S0 2 R y , or -S0 2 W 5 ; and
  • W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups;
  • each R 11 or R 12 is independently H, (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 - C 8 )alkynyl, (C 4 -C 8 )carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -S(0) n (C !
  • each (d-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl or aryl(Ci- C 8 )alkyl of each R 3 , R 5 , R 6 , R n or R 12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a ; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C 8 )alkyl may be optionally replaced with -0-, -
  • R 6 is N 3 , CN, halogen, (Ci-C 8 )alkyl, (C 1 -C 8 )substituted alkyl, (C 2 -C 8 )alkenyl,
  • R 6 is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R 6 is CN. In another aspect of this embodiment,
  • R 6 is methyl.
  • R 1 is H.
  • R 3 is OH. In another aspect of this embodiment,
  • R is
  • R 6 is N 3 , CN, halogen, (Ci-C 8 )alkyl, (Ci-Cg)substituted alkyl, (C 2 -Cg)alkenyl,
  • R 7 is H. In another aspect of this embodiment, R 7 is
  • R 6 is CN, methyl, ethenyl, or ethynyl, R 8 is N3 ⁇ 4, and R 9 is H.
  • R 1 is H.
  • R 6 is CN.
  • R is methyl.
  • R 3 is OH.
  • R 7 is H. In another aspect of this embodiment, R 7 is
  • Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formulas I-IV, wherein R 11 or R 12 is independently H, (d-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl,
  • (C 4 -Cg)carbocyclylalkyl optionally substituted aryl, optionally substituted heteroaryl, -S(0) n (Ci-C 8 )alkyl or aryl(d-C 8 )alkyl.
  • R 11 and R 12 taken together with a nitrogen to which they are both attached, form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NR a -.
  • the moiety -NR R can be represented by the heterocycles:
  • each R 3 , R 4 , R 5 , R 5 , R n or R 12 is, independently, (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 - C )alkynyl or aryl(Ci-C 8 )alkyl, wherein said (Ci-C 8 )alkyl, (C 2 -Cg)alkenyl, (C 2 - C8)alkynyl or aryl(Ci-Cs)alkyl are, independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a .
  • R 3 , R 4 , R 5 , R 6 , R 11 or R 12 could represent moieties such as - CH(NH 2 )CH 3 , -CH(OH)CH2CH3, -CH(NH 2 )CH(CH 3 ) 2 , -CH 2 CF 3 , - (CH 2 ) 2 CH(N 3 )CH 3 , -(CH 2 ) 6 NH 2 and the like.
  • Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I-IV, wherein R 3 , R 4 , R 5 , R 6 , R 11 or R 12 is (Ci-C 8 )alkyl wherein one or more of the non-terminal carbon atoms of each said (Q-Cs ⁇ lkyl may be optionally replaced with -0-, -S- or -NR a -.
  • R 3 , R 4 , R 5 , R 6 , R n or R 12 could represent moieties such as -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , - CH 2 OCH(CH 3 ) 2 , -CH 2 SCH 3 , -(CH 2 ) 6 OCH 3 , -(CH 2 ) 6 N(CH 3 ) 2 and the like.
  • a compound of the invention or "a compound of Formula I” means a compound of Formula I or a pharmaceutically acceptable salt, thereof.
  • a compound of Formula (number) means a compound of that formula and pharmaceutically acceptable salts, thereof.
  • Alkyl is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms.
  • an alkyl group can have 1 to 20 carbon atoms (i.e, C 1 -C 20 alkyl), 1 to 8 carbon atoms (i.e., Q-Q alkyl), or 1 to 6 carbon atoms (i.e., Ci-C alkyl).
  • alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1 -propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-l -propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl,
  • Alkoxy means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
  • the alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (i.e., Ci-C 20 alkoxy), 1 to 12 carbon atoms(z.e., Ci-Ci 2 alkoxy), or 1 to 6 carbon atoms(z ' .e., Cj- C 6 alkoxy).
  • alkoxy groups include, but are not limited to, methoxy (-0-CH 3 or -OMe), ethoxy (-OCH 2 CH 3 or -OEt), t-butoxy (-0-C(CH 3 ) 3 or -OtBu) and the like.
  • Haloalkyl is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
  • the alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 haloalkyl), 1 to 12 carbon atoms(z ' .e., C]-Ci 2 haloalkyl), or 1 to 6 carbon atoms(z ' .e., Ci-C 6 alkyl).
  • haloalkyl groups include, but are not limited to, -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 , and the like.
  • Alkenyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • an alkenyl group can have 2 to 20 carbon atoms ⁇ i.e., C 2 -C 2 o alkenyl), 2 to 8 carbon atoms ⁇ i.e., C 2 -C 8 alkenyl), or 2 to 6 carbon atoms ⁇ i.e., C 2 -C 6 alkenyl).
  • Alkynyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.
  • an alkynyl group can have 2 to 20 carbon atoms ⁇ i.e., C 2 -C 2 o alkynyl), 2 to 8 carbon atoms ⁇ i.e., C 2 -C 8 alkyne,), or 2 to 6 carbon atoms ⁇ i.e., C 2 -C 6 alkynyl).
  • suitable alkynyl groups include, but are not limited to, acetylenic (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH), and the like.
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkylene radicals include, but are not limited to, methylene (-CH 2 -), 1,1 -ethyl (-CH(CH 3 )-), 1,2-ethyl (-CH 2 CH 2 -), 1,1- propyl (-CH(CH 2 CH 3 )-), 1 ,2-propyl (-CH 2 CH(CH 3 )-), 1 ,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkynylene radicals include, but are not limited to, acetylene (-G ⁇ C-), propargyl (-CH 2 C ⁇ C-), and 4-pentynyl
  • Ammonia refers generally to a nitrogen radical which can be considered a derivative of ammonia, having the formula— N(X) 2 , where each "X” is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, etc.
  • the hybridization of the nitrogen is approximately sp .
  • Nonlimiting types of amino include -NH 2 , -N(alkyl) 2 , - NH(alkyl), -N(carbocyclyl) 2 , -NH(carbocyclyl), -N(heterocyclyl) 2 , - NH(heterocyclyl), -N(aryl) 2 , -NH(aryl), -N(alkyl)(aryl), -N(alkyl)(heterocyclyl), - N(carbocyclyl)(heterocyclyl), -N(aryl)(heteroaryl), -N(alkyl)(heteroaryl), etc.
  • alkylamino refers to an amino group substituted with at least one alkyl group.
  • Nonlimiting examples of amino groups include -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , - NH(CH 2 CH 3 ), - N(CH 2 CH 3 ) 2 , -NH(phenyl), -N(phenyl) 2 , -NH(benzyl), -N(benzyl) 2 , etc.
  • Substituted alkylamino refers generally to alkylamino groups, as defined above, in which at least one substituted alkyl, as defined herein, is attached to the amino nitrogen atom.
  • Non-limiting examples of substituted alkylamino includes - NH(alkylene-C(0)-OH), -NH(alkylene-C(0)-0-alkyl), -N(alkylene-C(0)-OH) 2 , - N(alkylene-C(0)-0-alkyl) 2 , etc.
  • Aryl means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
  • Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, is replaced with an aryl radical.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, naphthylm ethyl, 2-naphthylethan-l-yl,
  • the arylalkyl group can comprise 7 to 20 carbon atoms, e.g., the alkyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a tenninal or sp carbon atom, but also an sp carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein.
  • the arylalkenyl group can comprise 8 to 20 carbon atoms, e.g., the alkenyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein.
  • the arylalkynyl group can comprise 8 to 20 carbon atoms, e.g., the alkynyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • substituted in reference to alkyl, alkylene, aryl, arylalkyl, alkoxy, heterocyclyl, heteroaryl, carbocyclyl, etc. , for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”,
  • substituted heterocyclyl and “substituted carbocyclyl” means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
  • each X is independently a halogen: F, CI, Br, or I; and each R b is independently H, alkyl, aryl, arylalkyl, a heterocycle, or a protecting group or prodrug moiety.
  • Alkylene, alkenylene, and alkynylene groups may also be similarly substituted. Unless otherwise indicated, when the term "substituted" is used in conjunction with groups such as arylalkyl, which have two or more moieties capable of substitution, the substituents can be attached to the aryl moiety, the alkyl moiety, or both.
  • prodrug refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
  • a prodrag is thus a covalently modified analog or latent form of a therapeutically active compound.
  • substituents and other moieties of the compounds of Formula I-IV should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
  • Heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • a heteroatom e.g., O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH3).
  • the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH 2 CH 2 -0-CH 3 , etc.), an alkyl amine (e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.), or a thioalkyl ether (e.g.,-CH 2 -S-CH 3 ).
  • an alkyl ether e.g., -CH 2 CH 2 -0-CH 3 , etc.
  • an alkyl amine e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.
  • a thioalkyl ether e.g.,-CH 2 -S-CH 3
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH 2 CH 2 -OH), an aminoalkyl group (e.g., -CH 2 NH 2 ), or an alkyl thiol group (e.g., -CH 2 CH 2 -SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a -C heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • Heterocycle or “heterocyclyl” as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic
  • heterocycle includes a “carbocycle” as defined herein, wherein one or more ⁇ e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S).
  • heterocycle or “heterocyclyl” includes saturated rings, partially unsaturated rings, and aromatic rings (i.e., heteroaromatic rings).
  • Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
  • a non-limiting example of a carbonyl substituted heterocyclyl is:
  • heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl,
  • tetrahydrothiophenyl sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4- piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6- pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5- pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3- pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1 -imidazolyl, 1- pyrazolyl, and 1-piperidinyl.
  • Heterocyclylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkylene- moiety).
  • Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl- CH 2 -, 2-(heterocyclyl)ethan-l-yl, and the like, wherein the "heterocyclyl” portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry.
  • heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon- heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkyl group comprises 3 to 20 carbon atoms, e.g., the alkyl portion of the arylalkyl group is 1 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • heterocyclylalkyls include by way of example and not limitation 5-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as thiazolylm ethyl, 2-fhiazolylethan-l-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
  • heterocycles such as thiazolylm ethyl, 2-fhiazolylethan-l-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc.
  • 6-membered sulfur, oxygen, and or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl,
  • Heterocyclylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, but also a sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkenylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkenyl group comprises 4 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • Heterocyclylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkynyl group comprises 4 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclyl alkynyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
  • Heteroaryl refers to an aromatic heterocyclyl having at least one heteroatom in the ring.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen.
  • Non- limiting examples of heteroaryl rings include all of those aromatic rings listed in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
  • Carbocycle or “carbocyclyl” refers to a saturated (i.e., cycloalkyl), partially unsaturated (e.g., cycloakenyl, cycloalkadienyl, etc.) or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • Monocyclic carbocycles have 3 to 7 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
  • Non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l -enyl, 1 -cyclopent-2-enyl, l-cyclopent-3- enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, and phenyl.
  • Non-limiting examples of bicyclo carbocycles includes naphthyl, tetrahydronapthalene, and decaline.
  • Carbocyclylalkyl refers to to an acyclic akyl radical in which one of the hydrogen atoms bonded to a carbon atom is replaced with a carbocyclyl radical as described herein.
  • Typical, but non-limiting, examples of carbocyclylalkyl groups include cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl,
  • Arylheteroalkyl refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein.
  • the aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety.
  • an arylheteroalkyl group can have the general formulae -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene-S-alkylene-aryl, etc.
  • any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
  • Heteroarylalkyl refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein.
  • Non- limiting examples of heteroaryl alkyl include -CH 2 -pyridinyl, -CH 2 -pyrrolyl, -CH 2 -oxazolyl, -CH 2 -indolyl, -CH 2 -isoindolyl, -CH 2 -purinyl, -CH 2 -furanyl, -CH 2 -thienyl, -CH 2 -benzofuranyl, -CH 2 -benzothiophenyl, -CH 2 -carbazolyl, -CH2-imidazolyl, -CH 2 -thiazolyl, -CH 2 -isoxazolyl, -CH 2 -pyrazolyl,
  • the term "optionally replaced” in reference to a particular moiety of the compound of Formula I-III e.g., the carbon atoms of said (C ⁇ -Cg)alkyl may be optionally replaced by -0-, -S-, or -NR a -) means that one or more of the methylene groups of the (Ci-C 8 )alkyl may be replaced by 0, 1, 2, or more of the groups specified (e.g., -0-, -S-, or -NR a -).
  • non-terminal carbon atom(s) in reference to an alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene moiety refers to the carbon atoms in the moiety that intervene between the first carbon atom of the moiety and the last carbon atom in the moiety. Therefore, by way of example and not limitation, in the alkyl moiety -CH 2 (C * )H 2 (C * )H 2 CH 3 or alkylene moiety - CH 2 (C * )H 2 (C * )H 2 CH 2 - the C * atoms would be considered to be the non-terminal carbon atoms.
  • Certain Y and Y 1 alternatives are nitrogen oxides such as + N(0)(R) or
  • Linker or “link” means a chemical moiety comprising a covalent bond or a chain of atoms.
  • Linkers include repeating units of alkyloxy (e.g. polyethyleneoxy, PEG, polym ethyl eneoxy) and alkylamino (e.g.
  • polyethyleneamino, JeffamineTM polyethyleneamino, JeffamineTM
  • diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.
  • oxygen-linked means that if a bond between two moieties can be formed by using more than one type of atom in a moiety, then the bond formed between the moieties is through the atom specified.
  • a nitrogen-linked amino acid would be bonded through a nitrogen atom of the amino acid rather than through an oxygen or carbon atom of the amino acid.
  • W or W are independently a radical of a nitrogen-linked naturally occurring a- amino acid ester.
  • naturally occurring amino acids include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, selenocysteine, serine, tyrosine, argi ine, histidine, ornithine and taurine.
  • the esters of these amino acids comprise any of those described for the substitutent R, particularly those in which R is optionally substituted (Ci-Cs)alkyl.
  • purine or "pyrimidine” base comprises, but is not limited to, adenine, N 6 -alkylpurines, N 6 -acylpurines (wherein acyl is C(0)(alkyl, aryl, alkylaryl, or arylalkyl), N 6 -benzylpurine, N 6 -halopurine, N 6 -vinylpurine, N 6 - acetylenic purine, N 6 -acyl purine, N 6 -hydroxyalkyl purine, N 6 -allylaminopurine, N 6 -thioallyl purine, N 2 -alkylpurines, N 2 -alkyl-6-thiopurines, thymine, cytosine, 5- fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-ffuorouracil, C 5
  • N -alkylpurines N -alkyl-6-thiopurines
  • 5-azacytidinyl 5-azauracilyl
  • triazolopyridinyl imidazolopyridinyl
  • pyrrolopyrimidinyl pyrimidine, N -alkylpurines, N -alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and
  • Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine.
  • the purine and pyrimidine bases of Formula I-III are linked to the ribose sugar, or analog thereof, through a nitrogen atom of the base. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl,
  • the carbon atoms of the compounds of Formula I- IV are intended to have a valence of four.
  • the remaining carbon substitutents needed to provide a valence of four should be assumed to be hydrogen.
  • Protecting group refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole.
  • the chemical substructure of a protecting group varies widely.
  • One function of a protecting group is to serve as an intermediate in the synthesis of the parental drug substance.
  • Chemical protecting groups and strategies for protection/deprotection are well known in the art. See: “Protective Groups in Organic Chemistry", Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991.
  • Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g. making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools.
  • Chemically protected intermediates may themselves be biologically active or inactive.
  • Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs.
  • Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency in vivo than the parental drug.
  • Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g. alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.
  • Prodrug moiety means a labile functional group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, “Design and Application of Prodrugs” in Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 1 13-191).
  • Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases.
  • Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy.
  • a prodrug moiety may include an active metabolite or drug itself.
  • R 30 is Ci-C 6 alkyl, C,-C 6 substituted alkyl, C 6 -C 20 aryl or C 6 -C 2 o substituted aryl.
  • the acyloxyalkyl ester was used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al (1983) J. Pharm. Sci. 72: 324; also- US Patent Nos. 4816570, 4968788, 5663159 and 5792756.
  • a prodrug moiety is part of a phosphate group.
  • the acyloxyalkyl ester may be used to deliver phosphoric acids across cell membranes and to enhance oral bioavailability.
  • a close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester A close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester
  • the phosphate group may be a phosphate prodrug moiety.
  • the prodrug moiety may be sensitive to hydrolysis, such as, but not limited to those comprising a pivaloyloxymethyl carbonate (POC) or POM group.
  • the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.
  • Aryl esters of phosphorus groups are reported to enhance oral bioavailability (DeLambert et al (1994) J. Med. Chem. 37: 498).
  • Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described (Khamnei and Torrence, (1996) J. Med. Chem. 39:4109-4115). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the ortho-ov ara-position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, e.g. esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic C-0 bond to generate the phosphoric acid and the quinone methide intermediate.
  • enzymes e.g. esterases, oxidases, etc.
  • prodrugs examples include Mitchell et al (1992) J. Chem. Soc. Perkin Trans. 72345; Brook et al WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic ester-containing group attached to the benzylic methylene (Glazier et al WO 91/19721). Thio-containing prodrugs are reported to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide.
  • a compound of Formula I-IV and its pharmaceutically acceptable salts may exist as different polymorphs or pseudopolymorphs.
  • crystalline polymorphism means the ability of a crystalline compound to exist in different crystal structures. The crystalline polymorphism may result from differences in crystal packing (packing polymorphism) or differences in packing between different conformers of the same molecule (conformational
  • crystalline pseudopolymorphism means the ability of a hydrate or solvate of a compound to exist in different crystal structures.
  • the pseudopolymorphs of the instant invention may exist due to differences in crystal packing (packing pseudopolymorphism) or due to differences in packing between different conformers of the same molecule (conformational pseudopolymorphism).
  • the instant invention comprises all polymorphs and pseudopolymorphs of the compounds of Formula I-III and their pharmaceutically acceptable salts.
  • a compound of Formula I-IV and its pharmaceutically acceptable salts may also exist as an amorphous solid.
  • an amorphous solid is a solid in which there is no long-range order of the positions of the atoms in the solid. This definition applies as well when the crystal size is two nanometers or less.
  • Additives, including solvents, may be used to create the amorphous forms of the instant invention.
  • the instant invention comprises all amorphous forms of the compounds of Formula I-IV and their pharmaceutically acceptable salts.
  • R x comprises a R y substituent.
  • R y can be R.
  • R can be W 3 .
  • W 3 can be W 4 and W 4 can be R or comprise substituents comprising R y .
  • Such properties include, by way of example and not limitation, physical properties such as molecular weight, solubility or log P, application properties such as activity against the intended target, and practical properties such as ease of synthesis.
  • W 3 and R y are recursive substituents in certain embodiments.
  • each recursive substituent can independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 1 1, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 , or 0, times in a given embodiment.
  • each recursive substituent can independently occur 12 or fewer times in a given embodiment.
  • each recursive substituent can independently occur 3 or fewer times in a given embodiment.
  • W 3 will occur 0 to 8 times
  • R y will occur 0 to 6 times in a given embodiment.
  • W 3 will occur 0 to 6 times and R y will occur 0 to 4 times in a given embodiment.
  • Recursive substituents are an intended aspect of the invention.
  • One of ordinary skill in the art of medicinal chemistry understands the versatility of such substituents.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating, as “treating” is defined immediately above.
  • terapéuticaally effective amount is the amount of compound of Formula I-IV present in a composition described herein that is needed to provide a desired level of drug in the secretions and tissues of the airways and lungs, or alternatively, in the bloodstream of a subject to be treated to give an anticipated physiological response or desired biological effect when such a composition is administered by the chosen route of administration.
  • the precise amount will depend upon numerous factors, for example the particular compound of Formula I-IV, the specific activity of the composition, the delivery device employed, the physical characteristics of the composition, its intended use, as well as patient considerations such as severity of the disease state, patient cooperation, etc., and can readily be determined by one skilled in the art based upon the information provided herein.
  • normal saline means a water solution containing 0.9% (w/v)
  • hypertonic saline means a water solution containing greater than 0.9% (w/v) NaCl.
  • 3% hypertonic saline would contain 3% (w/v) NaCl.
  • the compounds of the Formula I-IV may comprise a phosphate group as
  • R 7 which may be a prodrug moiety wherein each Y or Y 1 is, independently, O, S, NR, + N(0)(R), N(OR), + N(0)(OR), or N-NR 2 ; W 1 and W 2 , when taken together, are -Y 3 (C(R y ) 2 )3Y 3 -; or one of W 1 or W 2 together with either R or R is -Y - and the other of W or W is Formula la; or W and W are each, independently, a group of Formula la:
  • each Y 2 is independently a bond, O, CR 2 , NR, + N(0)(R), N(OR),
  • each Y is independently O, S, or NR;
  • M2 is 0, 1 or 2;
  • Mia, Ml c, and Mid are independently 0 or 1 ;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
  • each R is H, halogen, (Ci-Cs) alkyl, (Ci-C 8 ) substituted alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl, (C 2 -C 8 ) substituted alkynyl, C6-C 20 aryl, C 6 -C 2 o substituted aryl, C 2 -C 2 o heterocycle, C2-C 20 substituted heterocyclyl, arylalkyl, substituted arylalkyl or a protecting group;
  • W 3 is W 4 or W 5 ;
  • W 4 is R, -C(Y 1 )R y , -C(Y')W 5 , -S0 2 R y , or -S0 2 W 5 ;
  • W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups.
  • W 5 carbocycles and W 5 heterocycles may be independently substituted with 0 to 3 R y groups.
  • W 5 may be a saturated, unsaturated or aromatic ring comprising a mono- or bi cyclic carbocycle or heterocycle.
  • W 5 may have 3 to 10 ring atoms, e.g., 3 to 7 ring atoms.
  • the W 5 rings are saturated when containing 3 ring atoms, saturated or mono-unsaturated when containing 4 ring atoms, saturated, or mono- or di-unsaturated when containing 5 ring atoms, and saturated, mono- or di-unsaturated, or aromatic when containing 6 ring atoms.
  • a W 5 heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S).
  • W 5 heterocyclic monocycles may have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S); or 5 or 6 ring atoms (3 to 5 carbon atoms and 1 to 2 heteroatoms selected from N and S).
  • W 5 heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S) arranged as a bicyclo [4,5], [5,5], [5,6], or [6,6] system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 hetero atoms selected from N and S) arranged as a bicyclo [5,6] or [6,6] system.
  • the W 5 heterocycle may be bonded to Y through a carbon, nitrogen, sulfur or other atom by a stable covalent bond.
  • W 5 heterocycles include for example, pyridyl, dihydropyridyl isomers, piperidine, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl.
  • W 5 also includes, but is not limited to, examples such as:
  • W 5 carbocycles and heterocycles may be independently substituted with 0 to 3 R groups, as defined above.
  • substituted W 5 carbocycles include:
  • substituted phenyl carbocycles examples include:
  • Embodiments of of Formula I-IV compounds include substractures such as:
  • each Y is, independently, O or N(R).
  • each Y is O and each R x is independently:
  • M12c is 1, 2 or 3 and each Y 2 is independently a bond, O, CR 2 , or S.
  • one Y 2 -R x is NH(R) and the other Y 2b -R x 0-R x wherein R is:
  • each Y 2b is O and each R x is independently:
  • each Y 2b is O and each R x is inde endently:
  • Ml 2c is 1 and Y is a bond, O, or CR 2 .
  • each Y is, independently, O or N(R). In another aspect of this embodiment, each Y is O. In another aspect of this embodiment, the substructure is:
  • R y is W 5 as defined herein.
  • Another embodiment of of Formula I-IV includes the substructures:
  • each Y lc is, independently, O, N(R y ) or S.
  • Another embodiment of of Formula I-IV compounds includes the substructures wherein one of W 1 or W 2 together with either R 3 or R 4
  • each Y and Y 3 is O.
  • W 1 or W 2 is Y 2b -R x ; each Y, Y 3 and Y 2b is O and R x is:
  • Ml 2c is 1, 2 or 3 and each Y is independently a bond, O, CR 2 , or S.
  • W 1 or W 2 is Y 2b -R x ; each Y, Y 3 and Y 2b is O and R x is:
  • W 1 or W 2 is Y 2b -R x ; each Y Y 3 and Y 2b is O and R x is:
  • Another embodiment of of Formula I-IV compounds includes a substructure:
  • W is a carbocycle such as phenyl or substituted phenyl.
  • th is a carbocycle such as phenyl or substituted phenyl.
  • R x is:
  • M12c is 1, 2 or 3 and each Y is independently a bond, O, CR 2 , or S.
  • I-IV includes substructures:
  • the chiral carbon of the amino acid and lactate moieties may be either the R or S configuration or the racemic mixture.
  • each Y 2 is, independently, -O- or -NH-.
  • R y is (CrC 8 ) alkyl, (Ci-C 8 ) substituted alkyl, (C 2 -Cg) alkenyl, (C 2 - C8) substituted alkenyl, (C 2 -C 8 ) alkynyl or (C 2 -Cg) substituted alkynyl.
  • R y is (Ci-Cg) alkyl, (Ci-Cg) substituted alkyl, (C 2 -Cg) alkenyl, (C 2 -Cg) substituted alkenyl, (C 2 -Cg) alkynyl or (C 2 -Cg) substituted alkynyl; and R is CH 3 .
  • R y is (Ci-C 8 ) alkyl, (Ci-Cg) substituted alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl or (C 2 -C 8 ) substituted alkynyl; R is CH 3 ; and each Y is -NH-.
  • W and W are, independently, nitrogen-linked, naturally occurring amino acids or naturally occurring amino acid esters.
  • W 1 and W 2 are, independently, naturally- occurring 2-hydroxy carboxylic acids or naturally-occurring 2-hydroxy carboxylic acid esters wherein the acid or ester is linked to P through the 2-hydroxy group.
  • each R x is, independently, (C]-C 8 ) alkyl. In another aspect of this embodiment, each R x is, independently, C 6 -C 2 o aryl or C 6 C 2 o substituted aryl.
  • W and W are independently selected from one of the formulas in Tables 20.1-20.37 and Table 30.1 below.
  • Tables 20.1-20.37 e.g., ⁇
  • each R is independently H or (Ci-Cg)alkyl
  • each R is independently H, R 21 1 , R ⁇ 2 i 3 or R , / 2 4 4 t wherein each R ,2 4 4 is independently substituted with 0 to 3 R ; each R is independently R ja , R , R JC or R id , provided that when R is bound to a heteroatom, then R 23 is R 23c or R 23d ;
  • each R 23a is independently F, CI, Br, I, -CN, N 3 or -N0 2 ;
  • each R 23b is independently Y 21 ;
  • each R 23c is independently -R 2x , -N(R 2x )(R 2x ), -SR 2x , -S(0)R 2x , -S(0) 2 R 2x ,
  • each R 2x is independently H, (d-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, aryl, heteroaryl; or two R 2x taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NR 21 -; and wherein one or more of the non-terminal carbon atoms of each said (C 1 -C 8 )alkyl may be optionally replaced with -0-, -S- or -NR 21 -;
  • each R 24 is independently (Ci-C 8 )alkyl, (C 2 -C 8 )alkenyl, or (C 2 -C 8 )alkynyl; each R 25 is independently R 24 wherein each R 24 is substituted with 0 to 3
  • each R 25a is independently (Ci-C 8 )alkylene, (C 2 -C 8 )alkenylene, or (C 2 -
  • each W 23 is independently W 24 or W 25 ;
  • each W 25 is independently carbocycle or heterocycle wherein W 25 is
  • each Y 21 is independently O or S.
  • Embodiments of R x include esters, carbamates, carbonates, thioesters, amides thioamides, and urea groups:
  • any reference to the compounds of the invention described heerein also includes a reference to a physiologically acceptable salt thereof.
  • physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal or an alkaline earth (for example, Na + , Li+ K+> Ca +2 and Mg +2 ), ammonium and NR 4 (wherein R is defined herein).
  • Physiologically acceptable salts of a nitrogen atom or an amino group include (a) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acids, phosphoric acid, nitric acid and the like; (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, sulfosalicylic acid
  • Physiologically acceptable salts of a compound of a hydroxy group include the anion of said compound in combination with a suitable cation such as Na + and NR 4 + .
  • salts of active ingredients of the compounds of the invention will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base.
  • salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.
  • compositions herein comprise compounds of the invention in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
  • the compounds of the invention may have chiral centers, e.g. chiral carbon or phosphorus atoms.
  • the compounds of the invention thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers.
  • the compounds of the invention include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures. Both racemic and
  • diastereomeric mixtures as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the invention.
  • the racemic mixtures are separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with optically active adjuncts, e.g., acids or bases followed by conversion back to the optically active substances.
  • optically active adjuncts e.g., acids or bases followed by conversion back to the optically active substances.
  • the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.
  • chiral refers to molecules which have the property of non- superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another.
  • Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, reactivities and biological properties.
  • the compounds of Formula I-IV may have a chiral phosphorus atom when R 7 is
  • W 1 and W 2 are different.
  • W or W also has a chiral center, for example with W or W is a nitrogen-linked, chiral, naturally occurring ot-amino acid ester, then the compound of Formula I-IV will exists as diastereomers because there are two centers of chirality in the molecule. All such diastereomers and their uses described herein are
  • Diastereomeres may have different physical attributes such as, but not limited to, solubility, chemical stabilities and crystallinity and may also have different biological properties such as, but not limited to, enzymatic stability, absorption and metabolic stability.
  • Enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
  • racemic mixture A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • racemic mixture and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • the compounds of the invention can also exist as tautomeric isomers in certain cases. Although only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention.
  • ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention.
  • Another aspect of the invention relates to methods of inhibiting the activity of Paramyxoviridae polymerase comprising the step of treating a sample suspected of containing Paramyxoviridae with a composition of the invention.
  • compositions of the invention may act as inhibitors of Paramyxoviridae polymerase , as intermediates for such inhibitors or have other utilities as described below.
  • the inhibitors will bind to locations on the surface or in a cavity of Paramyxoviridae polymerase having a geometry unique to Paramyxoviridae polymerase .
  • Compositions binding Paramyxoviridae polymerase may bind with varying degrees of reversibility. Those compounds binding substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, the substantially irreversibly binding compositions are useful as probes for the detection of Paramyxoviridae polymerase.
  • the invention relates to methods of detecting Paramyxoviridae polymerase in a sample suspected of containing Paramyxoviridae polymerase comprising the steps of: treating a sample suspected of containing Paramyxoviridae polymerase with a composition comprising a compound of the invention bound to a label; and observing the effect of the sample on the activity of the label.
  • Suitable labels are well known in the diagnostics field and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens.
  • the compounds herein are labeled in conventional fashion using functional groups such as hydroxyl, carboxyl, sulfhydryl or amino.
  • Paramyxoviridae polymerase include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein; and the like.
  • biological material samples blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like
  • laboratory samples food, water, or air samples
  • bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein; and the like.
  • the sample will be suspected of containing an organism which produces Paramyxoviridae polymerase, frequently a pathogenic organism such as a Paramyxoviridae virus.
  • Samples can be contained in any medium including water and organic
  • Samples include living organisms such as humans, and man made materials such as cell cultures.
  • the treating step of the invention comprises adding the composition of the invention to the sample or it comprises adding a precursor of the composition to the sample.
  • the addition step comprises any method of administration as described above.
  • the activity of Paramyxoviridae polymerase after application of the composition can be observed by any method including direct and indirect methods of detecting Paramyxoviridae polymerase activity. Quantitative, qualitative, and semiquantitative methods of determining Paramyxoviridae polymerase activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.
  • Organisms that contain Paramyxoviridae polymerase include the following:
  • Paramyxoviridae virus The compounds of this invention are useful in the treatment or prophylaxis of Paramyxoviridae infections in animals or in man.
  • Paramyxoviridae viruses it should be kept in mind that the results of enzyme assays may not correlate with cell culture assays. Thus, a cell based assay should be the primary screening tool.
  • compositions of the invention are screened for inhibitory activity against
  • compositions are first screened for inhibition of Paramyxoviridae polymerase in vitro and compositions showing inhibitory activity are then screened for activity in vivo.
  • the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like.
  • Aqueous solutions will contain excipients, glidants, fillers, binders and the like.
  • formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the "Handbook of
  • Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • the pH of the formulations ranges from about 3 to about 1 1 , but is ordinarily about 7 to 10.
  • the formulations both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients, particularly those additional therapeutic ingredients as discussed herein.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
  • the formulations include those suitable for the foregoing administration routes.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be administered as a bolus, electuary or paste.
  • a tablet is made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
  • compositions according to the present invention comprise a combination according to the invention together with one or more
  • compositions containing the active ingredient may be in any form suitable for the intended method of administration.
  • tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium
  • a naturally-occurring phosphatide e.g., lecithin
  • a condensation product of an alkylene oxide with a fatty acid e.g., polyoxyethylene stearate
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent e.g., sodium tartrate
  • suspending agent e.g., sodium EDTA
  • preservatives e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally-occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic
  • the amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a time-release formulation intended for oral administration to humans may contain
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10%, and particularly about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns, such as 0.5, 1, 30, 35 etc., which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of Paramyxoviridae infections as described below.
  • the invention is a novel, efficacious, safe, nonirritating and physiologically compatible inhalable composition
  • a compound of Formula I-IV or a pharmaceutically acceptable salt thereof, suitable for treating Paramyxoviridae infections and potentially associated bronchiolitis.
  • Preferred pharmaceutically acceptable salts are inorganic acid salts including hydrochloride, hydrobromide, sulfate or phosphate salts as they may cause less pulmonary irritation.
  • the inhalable formulation is delivered to the endobronchial space in an aerosol comprising particles with a mass median aerodynamic diameter (MMAD) between about 1 and about 5 ⁇ .
  • MMAD mass median aerodynamic diameter
  • the compound of Formula I-IV is formulated for aerosol delivery using a nebulizer, pressurized metered dose inhaler (pMDI), or dry powder inhaler (DPI).
  • Non-limiting examples of nebulizers include atomizing, jet, ultrasonic, pressurized, vibrating porous plate, or equivalent nebulizers including those nebulizers utilizing adaptive aerosol delivery technology (Denyer, J. Aerosol medicine Pulmonary Drug Delivery 2010, 23 Supp 1 , S1 -S10).
  • a jet nebulizer utilizes air pressure to break a liquid solution into aerosol droplets.
  • An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets.
  • a pressurized nebulization system forces solution under pressure through small pores to generate aerosol droplets.
  • a vibrating porous plate device utilizes rapid vibration to shear a stream of liquid into appropriate droplet sizes.
  • the formulation for nebulization is delivered to the endobronchial space in an aerosol comprising particles with a MMAD predominantly between about 1 ⁇ and about 5 ⁇ using a nebulizer able to aerosolize the formulation of the compound of Formula I-IV into particles of the required MMAD.
  • a nebulizer able to aerosolize the formulation of the compound of Formula I-IV into particles of the required MMAD.
  • the majority of aerosolized particles should not have a MMAD greater than about 5 ⁇ . If an aerosol contains a large number of particles with a MMAD larger than 5 ⁇ , the particles are deposited in the upper airways decreasing the amount of drug delivered to the site of inflammation and bronchoconstriction in the lower respiratory tract. If the MMAD of the aerosol is smaller than about 1 ⁇ , then the particles have a tendency to remain suspended in the inhaled air and are subsequently exhaled during expiration.
  • the aerosol formulation for nebulization delivers a therapeutically efficacious dose of the compound of Formula I-IV to the site of Paramyxoviridae infection sufficient to treat the Paramyxoviridae infection.
  • a combination of the aqueous aerosol formulation with the atomizing, jet, pressurized, vibrating porous plate, or ultrasonic nebulizer permits, depending on the nebulizer, about, at least, 20, to about 90%, typically about 70% delivery of the administered dose of the compound of Formula I-IV into the airways. In a preferred embodiment, at least about 30 to about 50% of the active compound is delivered. More preferably, about 70 to about 90% of the active compound is delivered.
  • a compound of Formula I- IV or a pharmaceutically acceptable salt thereof is delivered as a dry inhalable powder.
  • the compounds of the invention are administered endobronchially as a dry powder formulation to efficacious deliver fine particles of compound into the endobronchial space using dry powder or metered dose inhalers.
  • the compound of Formula I-IV is processed into particles with,
  • excipients are added to the compound of Formula I-IV before processing into particles of the required sizes.
  • excipients are blended with the particles of the required size to aid in dispersion of the drug particles, for example by using lactose as an excipient.
  • Particle size determinations are made using devices well known in the art. For example a multi-stage Anderson cascade impactor or other suitable method such as those specifically cited within the US Pharmacopoeia Chapter 601 as characterizing devices for aerosols within metered-dose and dry powder inhalers.
  • a compound of Formula I- IV is delivered as a dry powder using a device such as a dry powder inhaler or other dry powder dispersion devices.
  • a device such as a dry powder inhaler or other dry powder dispersion devices.
  • dry powder inhalers and devices include those disclosed in US5,458,135; US5,740,794; US5775320;
  • pharmaceutically acceptable salt thereof is delivered as a dry powder using either type of dry powder inhaler as described herein, wherein the MMAD of the dry powder, exclusive of any excipients, is predominantly in the range of 1 ⁇ to about 5 ⁇ .
  • a compound of Formula I-IV is delivered as a dry powder using a metered dose inhaler.
  • metered dose inhalers and devices include those disclosed in US5,261,538; US5,544,647; US5,622,163; US4,955,371 ; US3,565,070; US3,361306 and US6,1 16,234.
  • a compound of Formula I-IV, or a pharmaceutically acceptable salt thereof is delivered as a dry powder using a metered dose inhaler wherein the MMAD of the dry powder, exclusive of any e cipients, is predominantly in the range of about 1-5 ⁇ .
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried
  • sterile liquid carrier for example water for injection
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary earner therefor.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • controlled release formulations in which the release of the active ingredient are controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given active ingredient.
  • Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used
  • prophylactically or against an active viral infection, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be from about 0.0001 to about 100 mg/kg body weight per day; typically, from about 0.01 to about 10 mg/kg body weight per day; more typically, from about .01 to about 5 mg/kg body weight per day; most typically, from about .05 to about 0.5 mg/kg body weight per day.
  • the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses.
  • One or more compounds of the invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient.
  • An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
  • Combination Therapy Compositions of the invention are also used in combination with other active ingredients.
  • the other active therapeutic agent is active against Paramyxoviridae virus infections, particularly respiratory syncytial virus infections and/or parainfluenza virus infections.
  • Non-limiting examples of these other active therapeutic agents are ribavirin, palivizumab, motavizumab, RSV-IGIV
  • additional active therapeutics used to treat respiratory symptoms and sequelae of infection may be used in combination with the compounds of Formula I-IV.
  • the additional agents are preferrably administered orally or by direct inhalation.
  • other preferred additional therapeutic agents in combination with the compounds of Formula I-IV for the treatment of viral respiratory infections include, but are not limited to, bronchodilators and corticosteroids.
  • Glucocorticoids which were first introduced as an asthma therapy in 1950 (Carryer, Journal of Allergy, 21, 282-287, 1950), remain the most potent and consistently effective therapy for this disease, although their mechanism of action is not yet fully understood (Morris, J. Allergy Clin. Immunol., 75 (1 Pt) 1-13,
  • oral glucocorticoid therapies are associated with profound undesirable side effects such as truncal obesity, hypertension, glaucoma, glucose intolerance, acceleration of cataract formation, bone mineral loss, and
  • corticosteroids have been developed to mitigate the severe adverse effects of oral steroids.
  • corticosteroids that may be used in combinations with the compounds of Formula I-IV are dexamethasone, dexamethasone sodium phosphate, fluorometholone, fluorometholone acetate, loteprednol, loteprednol etabonate, hydrocortisone, prednisolone, fludrocortisones, triamcinolone, triamcinolone acetonide, betamethasone, beclomethasone diproprionate, methylprednisolone, fluocinolone, fluocinolone acetonide, flunisolide, fluocortin-21-butylate, flumethasone, flumetasone pivalate, budesonide, halobetasol propionate, mometasone furoate, fluticasone propionate, ciclesonide; or
  • anti-inflammatory signal transduction modulators like phosphodiesterase inhibitors (e.g. PDE-4, PDE-5, or PDE-7 specific), transcription factor inhibitors (e.g. blocking NFKB through IKK inhibition), or kinase inhibitors (e.g.
  • non-limiting additional therapeutic agents include: 5-(2,4-Difluoro-phenoxy)-l-isobutyl-lH-indazole-6- carboxylic acid (2-dimethylamino-ethyl)-amide (P38 Map kinase inhibitor ARRY-797); 3-Cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4- difluorormethoxy-benzamide (PDE-4 inhibitor Roflumilast); 4-[2-(3- cyclopentyloxy-4-methoxyphenyl)-2-phenyl-ethyl]-pyridine (PDE-4 inhibitor CDP-840); N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-8- [(methylsulfonyl)amino]- 1 -dibenzofurancarboxamide (PDE-4 inhibitor
  • bronchodilators such as formoterol, albuterol or salmeterol with the compounds of Formula I-IV are also suitable, but non-limiting, combinations useful for the treatment of respiratory viral infections.
  • Combinations of inhaled p2-adrenoreceptor agonist bronchodilators such as formoterol or salmeterol with ICS's are also used to treat both the
  • anticholinergics are of potential use and, therefore, useful as an additional therapeutic agents in combination with the compounds of Formula I-IV for the treatment of viral respiratory infections.
  • anticholinergics include, but are not limited to, antagonists of the muscarinic receptor (particularly of the M3 subtype) which have shown therapeutic efficacy in man for the control of cholinergic tone in COPD (Witek, 1999); l - ⁇ 4-Hydroxy-l-[3,3,3-tris-(4-fluoro- phenyl)-propionyl]-pyrrolidine-2-carbonyl ⁇ -pyrrolidine-2-carboxylic acid (1- methyl-piperidin-4-ylmethyl)-amide; 3-[3-(2-Diethylamino-acetoxy)-2-phenyl- propionyloxy]-8-isopropyl-8-methyl-8-azonia-bicyclo[3.2.1]octane
  • the compounds of Formula I-IV may also be combined with mucolytic agents to treat both the infection and symptoms of respiratory infections.
  • a non-limiting example of a mucolytic agent is ambroxol.
  • the compounds of Formula I-IV may be combined with expectorants to treat both the infection and symptoms of respiratory infections.
  • a non-limiting example of an expectorant is guaifenesin.
  • Nebulized hypertonic saline is used to improve immediate and lon-term clearance of small airways in patients with lung diseases (Kuzik, J. Pediatrics 2007, 266).
  • the compounds of Formula I-IV may also be combined with nebulized hypertonic saline particularly when the Paramyxoviridae virus infection is complicated with bronchiolitis.
  • the combination of the compounds of Formula I-IV with hypertonic saline may also comprise any of the additional agents discussed above.
  • nebulized about 3% hypertonic saline is used.
  • the combination therapy may be administered as a simultaneous or sequential regimen.
  • the combination may be administered in two or more
  • Co-administration of a compound of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the compound of the invention and one or more other active therapeutic agents are both present in the body of the patient.
  • Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the
  • a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents.
  • a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes.
  • the combination therapy may provide "synergy” and "synergistic", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
  • a synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
  • a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g. in separate tablets, pills or capsules, or by different injections in separate syringes.
  • an effective dosage of each active ingredient is administered sequentially, i.e. serially
  • effective dosages of two or more active ingredients are administered together.
  • a synergistic anti-viral effect denotes an antiviral effect which is greater than the predicted purely additive effects of the individual compounds of the combination.
  • the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
  • the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
  • the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
  • the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent, whereby Paramyxoviridae polymerase is inhibited.
  • the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent.
  • the invention includes novel and unobvious compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radiolabelled (e.g. or compound of the invention, administering it parenterally in a detectable dose (e.g.
  • the metabolite structures are determined in conventional fashion, e.g. by MS or NM analysis. In general, analysis of metabolites is done in the same way as conventional drag metabolism studies well-known to those skilled in the art.
  • the conversion products so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no HCV polymerase inhibitory activity of their own.
  • compositions and methods for determining stability of compounds in surrogate gastrointestinal secretions are known.
  • Compounds are defined herein as stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in surrogate intestinal or gastric juice upon incubation for 1 hour at 37°C. Simply because the compounds are stable to the gastrointestinal tract does not mean that they cannot be hydrolyzed in vivo.
  • the prodrugs of the invention typically will be stable in the digestive system but may be substantially hydrolyzed to the parental drag in the digestive lumen, liver or other metabolic organ, or within cells in general.
  • Ethyl alanine ester hydrochloride salt (1.69 g, 1 1 mmol) was dissolved in anhydrous CH 2 CI 2 (10 mL) and the mixture stirred with cooling to 0 °C under N 2 (g). Phenyl dichlorophosphate (1.49 mL, 10 mmol) was added followed by dropwise addition of Et 3 N over 10 min. The reaction mixture was then slowly warmed to RT and stirred for 12 h. Anhydrous Et 2 0 (50 mL) was added and the mixture stirred for 30 min. The solid that formed was removed by filtration, and the filtrate concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-50% EtOAc in hexanes to provide intermediate A (1.13 g, 39%).
  • the 2-ethylbutyl alanine chlorophosphoramidate ester B was prepared using the same procedure as chloridate A except substituting 2-ethylbutyl alanine ester for ethyl alanine ester. The material is used crude in the next reaction.
  • the isopropyl alanine chlorophosphoramidate ester C was prepared using the same procedure as chloridate A except substituting isopropyl alanine ester for the ethyl alanine ester. The material is used crude in the next reaction. Treatment with methanol or ethanol forms the displaced product with the requisite LCMS signal.
  • the commercially available lactol (10 g, 23.8 mmol) was dissolved in anhydrous DMSO (30 mL) under N 2 (g). Ac 2 0 (20 mL) was added and the resultant reaction mixture stirred at RT for 48 h. The reaction mixture was poured onto ice H 2 0 (500 mL) and the mixture stirred for 20 min. The mixture was extracted with EtOAc (3 x 200 mL) and the combined organic extracts were then washed with H 2 0 (3 x 200 mL). The organic extract was dried over anhydrous MgS0 4 , filtered and concentrated under reduced pressure. The residue was dissolved in CH 2 C1 2 and subjected to silica gel chromatography eluting with 25% EtOAc in hexanes to provide the lactone (9.55 g, 96%).
  • the bromopyrazole (prepared according to WO2009/132135) (0.5 g, 2.4 mmol) was suspended in anhydrous THF (10 mL) under N 2 (g). The suspension was stirred and TMSC1 (0.67 mL, 5.28 mmol) was added. The mixture was stirred for 20 min. at RT and then cooled to -78 °C after which time a solution of n-BuLi (6 mL, 1.6 N in hexanes, 9.6 mmol) was added slowly. The reaction mixture was stirred for 10 min. at -78 °C and then the lactone (1 g, 2.4 mmol) was added via syringe.
  • the hydroxy nucleoside (1.1 g, 2.0 mmol) was dissolved in anhydrous CH2CI2 (40 mL) and the solution cooled with stirring to 0 °C under N 2 (g).
  • TMSCN (0.931 mL, 7 mmol) was added and the mixture stirred for a further 10 min.
  • TMSOTf (1.63 mL, 9.0 mmol) was slowly added to the reaction and the mixture stirred for 1 h.
  • the reaction mixture was then diluted with CH 2 CI 2 (120 mL) and aqueous NaHC0 3 (120 mL) was added to quench the reaction.
  • the reaction mixture was stirred for a further 10 min and the organic layer separated.
  • the aqueous layer was extracted with CH 2 CI 2 (150 mL) and the combined organic extracts dried over anhydrous MgS0 4 , filtered and concentrated under reduced pressure.
  • the tribenzyl cyano nucleoside (70 mg, 0.124 mmol) was dissolved in anhydrous CH 2 Cl 2 (2 mL) and cooled to -78 °C under N 2 (g). A solution of BC1 3 (IN in CH 2 C1 2 , 0.506 mL, 0.506 mmol) was added and the reaction mixture stirred for 1 h. at -78 °C. When the reaction was complete by LC/MS, MeOH was added to quench the reaction. The reaction mixture was allowed to warm to room RT and the solvent removed under reduced pressure.
  • the solution was stirred at 70 °C for 18 h and then cooled to 0 °C.
  • the mixture was treated with saturated NaHC0 3 solution (20 drops) then warmed to RT and diluted with EtOAc (100 mL) and H 2 0 (50 mL).
  • EtOAc 100 mL
  • H 2 0 50 mL
  • the organic layer was separated and washed with saturated NaCl solution (50 mL), dried over MgS0 4 , filtered and concentrated under reduced pressure.
  • the reaction mixture was treated with BCI3 (1.0 M in CH 2 CI 2 , 766 ⁇ iL, 0.77 mmol) and stirred for 2 h. The mixture was then cooled to -78 °C and treated with Et 3 N (340 ⁇ ., 2.44 mmol) followed by MeOH (2 mL) before allowing to warm to RT. The reaction was concentrated under reduced pressure and then co-evaporated with MeOH (3 > ⁇ 5 mL). The residue was then suspended in 3 ⁇ 40 (5 mL) and treated with NaHC0 3 (1 g). The solution was stirred for 10 min and then concentrated under reduced pressure.
  • BCI3 1.0 M in CH 2 CI 2 , 766 ⁇ iL, 0.77 mmol
  • the starting nucleoside (prepared as described in the sysnthesis of compound 2) (0.355 g, 0.765 mmol) was dissolved in anhydrous THF (35 mL) and cooled to 0°C with stirring under N 2 (g). A solution of methyl magnesium chloride (2 mL, 6 mmol) (3N in THF) was added and the resultant mixture stirred overnight. Acetic acid (7 mmol) was added to quench the reaction and then the solvents were removed by rotory under reduced pressure. The residue was re- dissolved in CH 2 C1 2 and the solution subjected to a plug of silica gel to isolate the product (0.355 g) as a crude mixture.
  • the nucleoside 3 (0.011 g, 0.04 mmol) was dissolved in trimethylphosphate (2 mL) and cooled to 0°C. The mixture was stirred under an atmosphere of N 2 (g) andl-Methylimidazole(0.320 mL, 5 mmol) followed by the
  • the nucleoside 3 (0.026 g, 0.092 mmol) was dissolved in
  • the nucleoside 3 (0.022 g, 0.056 mmol) was dissolved in
  • the acetate material (1.2 g, 5.5 mmol) (J. Org. Chem. 1985, 50, 3547, De Bernardo et al) was dissolved in a 1 :1 mixture MeOH and THF (10 mL). A IN solution of NaOH(aq) (l OmL) was added until the pH was 13. The reaction mixture was stirred for 2h and then neutralized to pH 8-9 by the addition of AcOH. The mixture was extracted with EtOAc (10 x 30mL) and the combined organic extracts dried over anhydrous Na 2 S0 4 , filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-70% EtOAc in hexanes to give the desired product (866 mg, 90%).
  • the nucleoside 1 (45mg, 0.15mmol) was dissolved in anhydrous trimethyl phosphate (0.5 mL) and the solution stirred under N 2 (g) at 0°C. Methyl imidazole (36 ⁇ , 0.45 mmol) was added to the solution. Chlorophosphoramidate C (69 mg, 0.225 mmol) was dissolved in anhydrous THF (0.25 mL) and added dropwise to the nucleoside mixture. When the reaction was complete by LCMS, the reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHC0 3 solution, saturated NaCl, dried over anhydrous Na 2 S0 4> filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-5% MeOH in CH 2 C1 2 followed by preparative HPLC to give the product (20.9 mg, 25%).
  • Compound 11 was prepared from Compound 2 and chloridate A using same method as for the preparation of compound 8.
  • the nucleoside 1 (14.6 mg, 0.05 mmol) was dissolved in anhydrous trimethyl phosphate (0.5 mL) and stirred under N 2 (g) at RT.
  • POCl 3 (9.2 ⁇ ,, 0.1 mmol) was added and the mixture stirred for 60 min.
  • Alanine ethyl ester hydrochloride (61 mg, 0.4 mmol) and then Et 3 N (70 ⁇ , 0.5 mmol) was added.
  • the resultant mixture was stirred for 15 min. and then additional Et 3 N (70 ⁇ , 0.5 mmol) was added to give a solution pH of 9-10.
  • the mixture was stirred for 2 h.
  • the nucleoside alcohol (0.6 g, 1.08 mmol) (prepared as described in
  • the tribenzyl nucleoside (0.650 g, 1.16 mmol) was dissolved in anhydrous CH 2 CI 2 (30 mL) and cooled to -78°C under N 2 (g).
  • a solution of boron tribromide (1 N in CH 2 CI 2 , 5.5 mL) was added and the reaction mixture stirred for 1 h. at - 78°C.
  • a solution of MeOH (10 mL) and pyridine (2 mL) was added to quench the reaction and the mixture was allowed to rise to RT.
  • the mixture was concentrated under reduced pressure and subjected to preparative HPLC to provide the a- anomer (20 mg) and ⁇ -anomer 13 (110 mg)
  • the tribenzyl alcohol from Compound 1 synthesis (0.250 g, 0.453 mmol) was dissolved in anhydrous THF (25 mL) and stirred under N 2 (g). The reaction mixture was cooled to 0°C and then a 3.0 N solution of methyl magnesium chloride in THF(1.2 mL, 3.62 mmol) was added. The reaction mixture was stirred overnight at RT. Acetic acid (1.5 mL) was added to quench the reaction and then the mixture was concentrated under reduced pressure. The residue was redissoved in CH 2 C1 2 and subjected to a plug of silca gel eluting with 0 to 80% EtOAc in hexanes. The crude product (0.452 g) was then used in the next reaction without further purification.
  • the tribenzyl nucleoside (0.20 g, 0.364 mmol) was dissolved in AcOH (30 mL). and charged with Pd/C (Degussa) (400 mg). The stirred mixture was flushed with N 2 (g) three times and then H 2 (g) was introduced, The reaction was stirred under H 2 (g) for 2 h. and then the catalyst removed by filtration. The solution was concentrated under reduced pressure and under the residue was re-dissolved in H 2 0. The solution was subjected to preparative HPLC under neutral conditions to provide the a-anomer and ⁇ -anomer 14 in 81% yield.
  • the nucleoside 1 (0.028 g, 0.096 mmol) was dissolved in trimethylphosphate (1 niL). The reaction was stirred under N 2 (g) and then treated with lH-tetrazole (0.021 g, 0.29 mmol). The reaction mixture was cooled to 0°C and the phosphane (Nucleoside Nucleotides, Nucleic acids; 14; 3-5; 1995; 763 - 766. Lefebvre, Isabelle; Pompon, Alain; Perigaud, Christian; Girardet, Jean-Luc; Gosselin, Gilles; et al.) (87 mg, 0.192 mmol) was added. The reaction was stirred for 2 h.
  • Compound 16 was prepared using the same method as compound 15 except substituting compound 13 as the starting nucleoside.
  • Another aspect of the invention relates to methods of inhibiting viral infections, comprising the step of treating a sample or subject suspected of needing such inhibition with a composition of the invention.
  • samples suspected of containing a virus include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired
  • sample will be suspected of containing an organism which induces a viral infection, frequently a pathogenic organism such as a tumor virus.
  • Samples can be contained in any medium including water and organic solventWater mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.
  • the anti-virus activity of a compound of the invention after application of the composition can be observed by any method including direct and indirect methods of detecting such activity. Quantitative, qualitative, and semiquantitative methods of determining such activity are all contemplated.
  • the antiviral activity of a compound of the invention can be measured using standard screening protocols that are known.
  • the antiviral activity of a compound can be measured using the following general protocols.
  • Antiviral activity against RSV is determined using an in vitro
  • cytoprotection assay in Hep2 cells.
  • compounds inhibiting the virus replication exhibit cytoprotective effect against the virus-induced cell killing that can be quantified using a cell viability reagent.
  • the method used is similar to methods previously described in published literature (Chapman et al., Antimicrob Agents Chemother. 2007, 57(9):3346-53.)
  • Hep2 cells are obtained from ATCC (Manassas, VI) and maintained in MEM media supplemented with 10% fetal bovine serum and
  • Hep2 cells are seeded into 96-well plates 24 hours before the assay at a density of 3,000 cells/well.
  • compounds to be tested are serially diluted in cell culture media.
  • Eight concentrations in 3 -fold serial dilution increments are prepared for each tested compound and 100 uL/well of each dilution is transferred in duplicate onto plates with seeded Hep2 cells.
  • appropriate dilution of virus stock previously determined by titration is prepared in cell culture media and 100 uL/well is added to test plates containing cells and serially diluted compounds.
  • Each plate includes three wells of infected untreated cells and three wells of uninfected cells that served as 0% and 100% virus inhibition control, respectively.
  • testing plates are incubated for 4 days in a tissue culture incubator. After the incubation, RSV-induced cytopathic effect is determined using a Cell TiterGlo reagent (Promega, Madison, WI) followed by a luminescence read-out. The percentage inhibition is calculated for each tested concentration relative to the 0% and 100% inhibition controls and the EC50 value for each compound is determined by non-linear regression as a concentration inhibiting the RSV-induced cytopathic effect by 50%.
  • Ribavirin purchased from Sigma, St. Louis, MO
  • Ribavirin is used as a positive control for antiviral activity.
  • Cytotoxicity of tested compounds is determined in uninfected Hep2 cells in parallel with the antiviral activity using the cell viability reagent in a similar fashion as described before for other cell types (Cihlar et al., Antimicrob Agents Chemother. 2008,52(2):655-65.). The same protocol as for the determination of antiviral activity is used for the measurement of compound cytotoxicity except that the cells are not infected with RSV. Instead, fresh cell culture media (100 uL/well) without the virus is added to tested plates with cells and prediluted compounds. Cells are then incubated for 4 days followed by a cell viability test using CellTiter Glo reagent and a luminescence read-out.
  • Untreated cell and cells treated with 50 ug/mL puromycin (Sigma, St. Louis, MO) are used as 100% and 0% cell viability control, respectively.
  • the percent of cell viability is calculated for each tested compound concentration relative to the 0%> and 100% controls and the CC50 value is determined by non-linear regression as a compound
  • RSV ribonucleoprotein (RNP) complexes were prepared from a method modified from Mason et al (1).
  • HEp-2 cells were plated at a density of 7.1 x 10 4 cells/cm 2 in MEM + 10% fetal bovine serum (FBS) and allowed to attach overnight at 37°C (5% C0 2 ).
  • FBS fetal bovine serum
  • the media was replaced with MEM + 2% FBS supplemented with 2 ⁇ g/mL
  • actinomycin D and returned to 37°C for one hour.
  • the cells were then washed once with PBS and treated with 35 mL of PBS + 250 ⁇ g mL lyso-lecithin for one minute, after which all liquid was aspirated.
  • the cells were harvested by scrapping them into 1.2 mL of buffer A [50 mM TRIS acetate (pH 8.0), 100 mM potassium acetate, 1 mM DTT and 2 ⁇ g/mL actinomycin D] and lysed by repeated passage through an 18 gauge needle (10 times).
  • the cell lysate was placed in ice for 10 minutes and then centrifuged at 2400g for 10 minutes at 4°C.
  • Transcription reactions contained 25 ⁇ g of crude RSV RNP complexes in 30 ⁇ , of reaction buffer [50 mM TRIS-acetate (pH 8.0), 120 mM potassium acetate, 5% glycerol, 4.5 mM MgCl 2 , 3 mM DTT, 2 mM ethyleneglycol-bis(2- aminoethylether)-tetraacetic acid (EGTA), 50 ⁇ g/mL BSA, 2.5 U RNasin
  • ATP ATP
  • GTP GTP
  • UTP UTP
  • CTP CTP
  • 1.5 uCi [a- 32 P] NTP 3000 Ci/mmol
  • the radiolabled nucleotide used in the transcription assay was selected to match the nucleotide analog being evaluated for inhibition of RSV RNP transcription.
  • the three remaining nucleotides were added at a final concentration of 100 ⁇ .
  • RNA sample loading buffer (Sigma) at 65°C for 10 minutes and run on a 1.2% agarose/MOPS gel containing 2M formaldehyde. The agarose gel was dried and exposed to a Storm phosphorimager screen and developed using a Storm phosphorimager (GE Healthcare). The concentration of compound that reduced total radiolabled transcripts by 50% (IC 50 ) was calculated by non-linear regression analysis of two replicates.
  • the Parainfluenza Cytoprotection assay uses Vero cells and Parainfluenza 3 strain C 243. Briefly virus and cells are mixed in the presence of test compound and incubated for 7 days. The virus is pre-titered such that control wells exhibit 85 to 95% loss of cell viability due to virus replication. Therefore, antiviral effect or cytoprotection is observed when compounds prevent virus replication.
  • Each assay plate contains cell control wells (cells only), virus control wells (cells plus virus), compound toxicity control wells (cells plus compound only), compound colorimetric control wells (compound only), as well as experimental wells (compound plus cells plus virus).
  • Cytoprotection and compound cytotoxicity are assessed by MTS (CellTiter®96 Reagent, Promega, Madison WI) dye reduction.
  • MTS CellTiter®96 Reagent, Promega, Madison WI
  • IC 5 0 concentration inhibiting virus replication by 50%
  • TC 50 concentration resulting in 50% cell death
  • a calculated TI therapeutic index TC 5 0 / IC 5 0
  • Each assay includes ribavirin as a positive control.
  • Vero cells were obtained from the American Type Culture Collection (ATCC, Rockville,
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • growth medium 100 units/ml Penicillin and 100 ug/ml Streptomycin
  • Cells are sub-cultured twice a week at a split ratio of 1 : 10 using standard cell culture techniques. Total cell number and percent viability determinations are performed using a hemacytometer and trypan blue exclusion. Cell viability must be greater than 95% for the cells to be utilized in the assay.
  • the cells are seeded in 96-well tissue culture plates the day before the assay at a concentration of 1 x 10 4 cells/well.
  • the virus used for this assay is Parainfluenza 3 strain C 243. This virus was obtained from the American Type Culture Collection (ATCC) and was grown in Vero cells for the production of stock virus pools. For each assay, a pre-titered aliquot of virus is removed from the freezer (-80°C) and allowed to thaw slowly to room temperature in a biological safety cabinet. The virus is resuspended and diluted into tissue culture medium such that the amount of virus added to each well is the amount determined to give between 85 to 95% cell killing at 6-7 days post-infection. MTS Staining for Cell Viability
  • the assay plates are stained with the soluble tetrazolium-based dye MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; CellTiter®96 Reagent, Promega) to determine cell viability and quantify compound toxicity.
  • MTS is metabolized by the mitochondrial enzymes of metabolically active cells to yield a soluble formazan product, allowing the rapid quantitative analysis of cell viability and compound cytotoxicity.
  • This reagent is a stable, single solution that does not require preparation before use.
  • MTS reagent 20-25 ⁇ of MTS reagent is added per well and the microtiter plates are then incubated for 4-6 hrs at 37°C, 5% C0 2 to assess cell viability.
  • Adhesive plate sealers are used in place of the lids, the sealed plate is inverted several times to mix the soluble formazan product and the plate is read spectrophotometrically at 490/650 nm with a Molecular Devices Vmax or SpectraMax Plus plate reader.
  • CPE Cytopathic Effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

Description

METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE
VIRUS INFECTIONS
FIELD OF THE INVENTION
The invention relates generally to methods and compounds for treating
Paramyxoviridae virus infections, particularly methods and nucleosides for treating respiratory syncytial virus infections and parainfluenza virus infections.
BACKGROUND OF THE INVENTION
Paramyxoviruses of the Paramyxoviridae family are negative-sense, single-stranded, RNA viruses that are responsible for many prevalent human and animal diseases. These viruses comprise at least two major subfamilies, Paramyxovirinae and Pneumovirinae. The subfamily Paramyxovirina includes the human parainfluenza viruses (HP IV), measles virus and mumps virus.
Although, vaccines are available to prevent measles and mumps infections, these infections caused 745, 00 deaths in 2001 so additional treatments would be desireable for susceptible populations. HPFV are the second most common cause of lower respiratory tract infection in younger children and collectively cause about 75% of the cases of Croup
(http://www.cdc.gov/ncidod/dvrd/revb/respiratory/hpivfeat.htm). HPIVs can cause repeated infections throughout life including upper respiratory tract illness and even serious lower respiratory tract disease (e.g., pneumonia, bronchitis, and bronchiolitis), the latter being especially of concern among the elderly, and among patients with compromised immune systems (Sable, Infect. Dis. Clin. North Am. 1995, 9, 987-1003). Currently, no vaccines are available to prevent HPIV infections. Therefore there is a need for mti-Paramyxovirina therapeutics.
The subfamily Pneumovirinae includes Human respiratory syncytial virus (HRSV). Almost all children will have had an HRSV infection by their second birthday. HRSV is the major cause of lower respiratory tract infections in infancy and childhood with 0.5% to 2% of those infected requiring hospitalization. The elderly and adults with chronic heart, lung diease or those that are
immunosuppressed also have a high risk for developing severe HRSV disease (http://www.cdc.gov/rsv/index.html). No vaccine to prevent HRSV infection is currently available. The monoclonal antibody palivizumab is available for infants at high risk, e.g., premature infants or those with either cardiac or lung disease, but the cost for general use is often prohibitive. Ribavirin has also been used to treat HRSV infections but has limited efficacy. Therefore, there is a need for anti- Pneumovirinae therapeutics and anti- Paramyxoviridae therapeutics in general.
Ribosides of the nucleobases pyrrolo[l,2-fJ[l,2,4]triazine, imidazo[l,5- fj[l,2,4]triazine, imidazo[l,2-f][l ,2,4]triazine, and [l,2,4]triazolo[4,3- fj[l,2,4]triazine have been disclosed in Carbohydrate Research 2001, 331 (1), 77- 82; Nucleosides & Nucleotides (1996), 15(1-3), 793-807; Tetrahedron Letters (1994), 35(30), 5339-42; Heterocycles (1992), 34(3), 569-74; J. Chem. Soc.
Perkin Trans. 1 1985, 3, 621-30; J. Chem. Soc. Perkin Trans. 1 1984, 2, 229-38; WO 2000056734; Organic Letters (2001), 3(6), 839-842; J. Chem. Soc. Perkin Trans. 1 1999, 20, 2929-2936; and J. Med. Chem. 1986, 29(1 1), 2231-5.
Ribosides of pyrrolo[l,2-fJ[l,2,4]triazine nucleobases with antiviral, anti-HCV, and anti-RdRp activity have been disclosed by Babu (WO2008/089105 and WO2008/141079) and Francom(WO2010/002877).
Butler, et al., WO2009132135, disclose substituted ribosides and prodrugs comprising pyrrolo[l,2-fj[l ,2,4]triazine nucleobases which have anti- HCV and anti-RdRp activity. However, no methods of treating Paramyxoviridae infections with these compounds have been disclosed.
SUMMARY OF THE INVENTION
Provided are methods and compounds for the treatment of infections cased by the Paramyxoviridae virus family. Provided, is a method for treating a Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I:
Figure imgf000004_0001
Formula I
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen;
each R2, R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (Ci-Cg)alkyl, (C4-Cg)carbocyclylalkyl, (Ci-Cg)substituted alkyl,
(C2-Cs)alkenyl, (C2-Cg) substituted alkenyl, (C2-C8)alkynyl or (C2-Cg)substituted alkynyl;
2 3 5
or any two R , R or R on adjacent carbon atoms when taken together are -0(CO)0- or when taken together with the ring carbon atoms to which they are attached form a double bond;
R6 is ORa, N(Ra)2, N3, CN, N02, S(0)nRa, -C(=0)Rn, -C(=0)ORn, - C(=0)NRHR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, halogen, (C1-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-Cg)substituted alkyl, (C2-Cg)alkenyl, (C2-Cg)substituted alkenyl,
(C2-Cg)alkynyl, (C2-C8)substituted alkynyl, or aryl(Ci-Cg)alkyl;
each n is independently 0, 1, or 2;
each Ra is independently H, (Ci-Cg)alkyl, (C2-Cg)alkenyl, (C2-Cg)alkynyl, aryl(Ci-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), or -S02NRnR12;
R7 is H, -C(=0)Rn, -C(=0)ORH, -C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2R1 ], -S(0)(ORn), -S(0)2(ORn), -S02NRuR12, or
Figure imgf000005_0001
each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2;
W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W 2 is Formula la; or W 1' and W 2z are each, independently, a group of the Formula la:
Figure imgf000005_0002
Formula la
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR),
+N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is independently Ry or the formula:
Figure imgf000006_0001
each Mi a, Ml c, and Mid is independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each Ry is independently H, F, CI, Br, I, OH, R, -C(=Y1)R, -C(=Y1)OR, -
C(=Y1)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC(=Y1)R, -OC(=Y1)OR, -OC(=Y1)(N(R)2), -SC(=Y1)R, -SC(=Y1)OR, - SC(=Y1)(N(R)2), -N(R)C(=Y!)R, -N(R)C(=Y])OR, -N(R)C(=Y1)N(R)2,
-S02NR2, -CN, -N3, -N02, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (Q-C8) alkyl, (Ci-C8) substituted alkyl, (C2- C8)alkenyl, (C2-C8) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, C6-C2o aryl, C6-C2o substituted aryl, C2-C2o heterocyclyl, C2-C20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -0(Υ¾ -C^W5, -S02Ry, or -S02W5; and
W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRnR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NNHRn, -CH=N(ORH), -CH(ORH)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (d-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(d-C8)alkyl, -S(0)n(Ci-C8)alkyl, aryl(Cj-C8)alkyl, OR11 or SR11;
each R9 or R10 is independently H, halogen, NRnR12, N(RH)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NHNRn, -CH=N(ORn), -CH(ORn)2, -C(=0)NRHR12, -C(=S)NRnR12, -C(=0)ORu, R11, OR11 or SR11;
each Rn or R12 is independently H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- Cg)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl,
Figure imgf000007_0001
-S(0)n(Ci-C8)alkyl or aryl(Ci-
11 12
C8)alkyl; or R and R taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (C]-C8)alkyl, (C2-C8)alkenyl, (C2-Cg)alkynyl or aryl(Ci- C8)alkyl of each R2, R3, R5, R6, R11 or R12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C8)alkyl may be optionally replaced with -0-, -S- or -NRa-.
In another embodiment, the method comprises administering a
therapeutically effective amount of a racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate or solvate of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof to a mammal in need thereof.
In another embodiment, the method comprises treating a Paramyxovirina infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof.
In another embodiment, the method comprises treating a parainfluenza, measles or mumps virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a
pharmaceutically acceptable salt or ester thereof.
In another embodiment, the method comprises treating a parainfluenza virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof. In another embodiment, the method comprises treating a Pneumovirinae infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof.
In another embodiment, the method comprises treating a respiratory syncytial virus infection in a mammal in need thereof by administering a therapeutically effective amount of a compound of Formula I or a
pharmaceutically acceptable salt or ester thereof.
In another embodiment, the method comprises administering a
therapeutically effective amount of a pharmaceutical composition comprising an effective amount of a Formula I compound, or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable diluent or carrier.
In another embodiment, the method comprises administering a
therapeutically effective amount of a pharmaceutical composition comprising an effective amount of a Formula I compound, or a phannaceutically acceptable salt or ester thereof, in combination with at least one additional therapeutic agent.
In another embodiment, the method comprises administering a
therapeutically effective amount of a combination pharmaceutical agent comprising:
a) a first pharmaceutical composition comprising a compound of Formula I; or a pharmaceutically acceptable salt, solvate, or ester thereof; and b) a second pharmaceutical composition comprising at least one additional therapeutic agent active against infectious Paramyxoviridae viruses.
In another embodiment, the present application provides for a method of inhibiting a Paramyxoviridae R A-dependent RNA polymerase, comprising contacting a cell infected with a Paramyxoviridae virus with an effective amount of a compound of Formula I; or a pharmaceutically acceptable salts, solvate, and/or ester thereof. In another embodiment, provided is the use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, and/or ester thereof to treat a viral infection caused by a Paramyxoviridae virus.
In another aspect, the invention also provides processes and novel intermediates disclosed herein which are useful for preparing Formula I compounds of the invention.
In other aspects, novel methods for synthesis, analysis, separation, isolation, purification, characterization, and testing of the compounds of this invention are provided.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying description, structures and formulas. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention.
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I represented by Formula II:
Figure imgf000009_0001
Formula II
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen;
each R2 is ORa or halogen;
each R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (Ci-Cg)alkyl, (C4-Cg)carbocyclylalkyl, (Ci-C8)substituted alkyl, (C2-Cg)alkenyl, (C2-Cg)substituted alkenyl, (C2-Cg)alkynyl or (C2-Cg)substituted alkynyl;
or any two R2, R3 or R5 on adjacent carbon atoms when taken together are
-0(CO)0- or when taken together with the ring carbon atoms to which they are attached form a double bond;
R6 is ORa, N(Ra)2, N3, CN, S(0)nR\ -C(=0)Rn, -C(=0)ORH, - C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(OR 1), -S(0)2(ORn), -SO2NR1 'R12, halogen, (C1-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-Cg)substituted alkyl, (C2-Cg)alkenyl, (C2-C8)substituted alkenyl,
(C2-Cg)alkynyl, or (C2-C8)substituted alkynyl;
each n is independently 0, 1, or 2;
each Ra is independently H, (Ci-Cg)alkyl, (C2-Cg)alkenyl, (C2-Cg)alkynyl, aryl(Ci-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, -
C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORu), or -S02NRnR12;
R7 is H, -C(=0)Rn, -C(=0)ORH, -C(=0)NRnR12, -C(=0)SR, ], -S(0)R1 ], -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, or
Figure imgf000010_0001
each Y or Y is, independently, O, S, NR, N(0)(R), N(OR), +N(0)(OR), or N-NR2; W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R3 or R4 is -Y3- and the other of W1 or W2 is Formula la; or W and W are each, ind endentl a group of the Formula la:
Figure imgf000011_0001
Formula la
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR),
N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is inde endently Ry or the formula:
Figure imgf000011_0002
wherein:
each Mia, Ml c, and Mid is independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
each Ry is independently H, F, CI, Br, I, OH, R, -C(=YJ)R, -C(=Y1)OR, - C(=Y!)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC^Y^R, -OC(=Y1)OR, -OC(=Y')(N(R)2), -SC(=Y')R, -SC(=Y1)OR, - SC(=Y')(N(R)2), -N(R)C(=Y1)R, -N(R)C(=Y!)OR, -N(R)C(=Y')N(R)2,
-S02NR2, -CN, -N3, -N02, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms; each R is independently H, (Ci-C ) alkyl, (Ci-Cg) substituted alkyl, (C2- C8)alkenyl, (C2-Cg) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, C6-C2o aryl, C6-C2o substituted aryl, C2-C2o heterocyclyl, C2-C20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -C(Y )Ry, -QY^W5, -S02Ry, or -S02W5; and
W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRUR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NNHRn, -CH=N(ORn), -CH(ORu)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(d-C8)alkyl, -S(0)„(Ci-C8)alk l, aryl(Ci-C8)alkyl, OR1 1 or SR11;
each R9 is independently H, halogen, NRnR12, N(R )ORu, NRUNRHR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NHNRn, -CH=N(ORn),
-CH(ORn)2, -C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, R11, OR11 or SR11; each R11 or R12 is independently H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(C!-C8)alkyl, -S(0)n(C1-C8)alkyl or ary Q- C8)alkyl; or R 11 and R 12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or aryl(Ci- C8)alkyl of each R3, R5, R6, Rn or R12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(R )2 or ORa; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C8)alkyl may be optionally replaced with -0-, -S- or -NRa-.
In one embodiment of the method of treating a Paramyxoviridae infection by administering a compound of Formula II, R1 of Formula II is H. In another aspect of this embodiment R6 of Formula II is N3, CN, halogen, (Ci-C8)alkyl, (Ci-C8)substituted alkyl, (C2--C8)alkenyl, (C2-C8) substituted alkenyl,
(C2-C8)alkynyl, or (C2-C8)substituted alkynyl. In another aspect of this embodiment, R6 of Formula II is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R6 of Formula II is CN. In another aspect of this embodiment, R6 of Formula II is methyl. In another aspect of this embodiment, R5 of Formula II is H. In another aspect of this embodiment, R2 of Formula II is ORa. In another aspect of this embodiment, R of Formula II is OH. In another aspect of this embodiment, R2 of Formula II is F. In another aspect of this embodiment, R3 of Formula II is ORa. In another aspect of this embodiment, R3 of Formula II is OH, -OC(=0)R1 \ or -OC(=0)OR11. In another aspect of this embodiment, R3 of Formula II is OH. In another aspect of this embodiment, R of Formula II is
NR 11 R12. In another aspect of this embodiment, R 8 of Formula II is NH2. In
8 1 1
another aspect of this embodiment, R of Formula II is OR . In another aspect of this embodiment, R8 of Formula II is OH. In another aspect of this embodiment, R9 of Formula II is H. In another aspect of this embodiment, R9 of Formula II is NRnR12. In another aspect of this embodiment, R9 of Formula II is NH2. In another aspect of this embodiment, R7 of Formula II is H, -C(=0)Rn, -C(=0)ORn
Figure imgf000013_0001
. In another aspect of this embodiment, R7 of Formula II another aspect of this embodiment, R7 of Formula II is
Figure imgf000013_0002
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula II, the
Paramyxoviridae infection is caused by a Paramyxovirina virus. In another aspect of this embodiment, the Paramyxovirina virus is a parainfluenza, measles or mumps vims. In another aspect of this embodiment, the Paramyxovirina virus is a Respirovirus virus. In another aspect of this embodiment, the Paramyxovirina virus is a type 1 or 3 Human parainfluenza virus.
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula II, the
Paramyxoviridae infection is caused by a Pneumovirinae virus. In another aspect of this embodiment, the Pneumovirinae virus is a respiratory syncytial virus. In another aspect of this embodiment, the Pneumovirinae virus is a Human respiratory syncytial virus.
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I represented by Formula III:
Figure imgf000014_0001
Formula III
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R2 is ORa or F;
each R3 is ORa;
R6 is ORa, N(Ra)2, N3, CN, S(0)nRa, -C(=0)Ru, -C(=0)ORu, -
C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORu), -S(0)2(ORn) -S02NRnR12, halogen, (d-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-Cg)substituted alkyl, (C2-Cg)alkenyl, (C2-C8)substituted alkenyl,
-C8)alkynyl, or (C2-C8)substituted alkynyl; each n is independently 0, 1, or 2;
each Ra is independently H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-Cg)alkynyl, aryl(Ci-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2RH, -S(0)(ORu), -S(0)2(ORH), or -S02NRnR12;
R7 is H, -C(=0)Rn, -C(=0)ORn, -C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, or
Figure imgf000015_0001
each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2;
W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W2 is Formula la; or
W 11 and W 2 are each, independently, a group of the Formula la:
Figure imgf000015_0002
Formula la
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR),
+N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is independently Ry or the formula:
Figure imgf000016_0001
wherein:
each Mia, Ml c, and Mid is independently 0 or 1;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each Ry is independently H, F, CI, Br, I, OH, R, -C^Y^R, -C(=Y')OR, -
C(=Y!)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC(=Y')R, -Ο0(=Υ')Ο¾ -OC(=Y')(N(R)2), -SC(=Y')R, -SC^ R, - SC(=Y1)(N(R)2), -N(R)C(=Y')R, -N(R)C(=Y])OR, -N(R)C(=Y1)N(R)2,
-S02NR2, -CN, -N3, -N02, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (Q-Cg) alkyl, (Ci-C8) substituted alkyl, (C2- Cg)alkenyl, (C2-C8) substituted alkenyl, (C2-Cg) alkynyl, (C2-Cg) substituted alkynyl, C6-C2o aryl, C6-C2o substituted aryl, C2-C2o heterocyclyl, C2-C2o substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -0(Υ¾ -C(Y])W5, -S02Ry, or -S02W5; and
W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRnR12, N(Rn)ORH, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NNHRn, -CH=N(ORn), -CH(ORn)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (Ci-Cg)alkyl, (C2-C8)alkenyl, (C2- Cg)alkynyl, (C4-Cg)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl,
Figure imgf000016_0002
-S(0)n(Ci-C8)alkyl, aryl(C1-C8)alkyl, OR11 or SR11;
each R9 is independently H, halogen, NRnR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NR1 !), -CH=NHNRn, -CH=N(ORn), -CH(ORn)2, -C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, R1 1, OR11 or SR11; and
each R11 or R12 is independently H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(Ci-C8)alkyl, -S(0)„(Ci-C8)alkyl or aryl(Ci-
C8)alkyl; or R 1 1 and R 12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (Ci-C )alkyl, (C2-C8)alkenyl, (C2-Cg)alkynyl or aryl(Ci- C8)alkyl of each R6, R11 or R12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C8)alkyl may be optionally replaced with -O-, -S- or -NRa-.
In one embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula III, R6 of Formula III is N3, CN, halogen, (d-C8)alkyl, (Ci-C8)substituted alkyl, (C2-C8)alkenyl,
(C2-C8)substituted alkenyl, (C2-C8)alkynyl, or (C2-C8)substituted alkynyl. In another aspect of this embodiment, R6 of Formula III is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R6 of Formula III is CN. In another aspect of this embodiment, R6 of Formula III is methyl. In another aspect of this embodiment, R2 of Formula III is ORa. In another aspect of this
embodiment, R of Formula III is OH. In another aspect of this embodiment, R" of Formula III is F. In another aspect of this embodiment, R3 of Formula III is OH, - OC(=0)R11 , or -OC(=0)OR11. In another aspect of this embodiment, R3 of Formula III is OH. In another aspect of this embodiment, R8 of Formula III is NR1 lR . In another aspect of this embodiment, R8 of Formula III is NH2. In
8 1 1
another aspect of this embodiment, R of Formula III is OR . In another aspect of this embodiment, R of Formula III is OH. In another aspect of this embodiment, R9 of Formula III is H. In another aspect of this embodiment, R9 of Formula III is NRnR12. In another aspect of this embodiment, R9 of Formula III is NH2. In another aspect of this embodiment, R of Formula III is H, -C(=0)R , - C(=0)ORn or
Figure imgf000018_0001
. In another aspect of this embodiment, R7 of Formula III is H.
In another aspect of this embodiment, R7 of Formula III is
Figure imgf000018_0002
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula III, R6 of Formula III is N3, CN, halogen, (C1-C8)alkyl, (Ci-Cg)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl, (C2-C8)alkynyl, or (C2-C8)substituted alkynyl and R8 is NH2. In another aspect of this embodiment, R6 of Formula III is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R6 of Formula III is CN. In another aspect of this embodiment, R6 of Formula III is methyl. In another aspect of this embodiment, R2 of Formula III is ORa. In another aspect of this embodiment, R2 of Formula III is OH, -OC(=0)Rn, or -OC(=0)ORn In another aspect of this embodiment, R2 of Formula III is OH. In another aspect of this embodiment, R2 of Formula III is F. In another aspect of this embodiment, R3 of Formula III is OH, -OC(=0)Rn, or -OC(=0)ORu. In another aspect of this embodiment, R3 of Formula III is OH. In another aspect of this embodiment, R9 of Formula III is H. In another aspect of this embodiment, R9 of Formula III is NRnR12. In another aspect of this embodiment, R9 of Formula III is N¾. In another aspect of this embodiment, R7 of Formula III is H, -C(=0)Ru, - C(=0)ORn or
Figure imgf000019_0001
. In another aspect of this embodiment, R7 of Formula III is H.
In another aspect of this embodiment, R of Formula III is
Figure imgf000019_0002
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula III, R6 of Formula III is CN, methyl, ethenyl, or ethynyl, R8 is N¾, and R9 is H. In another aspect of this embodiment, R6 of Formula III is CN. In another aspect of this embodiment, R6 of Formula III is methyl. In another aspect of this embodiment, R2 of Formula III is ORa. In another aspect of this embodiment, R2 of Formula III is OH, - OC(=0)R1 !, or -OC(=0)OR11. In another aspect of this embodiment, R2 of
Formula III is OH. In another aspect of this embodiment, R2 of Formula III is F. In another aspect of this embodiment, R of Formula III is OH, -OC(=0)R , or - OC(=0)ORn. In another aspect of this embodiment, R3 of Formula III is OH. In another aspect of this embodiment, R7 of Formula III is H, -C(=0)Rn, - C(=0)OR1 ] or
Figure imgf000019_0003
. In another aspect of this embodiment, R7 of Formula III is H.
In another aspect of this embodiment, R7 of Formula III is
Figure imgf000019_0004
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula III, the
Paramyxoviridae infection is caused by a Paramyxovirina virus. In another aspect of this embodiment, the Paramyxovirina virus is a parainfluenza, measles or mumps virus. In another aspect of this embodiment, the Paramyxovirina virus is a Respirovirus virus. In another aspect of this embodiment, the Paramyxovirina virus is a type 1 or 3 Human parainfluenza virus.
In another embodiment of the method of treating a Paramyxoviridae infection comprising administering a compound of Formula III, the
Paramyxoviridae infection is caused by a Pneumovirinae virus. In another aspect of this embodiment, the Pneumovirinae virus is a respiratory syncytial virus. In another aspect of this embodiment, the Pneumovirinae virus is a Human respiratory syncytial virus.
In one embodiment, provided is a compound of Formula IV:
Figure imgf000020_0001
Formula IV
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen;
each R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (Ci-C8)alkyl, (C4-C )carbocyclylalkyl, (C1-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl, (C2-Cg)alkynyl or (C2-C8)substituted alkynyl; R6 is ORa, N(Ra)2, N3, CN, S(0)nRa, -C(=0)Rn, -C(=0)ORn, - C(=0)NRuR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, halogen, (d-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl,
(C2-Cg)alkynyl, or (C2-Cg)substituted alkynyl;
each n is independently 0, 1, or 2;
each Ra is independently H, (Ci-Cg)alkyl, (C2-Cg)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(-0)SRn, -S(0)Ru, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), or -S02NRnR12;
R7 is H, -C(=0)Rn, -C(=0)ORn, -C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, or
Figure imgf000021_0001
each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2;
W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R3 or R4 is -Y3- and the other of W1 or W2 is Fonnula la; or W1 and W2 are each, independently, a group of the Formula la:
Figure imgf000021_0002
Formula la
wherein: each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR), +N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is inde endently Ry or the formula:
Figure imgf000022_0001
wherein:
each Mia, Ml c, and Mid is independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
each Ry is independently H, F, Cl, Br, I, OH, R, -C(=Y1)R, -C(=Y1)OR, - C(=Y1)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC^Y^R, -OC(=Y')OR, -OC(=Y')(N(R)2), -SC(=Y1)R, -SC(=Y')OR, - SC(=Y')(N(R)2), -N(R)C(=Y1)R, -N(R)C(=Y')OR, -N(R)C(=Y')N(R)2,
-S02NR2, -CN, -N3, -N02, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (Ci-C8) alkyl, (Ci-Cg) substituted alkyl, (C2- C8)alkenyl, (C2-C8) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, C6-C2o aryl, C6-C2o substituted aryl, C2-C20 heterocyclyl, C2-C2o substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -C(Y')Ry, -CCY^W5, -S02Ry, or -S02W5; and W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRnR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=N HRn, -CH=N(ORn), -CH(ORu)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (Ci-Cg)alk l, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(Ci-C8)alkyl, -S(0)n(Ci-C8)alkyl, aryl(Ci-C8)alkyl, OR11 or SR11;
each R9 is independently H, halogen, NRHR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NHNRn, -CH=N(ORn),
-CH(ORu)2, -C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORH, R11, OR11 or SR11; each R11 or R12 is independently H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl,
Figure imgf000023_0001
-S(0)n(C!-C8)alkyl or aryl(Ci- C8)alkyl; or R1 1 and R12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (d-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or aryl(Ci- C8)alkyl of each R3, R5, R6, Rn or R12 is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C8)alkyl may be optionally replaced with -0-, -S- or -NRa-.
In one embodiment of the compound of Formula IV, R6 is N3, CN, halogen, (Ci-C8)alkyl, (C1-C8)substituted alkyl, (C2-C8)alkenyl,
(C2-C8) substituted alkenyl, (C2-C8)alkynyl, or (C2-C8)substituted alkynyl. In another aspect of this embodiment, R6 is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R6 is CN. In another aspect of this
embodiment, R6 is methyl. In another aspect of this embodiment, R1 is H. In another aspect of this embodiment, R3 is OH, -OC(=0)Rn, or -OC(=0)ORn. In another aspect of this embodiment, R3 is OH. In another aspect of this
embodiment, R8 is NR] 1R12. In another aspect of this embodiment, R8 is NH2. In another aspect of this embodiment, R8 is OR11. In another aspect of this embodiment, R8 is OH. In another aspect of this embodiment, R9 is H. In another aspect of this embodiment, R9 is NRnR12. In another aspect of this embodiment, R9 is NH2. In another aspect of this embodiment, R7 is H, -C(=0)Ru, - C(=0)ORn or
Figure imgf000024_0001
. In another aspect of this embodiment, R7 is H. In another
1
aspect of this embodiment, R is
Figure imgf000024_0002
In another embodiment of a compound of Formula IV, R6 is N3, CN, halogen, (Ci-C8)alkyl, (Ci-Cg)substituted alkyl, (C2-Cg)alkenyl,
(C2-Cg)substituted alkenyl, (C2-Cg)alkynyl, or (C2-Cg)substituted alkynyl and R8 is NH2. In another aspect of this embodiment, R6 is CN, methyl, ethenyl, or ethynyl. In another aspect of this embodiment, R6 is CN. In another aspect of this embodiment, R6 is methyl. In another aspect of this embodiment, R1 is H. In another aspect of this embodiment, R3 is OH, -OC(=0)R1 or -OC(=0)OR11. In another aspect of this embodiment, R is OH. In another aspect of this embodiment, R9 is H. In another aspect of this embodiment, R9 is NRUR12. In another aspect of this embodiment, R9 is NH2. In another aspect of this embodiment, R7 is H, -C(=0)Ru, -C(=0)ORn or
Figure imgf000024_0003
. In another aspect of this embodiment, R7 is H. In another aspect of this embodiment, R7 is
Figure imgf000024_0004
In another embodiment of the compound of Formula IV, R6 is CN, methyl, ethenyl, or ethynyl, R8 is N¾, and R9 is H. In another aspect of this embodiment, R1 is H. In another aspect of this embodiment, R6 is CN. In another aspect of this embodiment, R is methyl. In another aspect of this embodiment, R is OH, - OC(=0)R1 or -OC(=0)ORn. In another aspect of this embodiment, R3 is OH. In another aspect of this embodiment, R7 is H, -C(=0)Rn, -C(=0)ORn or
Figure imgf000025_0001
. In another aspect of this embodiment, R7 is H. In another aspect of this embodiment, R7 is
Figure imgf000025_0002
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formulas I-IV, wherein R11 or R12 is independently H, (d-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl,
(C4-Cg)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl,
Figure imgf000025_0003
-S(0)n(Ci-C8)alkyl or aryl(d-C8)alkyl. In another embodiment, R11 and R12 taken together with a nitrogen to which they are both attached, form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-.
1 1 12
Therefore, by way of example and not limitation, the moiety -NR R can be represented by the heterocycles:
Figure imgf000025_0004
and the like.
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I-IV, wherein each R3, R4, R5, R5, Rn or R12 is, independently, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C )alkynyl or aryl(Ci-C8)alkyl, wherein said (Ci-C8)alkyl, (C2-Cg)alkenyl, (C2- C8)alkynyl or aryl(Ci-Cs)alkyl are, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa. Therefore, by way of example and not limitation, R3, R4, R5, R6, R11 or R12 could represent moieties such as - CH(NH2)CH3, -CH(OH)CH2CH3, -CH(NH2)CH(CH3)2, -CH2CF3, - (CH2)2CH(N3)CH3, -(CH2)6NH2 and the like.
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of Formula I-IV, wherein R3, R4, R5, R6, R11 or R12 is (Ci-C8)alkyl wherein one or more of the non-terminal carbon atoms of each said (Q-Cs^lkyl may be optionally replaced with -0-, -S- or -NRa-. Therefore, by way of example and not limitation, R3, R4, R5, R6, Rn or R12 could represent moieties such as -CH2OCH3, -CH2OCH2CH3, - CH2OCH(CH3)2, -CH2SCH3, -(CH2)6OCH3, -(CH2)6N(CH3)2 and the like.
In another embodiment, provided is a method of treating a
Paramyxoviridae infection in a sample comprising administering an effective amount of a compound of Formula I selected from the group consisting of:
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
or a pharmaceutically acceptable salt or ester thereof.
In another embodiment, provided is a compound of Formula IV that is
Figure imgf000028_0002
Figure imgf000029_0001
; or a pharmaceutically acceptable salt or ester thereof.
In another embodiment, provided is a compound of Formula I that is
Figure imgf000029_0002
Figure imgf000030_0001
or a pharmaceutically acceptable salt or ester thereof. DEFINITIONS
Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:
When trade names are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.
As used herein, "a compound of the invention" or "a compound of Formula I" means a compound of Formula I or a pharmaceutically acceptable salt, thereof. Similarly, with respect to isolatable intermediates, the phrase "a compound of Formula (number)" means a compound of that formula and pharmaceutically acceptable salts, thereof.
"Alkyl" is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. For example, an alkyl group can have 1 to 20 carbon atoms (i.e, C1-C20 alkyl), 1 to 8 carbon atoms (i.e., Q-Q alkyl), or 1 to 6 carbon atoms (i.e., Ci-C alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1 -propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1 -butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-l -propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl,
-CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1 -pentyl (n- pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-l -butyl (-CH2CH2CH(CH3)2), 2-methyl-l -butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl
(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(C¾CH3)(CH2CH2CH3)), 2-methyl-2- pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (- C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl- 2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3, and octyl (-(CH2)7CH3).
"Alkoxy" means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom. The alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (i.e., Ci-C20 alkoxy), 1 to 12 carbon atoms(z.e., Ci-Ci2 alkoxy), or 1 to 6 carbon atoms(z'.e., Cj- C6 alkoxy). Examples of suitable alkoxy groups include, but are not limited to, methoxy (-0-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), t-butoxy (-0-C(CH3)3 or -OtBu) and the like.
"Haloalkyl" is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom. The alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., C1-C20 haloalkyl), 1 to 12 carbon atoms(z'.e., C]-Ci2 haloalkyl), or 1 to 6 carbon atoms(z'.e., Ci-C6 alkyl). Examples of suitable haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, and the like. "Alkenyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double bond. For example, an alkenyl group can have 2 to 20 carbon atoms {i.e., C2-C2o alkenyl), 2 to 8 carbon atoms {i.e., C2-C8 alkenyl), or 2 to 6 carbon atoms {i.e., C2-C6 alkenyl). Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2).
"Alkynyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond. For example, an alkynyl group can have 2 to 20 carbon atoms {i.e., C2-C2o alkynyl), 2 to 8 carbon atoms {i.e., C2-C8 alkyne,), or 2 to 6 carbon atoms {i.e., C2-C6 alkynyl). Examples of suitable alkynyl groups include, but are not limited to, acetylenic (-C≡CH), propargyl (-CH2C≡CH), and the like.
"Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. For example, an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkylene radicals include, but are not limited to, methylene (-CH2-), 1,1 -ethyl (-CH(CH3)-), 1,2-ethyl (-CH2CH2-), 1,1- propyl (-CH(CH2CH3)-), 1 ,2-propyl (-CH2CH(CH3)-), 1 ,3-propyl (-CH2CH2CH2-), 1,4-butyl (-CH2CH2CH2CH2-), and the like.
"Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. For example, and alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkenylene radicals include, but are not limited to, 1,2-ethylene (-CH=CH-).
"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. For example, an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkynylene radicals include, but are not limited to, acetylene (-G≡C-), propargyl (-CH2C≡C-), and 4-pentynyl
(-CH2CH2CH2C≡C-).
"Amino" refers generally to a nitrogen radical which can be considered a derivative of ammonia, having the formula— N(X)2, where each "X" is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, etc. The hybridization of the nitrogen is approximately sp . Nonlimiting types of amino include -NH2, -N(alkyl)2, - NH(alkyl), -N(carbocyclyl)2, -NH(carbocyclyl), -N(heterocyclyl)2, - NH(heterocyclyl), -N(aryl)2, -NH(aryl), -N(alkyl)(aryl), -N(alkyl)(heterocyclyl), - N(carbocyclyl)(heterocyclyl), -N(aryl)(heteroaryl), -N(alkyl)(heteroaryl), etc. The term "alkylamino" refers to an amino group substituted with at least one alkyl group. Nonlimiting examples of amino groups include -NH2, -NH(CH3), -N(CH3)2, - NH(CH2CH3), - N(CH2CH3)2, -NH(phenyl), -N(phenyl)2, -NH(benzyl), -N(benzyl)2, etc. Substituted alkylamino refers generally to alkylamino groups, as defined above, in which at least one substituted alkyl, as defined herein, is attached to the amino nitrogen atom. Non-limiting examples of substituted alkylamino includes - NH(alkylene-C(0)-OH), -NH(alkylene-C(0)-0-alkyl), -N(alkylene-C(0)-OH)2, - N(alkylene-C(0)-0-alkyl)2, etc.
"Aryl" means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
"Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, naphthylm ethyl, 2-naphthylethan-l-yl,
naphthobenzyl, 2-naphthophenylethan-l-yl and the like. The arylalkyl group can comprise 7 to 20 carbon atoms, e.g., the alkyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
"Arylalkenyl" refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a tenninal or sp carbon atom, but also an sp carbon atom, is replaced with an aryl radical. The aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein. The arylalkenyl group can comprise 8 to 20 carbon atoms, e.g., the alkenyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
"Arylalkynyl" refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical. The aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein. The arylalkynyl group can comprise 8 to 20 carbon atoms, e.g., the alkynyl moiety is 2 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
The term "substituted" in reference to alkyl, alkylene, aryl, arylalkyl, alkoxy, heterocyclyl, heteroaryl, carbocyclyl, etc. , for example, "substituted alkyl", "substituted alkylene", "substituted aryl", "substituted arylalkyl",
"substituted heterocyclyl", and "substituted carbocyclyl" means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -Rb, -O", =0, -ORb, -SRb, -S", -NRb 2, -N+Rb 3, =NRb, -CX3, -CN, -OCN, -SCN, -N=O0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)Rb, -OC(=0)Rb, -NHC(=0)NRb 2, -S(=0)2-, -S(=0)2OH, -S(=0)2Rb, -OS(=0)2ORb, -S(=0)2NRb 2, -S(=0)Rb, -OP(=0)(ORb)2, -P(=0)(ORb)2, -P(=0)(0")2, -P(=0)(OH)2, -P(0)(ORb)(0"), -C(=0)Rb, -C(=0)X, -C(S)Rb, -C(0)ORb, -C(0)0", -C(S)OR , -C(0)SRb, -C(S)SRb, -C(0)NRb 2, -C(S)NRb 2,
-C(=NRb)NRb 2, where each X is independently a halogen: F, CI, Br, or I; and each Rb is independently H, alkyl, aryl, arylalkyl, a heterocycle, or a protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted. Unless otherwise indicated, when the term "substituted" is used in conjunction with groups such as arylalkyl, which have two or more moieties capable of substitution, the substituents can be attached to the aryl moiety, the alkyl moiety, or both.
The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrag is thus a covalently modified analog or latent form of a therapeutically active compound.
One skilled in the art will recognize that substituents and other moieties of the compounds of Formula I-IV should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
Compounds of Formula I-IV which have such stability are contemplated as falling within the scope of the present invention.
"Heteroalkyl" refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S. For example, if the carbon atom of the alkyl group which is attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CH3)2, etc.), or a thioalkyl group (e.g., -SCH3). If a non-terminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH2CH2-0-CH3, etc.), an alkyl amine (e.g., -CH2NHCH3, -CH2N(CH3)2, etc.), or a thioalkyl ether (e.g.,-CH2-S-CH3). If a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g., O, N, or S), the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g., -CH2CH2-SH). A heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. A -C heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
"Heterocycle" or "heterocyclyl" as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic
Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566. In one specific embodiment of the invention "heterocycle" includes a "carbocycle" as defined herein, wherein one or more {e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S). The terms "heterocycle" or "heterocyclyl" includes saturated rings, partially unsaturated rings, and aromatic rings (i.e., heteroaromatic rings). Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups. A non-limiting example of a carbonyl substituted heterocyclyl is:
Figure imgf000036_0001
Examples of heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl,
tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4- piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, azocinyl, triazinyl, 6H-l ,2,5-thiadiazinyl, 2H,6H- 1,5,2- dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, lH-indazoly, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl,
isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl,
pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bis-tetrahydrofuranyl:
Figure imgf000037_0001
By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6- pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5- pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3- pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1 -imidazolyl, 1- pyrazolyl, and 1-piperidinyl.
"Heterocyclylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkylene- moiety). Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl- CH2-, 2-(heterocyclyl)ethan-l-yl, and the like, wherein the "heterocyclyl" portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon- heteroatom bond, with the proviso that the resulting group is chemically stable. The heterocyclyl alkyl group comprises 3 to 20 carbon atoms, e.g., the alkyl portion of the arylalkyl group is 1 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms. Examples of heterocyclylalkyls include by way of example and not limitation 5-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as thiazolylm ethyl, 2-fhiazolylethan-l-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
"Heterocyclylalkenyl" refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, but also a sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkenylene- moiety). The heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable. The heterocyclyl alkenyl group comprises 4 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
"Heterocyclylalkynyl" refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene- moiety). The heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable. The heterocyclyl alkynyl group comprises 4 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclyl alkynyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 2 to 14 carbon atoms.
"Heteroaryl" refers to an aromatic heterocyclyl having at least one heteroatom in the ring. Non-limiting examples of suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen. Non- limiting examples of heteroaryl rings include all of those aromatic rings listed in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
"Carbocycle" or "carbocyclyl" refers to a saturated (i.e., cycloalkyl), partially unsaturated (e.g., cycloakenyl, cycloalkadienyl, etc.) or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 7 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings. Non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l -enyl, 1 -cyclopent-2-enyl, l-cyclopent-3- enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, and phenyl. Non-limiting examples of bicyclo carbocycles includes naphthyl, tetrahydronapthalene, and decaline.
"Carbocyclylalkyl" refers to to an acyclic akyl radical in which one of the hydrogen atoms bonded to a carbon atom is replaced with a carbocyclyl radical as described herein. Typical, but non-limiting, examples of carbocyclylalkyl groups include cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl,
cyclopentylmethyl and cyclohexylmethyl.
"Arylheteroalkyl" refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein. The aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety. For example, an arylheteroalkyl group can have the general formulae -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene-S-alkylene-aryl, etc. In addition, any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
"Heteroarylalkyl" refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein. Non- limiting examples of heteroaryl alkyl include -CH2-pyridinyl, -CH2-pyrrolyl, -CH2-oxazolyl, -CH2-indolyl, -CH2-isoindolyl, -CH2-purinyl, -CH2-furanyl, -CH2-thienyl, -CH2-benzofuranyl, -CH2-benzothiophenyl, -CH2-carbazolyl, -CH2-imidazolyl, -CH2-thiazolyl, -CH2-isoxazolyl, -CH2-pyrazolyl,
-CH2-isothiazolyl, -CH2-quinolyl, -CH2-isoquinolyl, -CH2-pyridazyl,
-CH2-pyrimidyl, -CH2-pyrazyl, -CH(CH3)-pyridinyl, -CH(CH3)-pyrrolyl,
-CH(CH3)-oxazolyl, -CH(CH3)-indolyl, -CH(CH3)-isoindolyl, -CH(CH3)-purinyl, -CH(CH3)-furanyl, -CH(CH3)-thienyl, -CH(CH3)-benzofuranyl,
-CH(CH3)-benzothiophenyl, -CH(CH3)-carbazolyl, -CH(CH3)-imidazolyl, -CH(CH3)-thiazolyl, -CH(CH3)-isoxazolyl, -CH(CH3)-pyrazolyl, -CH(CH3)-isothiazolyl, -CH(CH3)-quinolyl, -CH(CH3)-isoquinolyl,
-CH(CH3)-pyridazyl, -CH(CH3)-pyrimidyl, -CH(CH3)-pyrazyl, etc.
The term "optionally substituted" in reference to a particular moiety of the compound of Formula I-III (e.g., an optionally substituted aryl group) refers to a moiety wherein all substiutents are hydrogen or wherein one or more of the hydrogens of the moiety may be replaced by substituents such as those listed under the definition of "substituted".
The term "optionally replaced" in reference to a particular moiety of the compound of Formula I-III (e.g., the carbon atoms of said (C}-Cg)alkyl may be optionally replaced by -0-, -S-, or -NRa-) means that one or more of the methylene groups of the (Ci-C8)alkyl may be replaced by 0, 1, 2, or more of the groups specified (e.g., -0-, -S-, or -NRa-).
The term "non-terminal carbon atom(s)" in reference to an alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene moiety refers to the carbon atoms in the moiety that intervene between the first carbon atom of the moiety and the last carbon atom in the moiety. Therefore, by way of example and not limitation, in the alkyl moiety -CH2(C*)H2(C*)H2CH3 or alkylene moiety - CH2(C*)H2(C*)H2CH2- the C* atoms would be considered to be the non-terminal carbon atoms.
Certain Y and Y1 alternatives are nitrogen oxides such as +N(0)(R) or
+N(0)(OR). These nitrogen oxides, as shown here attached to a carbon atom, can
also be represented by charge separated groups such as
Figure imgf000041_0001
or
Figure imgf000041_0002
} respectively, and are intended to be equivalent to the
aforementioned representations for the purposes of describing this invention.
"Linker" or "link" means a chemical moiety comprising a covalent bond or a chain of atoms. Linkers include repeating units of alkyloxy (e.g. polyethyleneoxy, PEG, polym ethyl eneoxy) and alkylamino (e.g.
polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.
The terms such as "oxygen-linked", "nitrogen-linked", "carbon-linked", "sulfur-linked", or "phosphorous-linked" mean that if a bond between two moieties can be formed by using more than one type of atom in a moiety, then the bond formed between the moieties is through the atom specified. For example, a nitrogen-linked amino acid would be bonded through a nitrogen atom of the amino acid rather than through an oxygen or carbon atom of the amino acid.
In some embodiments of the compounds of Formula I-IV, one or more of
1 2
W or W are independently a radical of a nitrogen-linked naturally occurring a- amino acid ester. Examples of naturally occurring amino acids include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, selenocysteine, serine, tyrosine, argi ine, histidine, ornithine and taurine. The esters of these amino acids comprise any of those described for the substitutent R, particularly those in which R is optionally substituted (Ci-Cs)alkyl.
The term "purine" or "pyrimidine" base comprises, but is not limited to, adenine, N6-alkylpurines, N6-acylpurines (wherein acyl is C(0)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6- acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-allylaminopurine, N6-thioallyl purine, N2-alkylpurines, N2-alkyl-6-thiopurines, thymine, cytosine, 5- fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-ffuorouracil, C5- alkylpyrimidines, C5-benzylpyrimidines, C5-halopyrimidines, C5-vinylpyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5- amidopyrimidine, C5-cyanopyrimidine, C5-5-iodopyrimidine, C6-iodo-pyrimidine, C5-Br-vinyl pyrimidine, C6-Br-vinyl pyriniidine, C5-nitropyrimidine, C5-amino-
2 2
pyrimidine, N -alkylpurines, N -alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and
pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. The purine and pyrimidine bases of Formula I-III are linked to the ribose sugar, or analog thereof, through a nitrogen atom of the base. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl,
dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p- toluenesulfonyl.
Unless otherwise specified, the carbon atoms of the compounds of Formula I- IV are intended to have a valence of four. In some chemical structure representations where carbon atoms do not have a sufficient number of variables attached to produce a valence of four, the remaining carbon substitutents needed to provide a valence of four should be assumed to be hydrogen. For example,
has the same meaning
Figure imgf000043_0001
"Protecting group" refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructure of a protecting group varies widely. One function of a protecting group is to serve as an intermediate in the synthesis of the parental drug substance. Chemical protecting groups and strategies for protection/deprotection are well known in the art. See: "Protective Groups in Organic Chemistry", Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g. making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools.
Chemically protected intermediates may themselves be biologically active or inactive.
Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency in vivo than the parental drug. Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g. alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.
"Prodrug moiety" means a labile functional group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, "Design and Application of Prodrugs" in Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 1 13-191). Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases. Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy.
A prodrug moiety may include an active metabolite or drug itself.
Exemplary prodrug moieties include the hydrolytically sensitive or labile acyloxym ethyl esters -CH2OC(=0)R 30 and acyloxymethyl carbonates
-CH2OC(=0)OR30 where R30 is Ci-C6 alkyl, C,-C6 substituted alkyl, C6-C20 aryl or C6-C2o substituted aryl. The acyloxyalkyl ester was used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al (1983) J. Pharm. Sci. 72: 324; also- US Patent Nos. 4816570, 4968788, 5663159 and 5792756. In certain compounds of the invention, a prodrug moiety is part of a phosphate group. The acyloxyalkyl ester may be used to deliver phosphoric acids across cell membranes and to enhance oral bioavailability. A close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester
(carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the invention. An exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM) -CH2OC(=0)C(CH3)3. An exemplary acyloxymethyl carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC) -CH2OC(=0)OC(CH3)3.
The phosphate group may be a phosphate prodrug moiety. The prodrug moiety may be sensitive to hydrolysis, such as, but not limited to those comprising a pivaloyloxymethyl carbonate (POC) or POM group. Alternatively, the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.
Aryl esters of phosphorus groups, especially phenyl esters, are reported to enhance oral bioavailability (DeLambert et al (1994) J. Med. Chem. 37: 498).
Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described (Khamnei and Torrence, (1996) J. Med. Chem. 39:4109-4115). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the ortho-ov ara-position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, e.g. esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic C-0 bond to generate the phosphoric acid and the quinone methide intermediate. Examples of this class of prodrugs are described by Mitchell et al (1992) J. Chem. Soc. Perkin Trans. 72345; Brook et al WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic ester-containing group attached to the benzylic methylene (Glazier et al WO 91/19721). Thio-containing prodrugs are reported to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide. Deesterification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and episulfide (Puech et al (1993) Antiviral Res., 22: 155-174; Benzaria et al (1996) J. Med. Chem. 39: 4958). Cyclic phosphonate esters have also been described as prodrugs of phosphorus-containing compounds (Erion et al, US Patent No. 6312662).
It is to be noted that all enantiomers, diastereomers, and racemic mixtures, tautomers, polymorphs, pseudopolymorphs of compounds within the scope of Formula I- IV and pharmaceutically acceptable salts thereof are embraced by the present invention. All mixtures of such enantiomers and diastereomers are within the scope of the present invention.
A compound of Formula I-IV and its pharmaceutically acceptable salts may exist as different polymorphs or pseudopolymorphs. As used herein, crystalline polymorphism means the ability of a crystalline compound to exist in different crystal structures. The crystalline polymorphism may result from differences in crystal packing (packing polymorphism) or differences in packing between different conformers of the same molecule (conformational
polymorphism). As used herein, crystalline pseudopolymorphism means the ability of a hydrate or solvate of a compound to exist in different crystal structures. The pseudopolymorphs of the instant invention may exist due to differences in crystal packing (packing pseudopolymorphism) or due to differences in packing between different conformers of the same molecule (conformational pseudopolymorphism). The instant invention comprises all polymorphs and pseudopolymorphs of the compounds of Formula I-III and their pharmaceutically acceptable salts.
A compound of Formula I-IV and its pharmaceutically acceptable salts may also exist as an amorphous solid. As used herein, an amorphous solid is a solid in which there is no long-range order of the positions of the atoms in the solid. This definition applies as well when the crystal size is two nanometers or less. Additives, including solvents, may be used to create the amorphous forms of the instant invention. The instant invention comprises all amorphous forms of the compounds of Formula I-IV and their pharmaceutically acceptable salts.
Selected substituents comprising the compounds of Formula I-IV are present to a recursive degree. In this context, "recursive substituent" means that a substituent may recite another instance of itself. Because of the recursive nature of such substituents, theoretically, a large number of compounds may be present in any given embodiment. For example, Rx comprises a Ry substituent. Ry can be R. R can be W3. W3 can be W4 and W4 can be R or comprise substituents comprising Ry. One of ordinary skill in the art of medicinal chemistry
understands that the total number of such substituents is reasonably limited by the desired properties of the compound intended. Such properties include, by way of example and not limitation, physical properties such as molecular weight, solubility or log P, application properties such as activity against the intended target, and practical properties such as ease of synthesis.
By way of example and not limitation, W3 and Ry are recursive substituents in certain embodiments. Typically, each recursive substituent can independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 1 1, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 , or 0, times in a given embodiment. More typically, each recursive substituent can independently occur 12 or fewer times in a given embodiment. Even more typically, each recursive substituent can independently occur 3 or fewer times in a given embodiment. For example, W3 will occur 0 to 8 times, Ry will occur 0 to 6 times in a given embodiment. Even more typically, W3 will occur 0 to 6 times and Ry will occur 0 to 4 times in a given embodiment.
Recursive substituents are an intended aspect of the invention. One of ordinary skill in the art of medicinal chemistry understands the versatility of such substituents. To the degree that recursive substituents are present in an embodiment of the invention, the total number will be determined as set forth above.
The modifier "about" used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (e.g., includes the degree of error associated with measurement of the particular quantity).
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.
The term "therapeutically effective amount", as used herein, is the amount of compound of Formula I-IV present in a composition described herein that is needed to provide a desired level of drug in the secretions and tissues of the airways and lungs, or alternatively, in the bloodstream of a subject to be treated to give an anticipated physiological response or desired biological effect when such a composition is administered by the chosen route of administration. The precise amount will depend upon numerous factors, for example the particular compound of Formula I-IV, the specific activity of the composition, the delivery device employed, the physical characteristics of the composition, its intended use, as well as patient considerations such as severity of the disease state, patient cooperation, etc., and can readily be determined by one skilled in the art based upon the information provided herein.
The term "normal saline" means a water solution containing 0.9% (w/v)
NaCl. The term "hypertonic saline" means a water solution containing greater than 0.9% (w/v) NaCl. For example, 3% hypertonic saline would contain 3% (w/v) NaCl.
The compounds of the Formula I-IV may comprise a phosphate group as
R7, which may be a prodrug moiety
Figure imgf000049_0001
wherein each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2; W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R or R is -Y - and the other of W or W is Formula la; or W and W are each, independently, a group of Formula la:
Figure imgf000049_0002
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR),
+N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Ry is independently H, F, CI, Br, I, OH, R, -C(=Y')R, -C(=Y1)OR, - C(=Y])N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC^Y^R, -OC(=Y1)OR, -OC(=Y1)(N(R)2), -SC(=Y1)R, -SC(=Y1)OR, - SC(=Y1)(N(R)2), -N(R)C(=Y1)R, -N(R)C(=Y1)OR, or -N(R)C(=Y1)N(R)2, -S02NR2, -CN, -N3, -N02, -OR, a protecting group or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms; each R is independently Ry, a protecting group, or the formula:
Figure imgf000050_0001
wherein:
Mia, Ml c, and Mid are independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
each R is H, halogen, (Ci-Cs) alkyl, (Ci-C8) substituted alkyl, (C2-C8) alkenyl, (C2-C8) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, C6-C20 aryl, C6-C2o substituted aryl, C2-C2o heterocycle, C2-C20 substituted heterocyclyl, arylalkyl, substituted arylalkyl or a protecting group;
W3 is W4 or W5; W4 is R, -C(Y1)Ry, -C(Y')W5, -S02Ry, or -S02W5; and
W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups.
W5 carbocycles and W5 heterocycles may be independently substituted with 0 to 3 Ry groups. W5 may be a saturated, unsaturated or aromatic ring comprising a mono- or bi cyclic carbocycle or heterocycle. W5 may have 3 to 10 ring atoms, e.g., 3 to 7 ring atoms. The W5 rings are saturated when containing 3 ring atoms, saturated or mono-unsaturated when containing 4 ring atoms, saturated, or mono- or di-unsaturated when containing 5 ring atoms, and saturated, mono- or di-unsaturated, or aromatic when containing 6 ring atoms.
A W5 heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S). W5 heterocyclic monocycles may have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S); or 5 or 6 ring atoms (3 to 5 carbon atoms and 1 to 2 heteroatoms selected from N and S). W5 heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S) arranged as a bicyclo [4,5], [5,5], [5,6], or [6,6] system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 hetero atoms selected from N and S) arranged as a bicyclo [5,6] or [6,6] system. The W5 heterocycle may be bonded to Y through a carbon, nitrogen, sulfur or other atom by a stable covalent bond.
W5 heterocycles include for example, pyridyl, dihydropyridyl isomers, piperidine, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl. W5 also includes, but is not limited to, examples such as:
Figure imgf000051_0001
W5 carbocycles and heterocycles may be independently substituted with 0 to 3 R groups, as defined above. For example, substituted W5 carbocycles include:
Figure imgf000052_0001
Figure imgf000052_0002
Figure imgf000052_0003
Examples of substituted phenyl carbocycles include:
Figure imgf000052_0004
Embodiments of
Figure imgf000053_0001
of Formula I-IV compounds include substractures such as:
wherein each Y is, independently, O or N(R). In another aspect of this embodiment each Y is O and each Rx is independently:
Figure imgf000053_0003
M12c
wherein M12c is 1, 2 or 3 and each Y2 is independently a bond, O, CR2, or S. another aspect of this embodiment, one Y2 -Rx is NH(R) and the other Y2b-Rx 0-Rx wherein R is:
Figure imgf000053_0004
M12c
wherein Ml 2c is 2. In another aspect of this embodiment, each Y2b is O and each Rx is independently:
Figure imgf000054_0001
M12c
wherein Ml 2c is 2. In another aspect of this embodiment, each Y2b is O and each Rx is inde endently:
Figure imgf000054_0002
M12C
wherein Ml 2c is 1 and Y is a bond, O, or CR2.
Other embodiments of
Figure imgf000054_0003
of Formulas I-IV compounds include substructures such as:
Figure imgf000054_0004
wherein each Y is, independently, O or N(R). In another aspect of this embodiment, each Y is O. In another aspect of this embodiment, the substructure is:
Figure imgf000054_0005
wherein Ry is W5 as defined herein.
Another embodiment of
Figure imgf000055_0001
of Formula I-IV includes the substructures:
Figure imgf000055_0002
wherein each Ylc is, independently, O, N(Ry) or S.
Another embodiment of
Figure imgf000055_0003
of Formula I-IV compounds includes the substructures wherein one of W1 or W2 together with either R3 or R4
3 1 2
is -Y - and the other of W or W is Formula la. Such an embodiment is represented by a compound of Formula lb selected from:
Figure imgf000055_0004
Figure imgf000056_0001
Formula lb
In another aspect of the embodiment of Formula lb, each Y and Y3 is O. In another aspect of the embodiment of Formula lb, W1 or W2 is Y2b-Rx; each Y, Y3 and Y2b is O and Rx is:
Figure imgf000056_0002
M12c
wherein Ml 2c is 1, 2 or 3 and each Y is independently a bond, O, CR2, or S. In another aspect of the embodiment of Formula lb, W1 or W2 is Y2b-Rx; each Y, Y3 and Y2b is O and Rx is:
Figure imgf000056_0003
M12c
wherein M12c is 2. In another aspect of the embodiment of Formula lb, W1 or W2 is Y2b-Rx; each Y Y3 and Y2b is O and Rx is:
Figure imgf000056_0004
M12c
wherein Ml 2c is 1 and Y2 is a bond, O, or CR2. Another embodiment of
Figure imgf000057_0001
of Formula I-IV compounds includes a substructure:
Figure imgf000057_0002
wherein W is a carbocycle such as phenyl or substituted phenyl. In another aspect of this embodiment, th
Figure imgf000057_0003
wherein Y is O or N(R) and the phenyl carbocycle is substituted with 0 to 3 R groups. In another as ect of this embodiment of the substructure, Rx is:
Figure imgf000057_0004
M12c
wherein M12c is 1, 2 or 3 and each Y is independently a bond, O, CR2, or S.
Another embodiment of
Figure imgf000057_0005
I-IV includes substructures:
Figure imgf000058_0001
The chiral carbon of the amino acid and lactate moieties may be either the R or S configuration or the racemic mixture.
Another embodiment of
Figure imgf000058_0002
of Formula I-IV is substructure
Figure imgf000058_0003
wherein each Y2 is, independently, -O- or -NH-. In another aspect of this embodiment, Ry is (CrC8) alkyl, (Ci-C8) substituted alkyl, (C2-Cg) alkenyl, (C2- C8) substituted alkenyl, (C2-C8) alkynyl or (C2-Cg) substituted alkynyl. In another aspect of this embodiment, Ry is (Ci-Cg) alkyl, (Ci-Cg) substituted alkyl, (C2-Cg) alkenyl, (C2-Cg) substituted alkenyl, (C2-Cg) alkynyl or (C2-Cg) substituted alkynyl; and R is CH3. In another aspect of this embodiment, Ry is (Ci-C8) alkyl, (Ci-Cg) substituted alkyl, (C2-C8) alkenyl, (C2-C8) substituted alkenyl, (C2-C8) alkynyl or (C2-C8) substituted alkynyl; R is CH3; and each Y is -NH-. In another aspect of this embodiment, W and W are, independently, nitrogen-linked, naturally occurring amino acids or naturally occurring amino acid esters. In another aspect of this embodiment, W1 and W2 are, independently, naturally- occurring 2-hydroxy carboxylic acids or naturally-occurring 2-hydroxy carboxylic acid esters wherein the acid or ester is linked to P through the 2-hydroxy group.
Another embodiment of
Figure imgf000059_0001
of Formula I-IV is substructure:
Figure imgf000059_0002
In one aspect of this embodiment, each Rx is, independently, (C]-C8) alkyl. In another aspect of this embodiment, each Rx is, independently, C6-C2o aryl or C6 C2o substituted aryl.
In a preferred embodiment,
Figure imgf000059_0003
is selected from
Figure imgf000060_0001
Another embodiment of of Formulas I- IV is substructure
Figure imgf000060_0002
1 2
wherein W and W are independently selected from one of the formulas in Tables 20.1-20.37 and Table 30.1 below. The variables used in Tables 20.1-20.37 (e.g.,
23 21
W , R , etc.) pertain only to Tables 20.1-20.37, unless otherwise indicated.
The variables used in Tables 20.1 to 20.37 have the following definitions: each R is independently H or (Ci-Cg)alkyl;
each R is independently H, R 211, R π 2i3 or R ,/244t wherein each R ,244 is independently substituted with 0 to 3 R ; each R is independently R ja, R , R JC or R id, provided that when R is bound to a heteroatom, then R23 is R23c or R23d;
each R23a is independently F, CI, Br, I, -CN, N3 or -N02;
each R23b is independently Y21;
each R23c is independently -R2x, -N(R2x)(R2x), -SR2x, -S(0)R2x, -S(0)2R2x,
-S(0)(OR2x), -S(0)2(OR2x), -OC(=Y21)R2x, -OC(=Y21)OR2x, - OC(=Y21)(N(R2x)(R2x)), -SC(=Y21)R2x, -SC(=Y21)OR2x, -SC(=Y21)(N(R2x)(R2x)), - N(R2x)C(=Y21)R2x, -N(R2x)C(=Y21)OR2x, or -N(R2x)C(=Y21)(N(R2x)(R2x)) ;
each R23d is independently -C(=Y21)R2x, -C(=Y21)OR2x or - C(=Y21)(N(R2x)(R2x));
each R2x is independently H, (d-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl, heteroaryl; or two R2x taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NR21-; and wherein one or more of the non-terminal carbon atoms of each said (C1-C8)alkyl may be optionally replaced with -0-, -S- or -NR21-;
each R24 is independently (Ci-C8)alkyl, (C2-C8)alkenyl, or (C2-C8)alkynyl; each R25 is independently R24 wherein each R24 is substituted with 0 to 3
R 23 groups;
each R25a is independently (Ci-C8)alkylene, (C2-C8)alkenylene, or (C2-
C )alkynylene any one of which said (Ci-C8)alkylene, (C2-C8)alkenylene, or (C2- C8)alkynylene is substituted with 0-3 R groups;
each W23 is independently W24 or W25;
each W24 is independently R25, -C(=Y21)R25, -C(=Y21)W25, -S02R25, or - S02W25;
each W25 is independently carbocycle or heterocycle wherein W25 is
22
independently substituted with 0 to 3 R groups; and
each Y21 is independently O or S.
Figure imgf000062_0001
61
Figure imgf000063_0001
62
Figure imgf000064_0001
63
Figure imgf000065_0001
64
Figure imgf000066_0001
Figure imgf000066_0002
65
Figure imgf000067_0001
66
Figure imgf000068_0001
Table 20.14
Figure imgf000068_0002
Figure imgf000068_0003
Figure imgf000069_0001
Figure imgf000069_0002

Figure imgf000070_0001
Figure imgf000070_0002
109
Figure imgf000070_0003
Figure imgf000070_0004
Figure imgf000071_0001
Figure imgf000071_0002
70 Table 20.23
Figure imgf000072_0001
136 137 138 139
Table 20.24
Figure imgf000072_0002
144 145 146 147
Table 20.25
. Λ Λ. A
W23 ^R 5 ^R 4 R21 R23
148 149 150 151 152 153 W23 ^ R25 ✓ R24 R21 u ✓ R23
0 o o
154 155 156 157 158 159 Table 20.26
^ /R24
N N N N
1 I N N
1 I 1
H H H H H H
160 161 162 163 164 165
N N N N
I N N
J j I
R23 R23 R23 R23 R23
R23
166 167 168 169 170 171
Table 20.27
Figure imgf000073_0001
Figure imgf000073_0002
174 175
Figure imgf000073_0003
176 177
Figure imgf000073_0004
178 179 Table 20.28
Figure imgf000074_0001
Figure imgf000075_0001
74 Table 20.31
207
206
Table 20.32
Figure imgf000076_0002
208 209
Figure imgf000076_0003
212
Figure imgf000077_0001
76 Table 20.34
Figure imgf000078_0001
222 223
Figure imgf000078_0002
Table 20.35
R5a X p25a r
O
228 O
229
Figure imgf000078_0003
Figure imgf000078_0004
Table 20.36
Figure imgf000079_0001
Figure imgf000079_0002
Figure imgf000079_0003
Figure imgf000079_0004
Figure imgf000079_0005
Figure imgf000080_0001
 Embodiments of Rx include esters, carbamates, carbonates, thioesters, amides thioamides, and urea groups:
Figure imgf000081_0001
Any reference to the compounds of the invention described heerein also includes a reference to a physiologically acceptable salt thereof. Examples of physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal or an alkaline earth (for example, Na+, Li+ K+> Ca+2 and Mg+2), ammonium and NR4 (wherein R is defined herein). Physiologically acceptable salts of a nitrogen atom or an amino group include (a) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acids, phosphoric acid, nitric acid and the like; (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, sulfosalicylic acid, glycolic acid, 2-hydroxy-3-naphthoate, pamoate, salicylic acid, stearic acid, phthalic acid, mandelic acid, lactic acid, ethanesulfonic acid, lysine, arginine, glutamic acid, glycine, serine, threonine, alanine, isoleucine, leucine and the like; and (c) salts formed from elemental anions for example, chlorine, bromine, and iodine. Physiologically acceptable salts of a compound of a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+ and NR4 +. For therapeutic use, salts of active ingredients of the compounds of the invention will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base. However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.
Finally, it is to be understood that the compositions herein comprise compounds of the invention in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
The compounds of the invention, exemplified by Formula I- IV may have chiral centers, e.g. chiral carbon or phosphorus atoms. The compounds of the invention thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers. In addition, the compounds of the invention include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures. Both racemic and
diastereomeric mixtures, as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the invention. The racemic mixtures are separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with optically active adjuncts, e.g., acids or bases followed by conversion back to the optically active substances. In most instances, the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.
The term "chiral" refers to molecules which have the property of non- superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner. The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
"Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another.
Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, reactivities and biological properties. For example, the compounds of Formula I-IV may have a chiral phosphorus atom when R7 is
Figure imgf000083_0001
and W1 and W2 are different. When at least one of either W or W also has a chiral center, for example with W or W is a nitrogen-linked, chiral, naturally occurring ot-amino acid ester, then the compound of Formula I-IV will exists as diastereomers because there are two centers of chirality in the molecule. All such diastereomers and their uses described herein are
encompassed by the instant invention. Mixtures of diastereomers may be separate under high resolution analytical procedures such as electrophoresis, crystallization and/or chromatography. Diastereomeres may have different physical attributes such as, but not limited to, solubility, chemical stabilities and crystallinity and may also have different biological properties such as, but not limited to, enzymatic stability, absorption and metabolic stability.
"Enantiomers" refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw- Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1, D and L, or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with S, (-), or 1 meaning that the compound is levorotatory while a compound prefixed with R, (+), or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
Whenever a compound described herein is substituted with more than one of the same designated group, e.g., "R" or "R1", then it will be understood that the groups may be the same or different, i.e., each group is independently selected. Wavy lines, - , indicate the site of covalent bond attachments to the adjoining substructures, groups, moieties, or atoms.
The compounds of the invention can also exist as tautomeric isomers in certain cases. Although only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention. For example, ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention.
Methods of Inhibition of a Paramyxoviridae polymerase
Another aspect of the invention relates to methods of inhibiting the activity of Paramyxoviridae polymerase comprising the step of treating a sample suspected of containing Paramyxoviridae with a composition of the invention.
Compositions of the invention may act as inhibitors of Paramyxoviridae polymerase , as intermediates for such inhibitors or have other utilities as described below. The inhibitors will bind to locations on the surface or in a cavity of Paramyxoviridae polymerase having a geometry unique to Paramyxoviridae polymerase . Compositions binding Paramyxoviridae polymerase may bind with varying degrees of reversibility. Those compounds binding substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, the substantially irreversibly binding compositions are useful as probes for the detection of Paramyxoviridae polymerase. Accordingly, the invention relates to methods of detecting Paramyxoviridae polymerase in a sample suspected of containing Paramyxoviridae polymerase comprising the steps of: treating a sample suspected of containing Paramyxoviridae polymerase with a composition comprising a compound of the invention bound to a label; and observing the effect of the sample on the activity of the label. Suitable labels are well known in the diagnostics field and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens. The compounds herein are labeled in conventional fashion using functional groups such as hydroxyl, carboxyl, sulfhydryl or amino.
Within the context of the invention, samples suspected of containing
Paramyxoviridae polymerase include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein; and the like. Typically the sample will be suspected of containing an organism which produces Paramyxoviridae polymerase, frequently a pathogenic organism such as a Paramyxoviridae virus. Samples can be contained in any medium including water and organic
solvent\water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.
The treating step of the invention comprises adding the composition of the invention to the sample or it comprises adding a precursor of the composition to the sample. The addition step comprises any method of administration as described above.
If desired, the activity of Paramyxoviridae polymerase after application of the composition can be observed by any method including direct and indirect methods of detecting Paramyxoviridae polymerase activity. Quantitative, qualitative, and semiquantitative methods of determining Paramyxoviridae polymerase activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.
Organisms that contain Paramyxoviridae polymerase include the
Paramyxoviridae virus. The compounds of this invention are useful in the treatment or prophylaxis of Paramyxoviridae infections in animals or in man.
However, in screening compounds capable of inhibiting human
Paramyxoviridae viruses, it should be kept in mind that the results of enzyme assays may not correlate with cell culture assays. Thus, a cell based assay should be the primary screening tool.
Screens for Paramyxoviridae polymerase Inhibitors.
Compositions of the invention are screened for inhibitory activity against
Paramyxoviridae polymerase by any of the conventional techniques for evaluating enzyme activity. Within the context of the invention, typically compositions are first screened for inhibition of Paramyxoviridae polymerase in vitro and compositions showing inhibitory activity are then screened for activity in vivo. Compositions having in vitro Ki (inhibitory constants) of less then about 5 X 10~6
M and preferably less than about 1 X 10" M are preferred for in vivo use.
Useful in vitro screens have been described in detail and will not be elaborated here. However, the examples describe suitable in vitro assays.
Pharmaceutical Formulations
The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous
formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the "Handbook of
Pharmaceutical Excipients" (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the formulations ranges from about 3 to about 1 1 , but is ordinarily about 7 to 10.
While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients, particularly those additional therapeutic ingredients as discussed herein. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.
A tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
For infections of the eye or other external tissues e.g. mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.
If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
Pharmaceutical formulations according to the present invention comprise a combination according to the invention together with one or more
pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium
carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally-occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally-occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain
approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10%, and particularly about 1.5% w/w.
Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns, such as 0.5, 1, 30, 35 etc., which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient.
Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of Paramyxoviridae infections as described below.
In another aspect, the invention is a novel, efficacious, safe, nonirritating and physiologically compatible inhalable composition comprising a compound of Formula I-IV, or a pharmaceutically acceptable salt thereof, suitable for treating Paramyxoviridae infections and potentially associated bronchiolitis. Preferred pharmaceutically acceptable salts are inorganic acid salts including hydrochloride, hydrobromide, sulfate or phosphate salts as they may cause less pulmonary irritation. Preferably, the inhalable formulation is delivered to the endobronchial space in an aerosol comprising particles with a mass median aerodynamic diameter (MMAD) between about 1 and about 5 μιη. Preferably, the compound of Formula I-IV is formulated for aerosol delivery using a nebulizer, pressurized metered dose inhaler (pMDI), or dry powder inhaler (DPI).
Non-limiting examples of nebulizers include atomizing, jet, ultrasonic, pressurized, vibrating porous plate, or equivalent nebulizers including those nebulizers utilizing adaptive aerosol delivery technology (Denyer, J. Aerosol medicine Pulmonary Drug Delivery 2010, 23 Supp 1 , S1 -S10). A jet nebulizer utilizes air pressure to break a liquid solution into aerosol droplets. An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets. A pressurized nebulization system forces solution under pressure through small pores to generate aerosol droplets. A vibrating porous plate device utilizes rapid vibration to shear a stream of liquid into appropriate droplet sizes.
In a preferred embodiment, the formulation for nebulization is delivered to the endobronchial space in an aerosol comprising particles with a MMAD predominantly between about 1 μιη and about 5 μπι using a nebulizer able to aerosolize the formulation of the compound of Formula I-IV into particles of the required MMAD. To be optimally therapeutically effective and to avoid upper respiratory and systemic side effects, the majority of aerosolized particles should not have a MMAD greater than about 5 μπι. If an aerosol contains a large number of particles with a MMAD larger than 5 μιη, the particles are deposited in the upper airways decreasing the amount of drug delivered to the site of inflammation and bronchoconstriction in the lower respiratory tract. If the MMAD of the aerosol is smaller than about 1 μηι , then the particles have a tendency to remain suspended in the inhaled air and are subsequently exhaled during expiration.
When formulated and delivered according to the method of the invention, the aerosol formulation for nebulization delivers a therapeutically efficacious dose of the compound of Formula I-IV to the site of Paramyxoviridae infection sufficient to treat the Paramyxoviridae infection. The amount of drug
administered must be adjusted to reflect the efficiency of the delivery of a therapeutically efficacious dose of the compound of Formula I-IV. In a preferred embodiment, a combination of the aqueous aerosol formulation with the atomizing, jet, pressurized, vibrating porous plate, or ultrasonic nebulizer permits, depending on the nebulizer, about, at least, 20, to about 90%, typically about 70% delivery of the administered dose of the compound of Formula I-IV into the airways. In a preferred embodiment, at least about 30 to about 50% of the active compound is delivered. More preferably, about 70 to about 90% of the active compound is delivered.
In another embodiment of the instant invention, a compound of Formula I- IV or a pharmaceutically acceptable salt thereof, is delivered as a dry inhalable powder. The compounds of the invention are administered endobronchially as a dry powder formulation to efficacious deliver fine particles of compound into the endobronchial space using dry powder or metered dose inhalers. For delivery by DPI, the compound of Formula I-IV is processed into particles with,
predominantly, MMAD between about 1 μηι and about 5 μιη by milling spray drying, critical fluid processing, or precipitation from solution. Media milling, jet milling and spray-drying devices and procedures capable of producing the particle sizes with a MMAD between about 1 μχη and about 5 μηι are well know in the art. In one embodiment, excipients are added to the compound of Formula I-IV before processing into particles of the required sizes. In another embodiment, excipients are blended with the particles of the required size to aid in dispersion of the drug particles, for example by using lactose as an excipient. Particle size determinations are made using devices well known in the art. For example a multi-stage Anderson cascade impactor or other suitable method such as those specifically cited within the US Pharmacopoeia Chapter 601 as characterizing devices for aerosols within metered-dose and dry powder inhalers.
In another preferred embodiment, a compound of Formula I- IV is delivered as a dry powder using a device such as a dry powder inhaler or other dry powder dispersion devices. Non-limiting examples of dry powder inhalers and devices include those disclosed in US5,458,135; US5,740,794; US5775320;
US5,785,049; US3,906,950; US4,013,075; US4,069,819; US4,995,385;
US5,522,385; US4,668,218; US4,667,668; US4,805,811 and US5,388,572. There are two major designs of dry powder inhalers. One design is a metering device in which a reservoir for the drug is place within the device and the patient adds a dose of the drug into the inhalation chamber. The second design is a factory- metered device in which each individual dose has been manufactured in a separate container. Both systems depend on the formulation of the drug into small particles of MMAD from 1 μιη and about 5 μιη, and often involve co-formulation with larger excipient particles such as, but not limited to, lactose. Drug powder is placed in the inhalation chamber (either by device metering or by breakage of a factory-metered dosage) and the inspiratory flow of the patient accelerates the powder out of the device and into the oral cavity. Non-laminar flow
characteristics of the powder path cause the excipient-drug aggregates to decompose, and the mass of the large excipient particles causes their impaction at the back of the throat, while the smaller drug particles are deposited deep in the lungs. In preferred embodiments, a compound of Formula I-IV, or a
pharmaceutically acceptable salt thereof, is delivered as a dry powder using either type of dry powder inhaler as described herein, wherein the MMAD of the dry powder, exclusive of any excipients, is predominantly in the range of 1 μηα to about 5 μπι.
In another preferred embodiment, a compound of Formula I-IV is delivered as a dry powder using a metered dose inhaler. Non-limiting examples of metered dose inhalers and devices include those disclosed in US5,261,538; US5,544,647; US5,622,163; US4,955,371 ; US3,565,070; US3,361306 and US6,1 16,234. In preferred embodiments, a compound of Formula I-IV, or a pharmaceutically acceptable salt thereof, is delivered as a dry powder using a metered dose inhaler wherein the MMAD of the dry powder, exclusive of any e cipients, is predominantly in the range of about 1-5 μιη.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
The formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
The invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary earner therefor.
Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
Compounds of the invention are used to provide controlled release pharmaceutical formulations containing as active ingredient one or more compounds of the invention ("controlled release formulations") in which the release of the active ingredient are controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given active ingredient.
Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used
prophylactically (lower doses) or against an active viral infection, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be from about 0.0001 to about 100 mg/kg body weight per day; typically, from about 0.01 to about 10 mg/kg body weight per day; more typically, from about .01 to about 5 mg/kg body weight per day; most typically, from about .05 to about 0.5 mg/kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses. Routes of Administration
One or more compounds of the invention (herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
Combination Therapy Compositions of the invention are also used in combination with other active ingredients. For the treatment of Paramyxoviridae virus infections, preferably, the other active therapeutic agent is active against Paramyxoviridae virus infections, particularly respiratory syncytial virus infections and/or parainfluenza virus infections. Non-limiting examples of these other active therapeutic agents are ribavirin, palivizumab, motavizumab, RSV-IGIV
(RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, and mixtures thereof.
Many of the infections of the Paramyxoviridae viruses are respiratory infections. Therefore, additional active therapeutics used to treat respiratory symptoms and sequelae of infection may be used in combination with the compounds of Formula I-IV. The additional agents are preferrably administered orally or by direct inhalation. For example, other preferred additional therapeutic agents in combination with the compounds of Formula I-IV for the treatment of viral respiratory infections include, but are not limited to, bronchodilators and corticosteroids.
Glucocorticoids, which were first introduced as an asthma therapy in 1950 (Carryer, Journal of Allergy, 21, 282-287, 1950), remain the most potent and consistently effective therapy for this disease, although their mechanism of action is not yet fully understood (Morris, J. Allergy Clin. Immunol., 75 (1 Pt) 1-13,
1985). Unfortunately, oral glucocorticoid therapies are associated with profound undesirable side effects such as truncal obesity, hypertension, glaucoma, glucose intolerance, acceleration of cataract formation, bone mineral loss, and
psychological effects, all of which limit their use as long-term therapeutic agents (Goodman and Gilman, 10th edition, 2001). A solution to systemic side effects is to deliver steroid drugs directly to the site of inflammation. Inhaled
corticosteroids (ICS) have been developed to mitigate the severe adverse effects of oral steroids. Non-limiting examples of corticosteroids that may be used in combinations with the compounds of Formula I-IV are dexamethasone, dexamethasone sodium phosphate, fluorometholone, fluorometholone acetate, loteprednol, loteprednol etabonate, hydrocortisone, prednisolone, fludrocortisones, triamcinolone, triamcinolone acetonide, betamethasone, beclomethasone diproprionate, methylprednisolone, fluocinolone, fluocinolone acetonide, flunisolide, fluocortin-21-butylate, flumethasone, flumetasone pivalate, budesonide, halobetasol propionate, mometasone furoate, fluticasone propionate, ciclesonide; or a pharmaceutically acceptable salts thereof.
Other anti-infiamatory agents working through anti-inflamatory cascade mechanisms are also useful as additional therapeutic agents in combination with the compounds of Formula I-IV for the treatment of viral respiratory infections. Applying "anti-inflammatory signal transduction modulators" (referred to in this text as AISTM), like phosphodiesterase inhibitors (e.g. PDE-4, PDE-5, or PDE-7 specific), transcription factor inhibitors (e.g. blocking NFKB through IKK inhibition), or kinase inhibitors (e.g. blocking P38 MAP, JNK, PI3K, EGFR or Syk) is a logical approach to switching off inflammation as these small molecules target a limited number of common intracellular pathways - those signal transduction pathways that are critical points for the anti-inflammatory therapeutic intervention (see review by P.J. Barnes, 2006). These non-limiting additional therapeutic agents include: 5-(2,4-Difluoro-phenoxy)-l-isobutyl-lH-indazole-6- carboxylic acid (2-dimethylamino-ethyl)-amide (P38 Map kinase inhibitor ARRY-797); 3-Cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4- difluorormethoxy-benzamide (PDE-4 inhibitor Roflumilast); 4-[2-(3- cyclopentyloxy-4-methoxyphenyl)-2-phenyl-ethyl]-pyridine (PDE-4 inhibitor CDP-840); N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-8- [(methylsulfonyl)amino]- 1 -dibenzofurancarboxamide (PDE-4 inhibitor
Oglemilast); N-(3,5-Dichloro-pyridin-4-yl)-2-[l-(4-fluorobenzyl)-5-hydroxy-lH- indol-3-yl]-2-oxo-acetamide (PDE-4 inhibitor A WD 12-281); 8-Methoxy-2- trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-l -oxy-pyridin-4-yl)- amide (PDE-4 inhibitor Sch 351591); 4-[5-(4-Fluorophenyl)-2-(4- methanesulfmyl-phenyl)-lH-imidazol-4-yl]-pyridine (P38 inhibitor SB-203850); 4-[4-(4-Fluoro-phenyl)- 1 -(3-phenyl-propyl)-5-pyridin-4-yl- 1 H-imidazol-2-yl]- but-3-yn-l-ol (P38 inhibitor RWJ-67657); 4-Cyano-4-(3-cyclopentyloxy-4- methoxy-phenyl)-cyclohexanecarboxylic acid 2-diethylamino-ethyl ester (2- diethyl-ethyl ester prodrug of Cilomilast, PDE-4 inhibitor); (3-Chloro-4- fluorophenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (Gefitinib, EGFR inhibitor); and 4-(4-Methyl-piperazin-l-ylmethyl)-N-[4-methyl- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (Imatinib, EGFR inhibitor).
Combinations comprising inhaled p2-adrenoreceptor agonist
bronchodilators such as formoterol, albuterol or salmeterol with the compounds of Formula I-IV are also suitable, but non-limiting, combinations useful for the treatment of respiratory viral infections.
Combinations of inhaled p2-adrenoreceptor agonist bronchodilators such as formoterol or salmeterol with ICS's are also used to treat both the
bronchoconstriction and the inflammation (Symbicort® and Advair®,
respectively). The combinations comprising these ICS and p2-adrenoreceptor agonist combinations along with the compounds of Formula I-IV are also suitable, but non-limiting, combinations useful for the treatment of respiratory viral infections.
For the treatment or prophylaxis of pulmonary broncho-constriction, anticholinergics are of potential use and, therefore, useful as an additional therapeutic agents in combination with the compounds of Formula I-IV for the treatment of viral respiratory infections. These anticholinergics include, but are not limited to, antagonists of the muscarinic receptor (particularly of the M3 subtype) which have shown therapeutic efficacy in man for the control of cholinergic tone in COPD (Witek, 1999); l - {4-Hydroxy-l-[3,3,3-tris-(4-fluoro- phenyl)-propionyl]-pyrrolidine-2-carbonyl}-pyrrolidine-2-carboxylic acid (1- methyl-piperidin-4-ylmethyl)-amide; 3-[3-(2-Diethylamino-acetoxy)-2-phenyl- propionyloxy]-8-isopropyl-8-methyl-8-azonia-bicyclo[3.2.1]octane (Ipratropium- N,N-di ethyl glycinate); 1 -Cyclohexyl-3 ,4-dihydro- 1 H-isoquinoline-2-carboxylic acid l-aza-bicyclo[2.2.2]oct-3-yl ester (Solifenacin); 2-Hydroxymethyl-4- methanesulfmyl-2-phenyl-butyric acid l-aza-bicyclo[2.2.2]oct-3-yl ester
(Revatropate): 2-{l-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-pyiTolidin-3-yl}-2,2- diphenyl-acetamide (Darifenacin); 4-Azepan-l -yl-2,2-diphenyl-butyramide (Buzepide); 7-[3-(2-Diethylamino-acetoxy)-2-phenyl-propionyloxy]-9-ethyl-9- methyl-3-oxa-9-azonia-tricyclo[3.3.1.02,4]nonane (Oxitropium-N,N- diethylglycinate); 7-[2-(2-Diethylamino-acetoxy)-2,2-di-thiophen-2-yl-acetoxy]- 9,9-dimethyl-3-oxa-9-azonia-tricyclo[3.3.1.02,4]nonane (Tiotropium-N,N- diethylglycinate); Dimethylamino-acetic acid 2-(3-diisopropylamino-l-phenyl- propyl)-4-methyl-phenyl ester (Tolterodine-N,N-dimethylglycinate); 3-[4,4-Bis- (4-fluoro-phenyl)-2-oxo-imidazolidin- 1 -yl]-l -methyl- 1 -(2-oxo-2-pyridin-2-yl- ethyl)-pyrrolidinium; l-[l-(3-Fluoro-benzyl)-piperidin-4-yl]-4,4-bis-(4-fluoro- phenyl)-imidazolidin-2-one; l-Cyclooctyl-3-(3-methoxy-l-aza-bicyclo[2.2.2]oct- 3-yl)-l-phenyl-prop-2-yn-l-ol; 3-[2-(2-Diethylamino-acetoxy)-2,2-di-thiophen-2- yl-acetoxy] - 1 -(3 -phenoxy-propyl)- 1 -azonia-bicyclo[2.2.2]octane (Aclidinium- N,N-di ethyl glycinate); or (2-Diethylamino-acetoxy)-di-thiophen-2-yl-acetic acid 1 -methyl- 1 -(2-phenoxy-ethyl)-piperidin-4-yl ester.
The compounds of Formula I-IV may also be combined with mucolytic agents to treat both the infection and symptoms of respiratory infections. A non- limiting example of a mucolytic agent is ambroxol. Similarly, the compounds of Formula I-IV may be combined with expectorants to treat both the infection and symptoms of respiratory infections. A non-limiting example of an expectorant is guaifenesin.
Nebulized hypertonic saline is used to improve immediate and lon-term clearance of small airways in patients with lung diseases (Kuzik, J. Pediatrics 2007, 266). The compounds of Formula I-IV may also be combined with nebulized hypertonic saline particularly when the Paramyxoviridae virus infection is complicated with bronchiolitis. The combination of the compounds of Formula I-IV with hypertonic saline may also comprise any of the additional agents discussed above. In a preferred aspect, nebulized about 3% hypertonic saline is used.
It is also possible to combine any compound of the invention with one or more additional active therapeutic agents in a unitary dosage form for
simultaneous or sequential administration to a patient. The combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more
administrations.
Co-administration of a compound of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the compound of the invention and one or more other active therapeutic agents are both present in the body of the patient.
Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the
administration of one or more other active therapeutic agents. For example, a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents. Alternatively, a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes. In some cases, it may be desirable to administer a unit dose of a compound of the invention first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention.
The combination therapy may provide "synergy" and "synergistic", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately. A synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g. in separate tablets, pills or capsules, or by different injections in separate syringes. In general, during alternation therapy, an effective dosage of each active ingredient is administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together. A synergistic anti-viral effect denotes an antiviral effect which is greater than the predicted purely additive effects of the individual compounds of the combination.
In still yet another embodiment, the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
contacting a cell infected with HCV with an effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, whereby Paramyxoviridae polymerase is inhibited.
In still yet another embodiment, the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
contacting a cell infected with HCV with an effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent, whereby Paramyxoviridae polymerase is inhibited.
In still yet another embodiment, the present application provides for methods of inhibiting Paramyxoviridae polymerase in a cell, comprising:
contacting a cell infected with Paramyxoviridae virus with an effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent selected In still yet another embodiment, the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In still yet another embodiment, the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent, whereby Paramyxoviridae polymerase is inhibited.
In still yet another embodiment, the present application provides for methods of treating Paramyxoviridae virus infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active therapeutic agent.
Metabolites of the Compounds of the Invention
Also falling within the scope of this invention are the in vivo metabolic products of the compounds described herein, to the extent such products are novel and unobvious over the prior art. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes novel and unobvious compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabelled (e.g. or compound of the invention, administering it parenterally in a detectable dose (e.g. greater than about 0.5 mg kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g. by MS or NM analysis. In general, analysis of metabolites is done in the same way as conventional drag metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no HCV polymerase inhibitory activity of their own.
Recipes and methods for determining stability of compounds in surrogate gastrointestinal secretions are known. Compounds are defined herein as stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in surrogate intestinal or gastric juice upon incubation for 1 hour at 37°C. Simply because the compounds are stable to the gastrointestinal tract does not mean that they cannot be hydrolyzed in vivo. The prodrugs of the invention typically will be stable in the digestive system but may be substantially hydrolyzed to the parental drag in the digestive lumen, liver or other metabolic organ, or within cells in general.
Examples
Certain abbreviations and acronyms are used in describing the
experimental details. Although most of these would be understood by one skilled in the art, Table 1 contains a list of many of these abbreviations and acronyms.
Table 1. List of abbreviations and acronyms.
Figure imgf000105_0001
DCC dicyclohexylcarbodiimide
DCM dichloromethane
DMAP 4-dimethylaminopyridine
DME 1 ,2-dimethoxyethane
DMTC1 dimethoxytrityl chloride
DMSO dimethylsulfoxide
DMTr 4, 4' -dimethoxytrityl
DMF dim ethylform amide
EtOAc ethyl acetate
ESI electrospray ionization
HMDS hexamethyldisilazane
HPLC High pressure liquid chromatography
LDA lithium diisopropylamide
LRMS low resolution mass spectrum
MCPBA meta-chloroperbenzoic acid
MeCN acetonitrile
MeOH methanol
MMTC mono methoxytrityl chloride m/z or m/e mass to charge ratio
MH+ mass plus 1
MH" mass minus 1
MsOH methanesulfonic acid
MS or ms mass spectrum
NBS N-bromo succinimide
Ph phenyl
rt or r.t. room temperature
TBAF tetrabutyl ammonium fluoride
TMSC1 chlorotrimethylsilane
TMSBr bromotrimethylsilane
TMSI iodotrimethylsilane TMSOTf (trimethylsilyl)trifluoromethylsulfonate
TEA triethylamine
TBA tributylamine
TBAP tributylammonium pyrophosphate
TBSC1 t-butyldimethylsilyl chloride
TEAB triethylammonium bicarbonate
TFA trifluoroacetic acid
TLC or tic thin layer chromatography
Tr triphenylmethyl
Tol 4-methylbenzoyl
Turbo 1 : 1 mixture of isopropylmagnesium chloride and lithium Grignard chloride
δ parts per million down field from tetramethylsilane
Preparation of Compounds
(2S)-ethyl 2-(chloro(phenoxy)phosphorylamiiio)propanoate (Chloridate A)
Figure imgf000107_0001
Ethyl alanine ester hydrochloride salt (1.69 g, 1 1 mmol) was dissolved in anhydrous CH2CI2 (10 mL) and the mixture stirred with cooling to 0 °C under N2(g). Phenyl dichlorophosphate (1.49 mL, 10 mmol) was added followed by dropwise addition of Et3N over 10 min. The reaction mixture was then slowly warmed to RT and stirred for 12 h. Anhydrous Et20 (50 mL) was added and the mixture stirred for 30 min. The solid that formed was removed by filtration, and the filtrate concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-50% EtOAc in hexanes to provide intermediate A (1.13 g, 39%).
1H NMR (300 MHz, CDC13) δ 7.39-7.27 (m, 5H), 4.27 (m, 3H), 1.52 (m, 3H), 1.32 (m, 3H).
31P NMR (121.4 MHz, CDC13) δ 8.2, 7.8.
(2S)-2-ethvlbutvl 2-(chIoro(phenoxy)phosphorylamino)propanoate
(Chloridate B)
Figure imgf000108_0001
The 2-ethylbutyl alanine chlorophosphoramidate ester B was prepared using the same procedure as chloridate A except substituting 2-ethylbutyl alanine ester for ethyl alanine ester. The material is used crude in the next reaction.
Treatment with methanol or ethanol forms the displaced product with the requisite LCMS signal.
(2S)-isopropyI 2-(chloro(phenoxy)phosphoryIamino)propanoate (Chloridate C
Figure imgf000108_0002
C The isopropyl alanine chlorophosphoramidate ester C was prepared using the same procedure as chloridate A except substituting isopropyl alanine ester for the ethyl alanine ester. The material is used crude in the next reaction. Treatment with methanol or ethanol forms the displaced product with the requisite LCMS signal.
(2R, 3R. 4S. 5R)-2-(4-aminopv rrolo[ i -f| | 1.2.4|triazm-7-vl)-3.4-dihvdrox\-5- (hydroxymethyl)tetrahvdrofuran-2-carbonitrile (Compound 1)
Figure imgf000110_0001
The commercially available lactol (10 g, 23.8 mmol) was dissolved in anhydrous DMSO (30 mL) under N2(g). Ac20 (20 mL) was added and the resultant reaction mixture stirred at RT for 48 h. The reaction mixture was poured onto ice H20 (500 mL) and the mixture stirred for 20 min. The mixture was extracted with EtOAc (3 x 200 mL) and the combined organic extracts were then washed with H20 (3 x 200 mL). The organic extract was dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The residue was dissolved in CH2C12 and subjected to silica gel chromatography eluting with 25% EtOAc in hexanes to provide the lactone (9.55 g, 96%).
lH NMR (400 MHz, DMSO) δ 7.30-7.34 (m, 13H), 7.19-7.21 (m, 2H), 4.55-4.72 (m, 6H), 4.47 (s, 2H), 4.28 (d, J = 3.9 Ηζ,ΙΗ), 3.66 (m, 2H).
LCMS m/z 436.1 [M+H20], 435.2 [M+OH]- Tr = 2.82 min
HPLC Tr = 4.59 [2-98% ACN in H2) over 5 min @ 2ml / min flow.
Figure imgf000110_0002
The bromopyrazole (prepared according to WO2009/132135) (0.5 g, 2.4 mmol) was suspended in anhydrous THF (10 mL) under N2(g). The suspension was stirred and TMSC1 (0.67 mL, 5.28 mmol) was added. The mixture was stirred for 20 min. at RT and then cooled to -78 °C after which time a solution of n-BuLi (6 mL, 1.6 N in hexanes, 9.6 mmol) was added slowly. The reaction mixture was stirred for 10 min. at -78 °C and then the lactone (1 g, 2.4 mmol) was added via syringe. When the reaction was complete as measured by LCMS, AcOH was added to quench the reaction. The mixture was concentrated under reduced pressure and the residue dissolved in a mixture of CH2C12 and H20 (100 mL, 1 :1). The organic layer was separated and washed with H20 (50 mL). The organic layer was then dried over anhydrous MgSC>4, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with
0-50% EtOAc in hexanes to provide the product as a 1 :1 mixture of anomers (345 mg, 26% yield).
LCMS m/z 553 [M+H].
Figure imgf000111_0001
The hydroxy nucleoside (1.1 g, 2.0 mmol) was dissolved in anhydrous CH2CI2 (40 mL) and the solution cooled with stirring to 0 °C under N2(g).
TMSCN (0.931 mL, 7 mmol) was added and the mixture stirred for a further 10 min. TMSOTf (1.63 mL, 9.0 mmol) was slowly added to the reaction and the mixture stirred for 1 h. The reaction mixture was then diluted with CH2CI2 (120 mL) and aqueous NaHC03 (120 mL) was added to quench the reaction. The reaction mixture was stirred for a further 10 min and the organic layer separated. The aqueous layer was extracted with CH2CI2 (150 mL) and the combined organic extracts dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The residue was dissolved in a minimal amount of CH2CI2 and subjected to silica gel chromatography eluting with a gradient of 0-75% EtOAc and hexanes to provide the tribenzyl cyano nucleoside as a mixture of anomers.
(0.9 g, 80%).
'H MR (300 MHz, CD3CN) δ 7.94 (s, 0.5H), 7.88 (s, 0.5H), 7.29-7.43 (m, 13H), 7.11-7.19 (m, 1H), 6.82-6.88 (m,lH), 6.70-6.76 (m, 1H), 6.41 (bs, 2H), 5.10 (d, J = 3.9 Hz, 0.5H), 4.96 (d, J = 5.1 Hz, 0.5H), 4.31-4.85 (m, 7H), 4.09-4.18 (m, 2H), 3.61-3.90 (m, 2H).
LCMS m/z 562 [M+H].
Figure imgf000112_0001
The tribenzyl cyano nucleoside (70 mg, 0.124 mmol) was dissolved in anhydrous CH2Cl2 (2 mL) and cooled to -78 °C under N2(g). A solution of BC13 (IN in CH2C12, 0.506 mL, 0.506 mmol) was added and the reaction mixture stirred for 1 h. at -78 °C. When the reaction was complete by LC/MS, MeOH was added to quench the reaction. The reaction mixture was allowed to warm to room RT and the solvent removed under reduced pressure. The residue was subjected to CI 8 reverse phase HPLC, eluting for 5 min with H20 (0.1 % TFA), followed by a gradient of 0-70% MeCN in H20 (0.1 % TFA) over 35 min, to elute the a-anomer (20 mg, 37%), and β-anomer 1 (20 mg, 37%).
(a-anomer)
1H NMR (300 MHz, D20) δ 7.96 (s, 1H), 7.20 (d, J= 4.8 Hz, 1H), 6.91 (d, J= 4.8 Hz, 1H), 4.97 (d, J= 4.4 Hz, 1H), 4.56-4.62 (m, 1H), 4.08-4.14 (m, 1H), 3.90 (dd, J = 12.9, 2.4 Hz, 1H), 3.70 (dd, J = 13.2, 4.5 Hz, 1H).
(β-anomer) 1H NMR (400 MHz, DMSO) δ 7.91 (s, 1H), 7.80-8.00 (br s, 2H), 6.85-6.89 (m, 2H), 6.07 (d, J= 6.0 Hz, 1H), 5.17 (br s, 1H), 4.90 (br s, 1H), 4.63 (t, J= 3.9 Hz, 1H), 4.02-4.06 (m, 1H), 3.94 (br s, 1H), 3.48-3.64 (m, 2H).
LCMS m/z 292.2 [M+H], 290.0 [M-H]. Tr= 0.35 min.
13C NMR (400 MHZ, DMSO), 156.0, 148.3, 124.3, 117.8, 1 17.0, 111.2, 101.3, 85.8, 79.0, 74.7, 70.5, 61.4
HPLC Tr = 1.32 min
(2R.3R.4R,5R -2-(4-aminopyrrolo[l,2-firi<2.41triazin-7-yl)-3-fluoro-4- hvdroxv-5-(hvdroxvmethv )tctrahvdrofuran-2-carbonitrile (Compound 2)
Figure imgf000113_0001
2-Deoxy-2-fluoro-4,5-0,0-dibenzyl-D-arabinose. l '-Methoxy-2-deoxy-2- fluoro-4,5-0,O-dibenzyl-D-arabinose (1.0 g, 2.88 mmol) in TFA (13.5 mL) was treated with H20 (1.5 mL) and the resultant mixture stirred for 5 h. The mixture was then diluted with EtOAc (100 mL) and treated with saturated NaHC03 (50 mL). The organic layer was separated and washed with NaCl (50 mL), dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography (80 g Si02 Combiflash HP Gold Column) eluting with 0-100% EtOAc in hexanes to afford 2-deoxy-2-fluoro-4,5- 0,0-dibenzyl-D-arabinose (695 mg, 72%) as a white solid: Rf = 0.52 (25% EtOAc in hexanes);
1H NMR (300 MHz, CDC13) δ 7.30 (m, 10H), 5.35 (m, 1H), 4.68-4.29 (m, 7H), 3.70 (d, J= 10.5 Hz, 1H), 3.50 (d, J= 10.5 Hz, 2H).
19F NMR (282.2 MHz, CDC13) δ -207 (m), -21 1 (m).
LCMS m/z 350 [M+H20].
Figure imgf000114_0001
(3R, 4R, 5R)-4-(benzyloxy)-5-(benzyloxymethyI)-3-fluorodihydrofuran-2(3H)- one. 2-Deoxy-2-fluoro-4, 5-0,0-dibenzyl-D-arabinose (4.3 g, 12.8 mmol) was dissolved in C¾C12 (85 mL) was treated with 4 A MS (10 g) and pyridinium dichromate (14.4 g, 38.3 mmol). The resultant mixture was stirred for 24 h and then filtered through a pad of Celite. The eluant was concentrated under reduced pressure and the residue subjected to silica gel chromatography (120 g Si02 HP Gold Combiflash Column) eluting with 0-100% EtOAc in hexanes to afford (3R, 4R, 5i?)-4-(benzyloxy)-5-(benzyloxymethyl)-3-fluorodihydrofuran-2(3H)-one as a clear oil (3.5 g, 83%): Rf= 0.25 (25% EtOAc in hexanes).
1H NMR (300 MHz, CDC13) δ 7.37 (m, 10H), 5.45 (dd, J = 49, 5.7, Hz, 1H), 4.85 (d, J= 1 1.7 Hz, 1H), 4.52 (m, 4 H), 4.29 (d, J= 5.4 Hz, 1H), 2.08 (dd, J = 15.3, 10.2 Hz, 2H).
19F NMR (282.2 MHz, CDC13) δ -216.
LCMS m/z 348 [M+H20].
HPLC (6-98% MeCN-H20 gradient, 0.05% TFA modifier) tR = 5.29 min.
Phenomenex Synergi 4 m Hydro-RP 80 A, 50 x 4.60 mm, 4 micron; 2 mL/min flow rate
Figure imgf000114_0002
(3R, 4R, 5/?)-2-(4-aminopyrroIo| l,2-f] [l,2,4]triazin-7-yl)-4-(benzyloxy)-5- (benzyloxymethyl)-3-fluorotetrahydrofuran-2-ol. 7-Brornopyrrolo [1 ,2- fj[l,2,4]-triazin-4-amine (68 mg, 0.319 mmol) in THF (1.4 mL) was treated with TMSC1 (89 μΐ , 0.703 mmol) and the mixture stirred for 2 h. The mixture was then cooled to -78 °C and treated with «BuLi (1.0 M in hexanes, 1.09 mL, 1.09 mmol). The solution was stirred for 30 min and then treated with (3R, 4R, 5R)-4- (benzyloxy)-5-(benzyloxymethyl)-3-fiuorodihydrofuran-2(3H)-one (106 mg, 0.319 mmol) drop wise in THF (1.4 mL). The resultant mixture was stirred for 30 min and then AcOH (83 μί, 1.44 mmol) in THF (1.0 mL) was added to quench the reaction. The mixture was warmed to RT and then concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL) and washed with saturated NaCl solution (50 mL). The organic layer was dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography (40 g Si02 HP Gold Combiflash Column) eluting with 0-100% EtOAc in hexanes followed by a 0-100% gradient of (20% MeOH in EtOAc) in EtOAc to afford (3R, 4R, 5i?)-2-(4-aminopyrrolo[l,2- fj [ 1 ,2,4]triazin-7-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-3 -fluorotetrahydrofuran- 2-ol as a white solid (68 mg, 44%, 60/40 mixture of α/β isomers). R = 0.32 (EtOAc).
1H NMR (300 MHz, CTX¾) δ 8.05 (s, 1H), 7.86 (s, 1H), 7.81 (s, 1H), 7.64 (s, 1H), 7.26 (m, 10H), 6.95 (m, 1H), 6.71 (m, 1H), 6.08 (m, 1H), 5.34 (m, 1H), 4.65 (m, 6H), 4.71 (m, 2H).
19F NMR (282.2 MHz, CDC13) δ -21 1 (m).
LCMS m/z 465 [M+H].
HPLC (6-98% MeCN-H20 gradient, 0.05% TFA modifier) tR = 4.37 min. (a- isomer), 4.54 min. (β-isomer).
Figure imgf000115_0001
(3R, 4R, 5R)-2-(4-aniinopyrrolo| l,2-fl [l,2,4]triazin-7-yl)-4-(benzyloxy)-5- (benzyloxymethyl)-3-fluorotetrahydrofuran-2-carbonitrile: (3R, 4R, 5i?)-2-(4- aminopyrrolo[l ,2-fJ[l,2,4]triazin-7-yl)-4-(benzyloxy)-5-(benzyloxyinethyl)-3- fluorotetrahydrofuran-2-ol (195 mg, 0.42 mmol) was dissolved in MeCN (1.4 mL) was treated with TMSCN (336 μΐ,, 2.52 mmol) and In(OTf)3 (708 mg, 1.26 mmol). The solution was stirred at 70 °C for 18 h and then cooled to 0 °C. The mixture was treated with saturated NaHC03 solution (20 drops) then warmed to RT and diluted with EtOAc (100 mL) and H20 (50 mL). The organic layer was separated and washed with saturated NaCl solution (50 mL), dried over MgS04, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography (40 g Si02 HP Gold Combiflash Column) eluting with 0-100% EtOAc in hexanes to afford (3R, 4R, 5i?)-2-(4-aminopyrrolo[l ,2- f] [ 1 ,2,4]triazin-7-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-3 -fluorotetrahydrofuran- 2-earbonitrile as a white solid (1 10 mg, 55%, 60/40 mixture of α/β isomers). Data for both isomers: Rf= 0.53 (EtOAc).
1H NMR (300 MHz, CDC13) 5 8.01 (s, 1H), 7.94 (s, 1H), 7.30 (m, 10H), 7.00 (d, J = 4.5 Hz, 1 H), 6.93 (d, J = 4.8 Hz, 1H), 6.87 (d, J = 5.4 Hz, 1H), 6.70 (d, J = 4.8 Hz, 1H), 5.85 (dd, J = 52, 3.3 Hz, 1H), 5.55 (dd, J = 53, 4.5 Hz, 1H), 4.71 (m, 7H), 3.87 (m, 2H), 3.72 (m, 2H).
19F NMR (282.2 MHz, CDC13) δ -196 (m), -203 (m).
LCMS m z 474 [M+H].
HPLC (6-98% MeCN-H20 gradient, 0.05% TFA modifier) tR = 4.98 min.
Figure imgf000116_0001
(2R, 3R, 4R, 5R)-2-(4-aminopyrrolo| l,2-f| 11,2,4 |triazin-7-yl)-3-fluoro-4- hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile (2) (3R, 4R, 5R)-2- (4-aminopyrrolo[ 1 ,2-fJ [ 1 ,2,4]triazin-7-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-3- fluorotetrahydrofuran-2-carbonitrile (1 10 mg, 0.23 mmol) was dissolved in CH2CI2 (1.5 niL) and cooled to 0 °C. The reaction mixture was treated with BCI3 (1.0 M in CH2CI2, 766 \iL, 0.77 mmol) and stirred for 2 h. The mixture was then cooled to -78 °C and treated with Et3N (340 μΐ., 2.44 mmol) followed by MeOH (2 mL) before allowing to warm to RT. The reaction was concentrated under reduced pressure and then co-evaporated with MeOH (3 >< 5 mL). The residue was then suspended in ¾0 (5 mL) and treated with NaHC03 (1 g). The solution was stirred for 10 min and then concentrated under reduced pressure. The residue was filtered and washed with MeOH (3 x 10 mL) on a fritted glass funnel (coarse) and the eluant concentrated under reduced pressure. The residue was subjected to reverse phase HPLC (6-98% MeCN in H20 gradient with 0.05% TFA modifier) to afford (2R, 3R, 4R, 5JR)-2-(4-aminopyrrolo[l ,2-fJ[l,2,4]triazin-7-yl)-3-fluoro-4- hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile 2 as a white solid (16.8 mg, 25%) and the a-isomer.
Data for the β-isomer: Rf= 0.13 (10% MeOH in EtOAc).
1H NMR (300 MHz, CD3OD) δ 8.09 (s, 1H), 7.28 (d, J= 5.1 Hz, 1H), 7.17 (d, J= 5.1 Hz, 1H), 5.42 (dd, J = 53, 3.3 Hz, 1H), 4.20 (m, 2H), 3.99 (d, J= 3.6 Hz, 1H), 3.77 (d, J= 3.6 Hz, 1H).
19F NMR (282.2 MHz, CDC13) δ -197 (m).
LCMS m/ 294 [M+H].
HPLC (2-98% MeCN-H20 gradient, 0.05% TFA modifier) tR = 1.49 min.
(2R, 3R. 4R, 5S -5-(4-aminopyrrolo[l,2-firi,2,41triazin-7-yI)-4-fluoro-2- (hvdroxvmcthvl)-5-nietli\ltctrahvdrofuran-3-ol (Compound 3)
Figure imgf000118_0001
The starting nucleoside (prepared as described in the sysnthesis of compound 2) (0.355 g, 0.765 mmol) was dissolved in anhydrous THF (35 mL) and cooled to 0°C with stirring under N2(g). A solution of methyl magnesium chloride (2 mL, 6 mmol) (3N in THF) was added and the resultant mixture stirred overnight. Acetic acid (7 mmol) was added to quench the reaction and then the solvents were removed by rotory under reduced pressure. The residue was re- dissolved in CH2C12 and the solution subjected to a plug of silica gel to isolate the product (0.355 g) as a crude mixture. LC/MS (m/z : 480, M+1). The crude material was dissolved in anhydrous CH2C12 (20 mL) and placed under N2(g). The solution was stirred and treated with methanesulfonic acid (0.2 mL, 2.74 mmol). The reaction mixture was stirred for 12 h at RT and then quenched by the addition of Et3N (3.5 mmol). The mixture was concentrated under reduced pressure and the residue subjected to silica gel chromatography to provide the methyl substituted nucleoside (0.174 g, 0.377 mmol, 44% yield) as a 4:1 mixture of beta- and alpha-anomers respectively.
1H NMR (300 MHz, CD3CN) major anomer δ 7.87 (s, 1H), 7.27-7.40 (m, 10 H), 6.77 (d, J = 4.5 HZ, 1H), 6.70 (d, J = 4.5 Hz, 1H), 6.23 (br s, 2H), 5.53 (dd, J = 55, 3.3 Hz, 1H), 4.42-4.75 (m, 4H), 4.19-4.26 (m, 1H), 3.65-4.00 (m, 3H), 1.74 (d, J = 3.9 Hz, 3H).
19F NMR (282.2 MHz, CD3CN) major anomer δ -207 (m, IF)
LCMS m/z 463 [M+H].
Figure imgf000119_0001
beta alpha 3 The benzylated nucleoside material (0.134 g, 0.290 mmol), Degussa catalyst (0.268 g) and AcOH (30 mL) were mixed together. The reaction atmosphere was charged with H2 (g) and the reaction stirred for 2 h. The catalyst was removed by filtration and the mixture concentrated under reduced pressure. The residue was dissolved in a minimal amount of H20 and subjected to reverse phase HPLC (C18 hydro RP column) to isolate the β-anomer 3 (0.086 g, 0.217 mmol, 57% yield).
1H NMR (300 MHz, D20) 57.87 (s, 1H), 7.22 (d, J = 4.8 Hz, 1H), 6.87 (d, J = 4.8 Hz, 1H), 5.35 (dd, J = 54, 3.6 Hz, 1H), 3.97-4.10 (m, 2H), 3.81 (dd, J = 12.6, 2.1 Hz, 1H), 3.64 (dd, J = 12.6, 4.8 Hz, 1H), 1.65 (d, J = 4.2 Hz, 3H).
19F NMR (282.2 MHz, CD3CN) 5 -207 (m, IF).
A small amount of alpha anomer was characterized as follows.
Ή NMR (300 MHz, D20) 57.86 (s, 1H), 7.26 (d, J = 4.8 Hz, 1H), 6.85 (d, J = 4.8 Hz, 1H), 5.31 (dd, J = 54, 3.9 Hz, 1H), 4.39 (ddd, J = 26.1 , 9.9, 3.6 Hz, 2H), 4.00 - 4.05 (m, 1H), 3.90 (dd, J = 12.3, 2.1 Hz, 1H), 3.66 (dd, J = 12.6, 4.8, 1H), 1.56 (s, 3H).
19F NMR (282.2 MHz, CD3CN) 5 -198 (dd, J = 54, 26 Hz, IF).
(2R)-isopi opvI 2-i(((2R.3R<4R.5S)-5-(4-aminopvrrolo| l>2-fl H .2.4|tria/in-7- vl)-4-fluoro-3-hvdroxy-5-methv!tctrahvdrofuran-2-vl)mcthoxy)- (phenoxy)phosphorvlamino)propanoate (Compound 4)
Figure imgf000120_0001
The nucleoside 3 (0.011 g, 0.04 mmol) was dissolved in trimethylphosphate (2 mL) and cooled to 0°C. The mixture was stirred under an atmosphere of N2(g) andl-Methylimidazole(0.320 mL, 5 mmol) followed by the
alaninylmonoisopropyl, monophenol phosphorchloridate C (0.240 mL, 4.4 mmol) was added. The reaction mixture was stirred for 2 h. at 0°C and then allowed to warm slowly to RT. while monitoring by LC/MS. When complete by LCMS, the reaction mixture was treated with H20 (5 mL) and then concentrated under reduced pressure. The residue was dissolved in CH2C12 and subjected to silica gel chromatography eluting with 0-100% EtOAc in hexanes. The product fractions were collected and concentrated. The residue was subjected to prep HPLC to yield the alanine isopropyl monoamidate prodrug 4 as a mixture of isomers (4.7 mg, 0.003 mmol, 6%).
JH NMR (300 MHz, CD3CN) δ 7.87 (s, 1H), 7.17-7.44 (m, 5 H), 6.71-6.83 (m, 2H), 6.14 (br, s, 2H), 5.38 (dd, J = 56, 3.3 Hz, 1H), 4.92-5.01 (m, 1H), 3.86-4.46 (m, 6H), 3.58 (m, 1H), 1.73 (m, 3H), 1.18-1.34 (m, 9H)
LCMS m/z 552 [M+H].
(2R)-ethyl 2-((((2R<3R<4R,5S)-5-r4-aminopyrrolo[l,2-f|[l,2,41triazin-7-yl)-4- fluoro-3-hydroxy-5-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound 5)
Figure imgf000121_0001
beta
5
The nucleoside 3 (0.026 g, 0.092 mmol) was dissolved in
trimethylphosphate (2 mL) and cooled to 0°C. The mixture was stirred under N2(g) and 1-methylimidazole (0.062 mL, 0.763 mmol) followed by the chloridate A (0.160 g, 0.552 mmol) were added. The reaction mixture was stirred for 2 h. at 0°C and then allowed to warm slowly to RT. ¾0 (5 mL) was added to quench the reaction and then the mixture concentrated under reduced pressure. The residue was dissolved in CH2C12 and subjected to silica gel chromatography eluting with 0-100% EtOAc in hexanes. The product fractions were collected and concentrated. . Crude product was eluted using 0 to 100 percent EtOAc in hexanes. The crude product was collected and concentrated under reduced pressure. The residue was subjected to prep HPLC to yield 5 (2.0 mg, 4% yield). LCMS m/z 538 [M+H].
((2R, 3R, 4R, 5S)-5-(4-aminopvrrolo| 1.2-f I [ 1.2.4 |triazin-7-vl)-4-fluoro-3- hydroxy-5-methyltetrahvdrofuran-2-yl)methyl tetrahydrogen triphosphate (Compound 6)
Figure imgf000122_0001
beta
6
The nucleoside 3 (0.022 g, 0.056 mmol) was dissolved in
trimethylphosphate (1 mL) and stirred under N2(g). Phosphorous oxychloride (0.067 mL, 0.73 mmol) was added and the mixture stirred for 2 h. Monitoring by analytical ion-exchange column determined the time at which > 80 percent of monophosphate was formed. A solution of tributylamine (0.44 mL, 1.85 mmol) and triethylammonium pyrophosphate (0.327 g, 0.72 mmol) dissolved in anhydrous DMF (1 mL) was added. The reaction mixture was stirred for 20 min and then quenched by the addition of IN triethylammonium bicarbonate solution in H20 (5 mL). The mixture was concentrated under reduced pressure and the residue re-dissolved in H20. The solution was subjected to ion exchange chromatography to yield the title product 6 (1.7 mg, 6% yield).
LCMS m/z 521 [M-H]. Tr = 0.41
HPLC ion exchange TR = 9.40 min
(2R.3R,5S)-2-(4-aminopyrrolon,2-fi ri,2,41triazin-7-yl)-3-hvdroxy-5-
(hvdroxymethyl)-tetrahydrofuran-2-carbonitrile (Compound 7)
Figure imgf000122_0002
((3aR,5S,6aR)-2,2-dimethyl-tetrahydrofuro[2,3-d] [l,3]dioxol-5-yl)methanol
The acetate material (1.2 g, 5.5 mmol) (J. Org. Chem. 1985, 50, 3547, De Bernardo et al) was dissolved in a 1 :1 mixture MeOH and THF (10 mL). A IN solution of NaOH(aq) (l OmL) was added until the pH was 13. The reaction mixture was stirred for 2h and then neutralized to pH 8-9 by the addition of AcOH. The mixture was extracted with EtOAc (10 x 30mL) and the combined organic extracts dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-70% EtOAc in hexanes to give the desired product (866 mg, 90%).
1H NMR (300 MHz, CDC13) δ 5.84 (d, J= 3.6 Hz, 1H), 4.78 (t, J= 4.5 Hz, 1H), 4.38 (m, 1H), 3.93-3.54 (m, 2H), 2.04-1.84 (m, 2H), 1.52 (s, 3H), 1.33 (s, 3H).
Figure imgf000123_0001
(3aR,5S,6aR)-5-(benzyloxymethyl)-2,2-dimethyl-tetrahydrofuro[2,3- d][l,3]dioxole. Sodium hydride (188 mg, 7.46 mmol) was dissolved in anhydrous THF (5 mL) and stirred under N2(g) at RT. The alcohol (866 mg, 4.97 mmol) was dissolved in anhydrous THF (3 mL) and then added in portions over 5 min. to the sodium hydride mixture. The resultant mixture was stirred for 20 min. and then benzyl bromide (892 μΕ, 7.46 mmol) was added. The reaction was stirred for 2 h and then poured onto a mixture of ice cold aqueous NaHC03 and EtOAc (30mL). The organic layer was separated and then the aqueous layer re-extracted with EtOAc (30 mL). The combined organic extracts were dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-40% EtOAc in hexanes to give the benzyl ether product (912 mg, 69%).
*H NMR (300 MHz, CDC13) δ 7.35-7.27 (m, 5H), 5.86 (d, J= 3.6 Hz, 1H), 4.74 (t, J= 4.2 Hz, 1H), 4.60 (s, 2H), 4.42 (m, 1H), 3.69-3.53 (m, 2H), 2.10-2.04 (m, 1H), 1.83-1.77 (m, 1H), 1.52 (s, 3H), 1.33 (s, 3H).
Figure imgf000124_0001
(3R,5S)-5-(benzyIoxymethyl)-tetrahydrofuran-2,3-diol. The benzyl ether (910 mg, 3.44 mmol) was dissolved in a 1 : 1 AcOH and H20 (20 mL) mixture and stirred at 60°C for 7h. The mixture was concentrated under reduced pressure and the residue subjected to silica gel chromatography eluting with 0-70% EtOAc in hexanes to give the diol product (705 mg, 91%).
Ή NMR (300 MHz, CDC13) δ 7.36-7.27 (m, 5H), 5.40 (d, J= 3.9 Hz, 0.5H), 5.17 (s, 0.5H), 4.67-4.56 (m, 3H), 4.33 (m, 0.5H), 4.24 (d, J= 4.8 Hz, 0.5H), 3.71-3.67 (m, 1H), 3.56-3.42 (m, 2H), 2.31-2.22 (m, 1H), 2.08-1.89 (m, 2H).
Figure imgf000124_0002
(3R,5S)-5-(benzyloxymethyl)-3-hydroxy-dihydrofuran-2(3H)-one. The diol (705 mg, 3.14 mmol) was dissolved in benzene (30 mL) and treated with a silver carbonate celite mixture (3.46 g, 6.28 mmol). The resultant mixture was stirred at 80°C under N2(g) for 2h. The mixture was then cooled to RT, filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-70% EtOAc in hexanes to give the lactone product (600 mg, 86%).
Ή NMR (300 MHz, CDC13) δ 7.39-7.27 (m, 5H), 4.75-4.68 (m, 1H), 4.60-4.49 (m, 2H), 3.74-3.54 (m, 2H), 2.61-2.35 (m, 2H), 2.38-2.28 (m, 1H).
Figure imgf000124_0003
(3R, 5S)-3-(benzyloxy)-5-(benzyIoxymethyl)-dihydrofuran-2(3H)-one. The lactone (600 mg, 2.7 mmol) was dissolved in EtOAc (30mL) and treated with silver oxide (626 mg, 2.7 mmol) followed by benzyl bromide (387 μί, 3.24 mmol). The reaction mixture was then stirred at 50°C under N2(g) for 8h.
Additional silver oxide (300 mg) was then added and the resultant mixture stirred at 50°C for 16h. Additional benzyl bromide (50 uL) and silver oxide (150 mg) were added and the mixture stirred for an additional 8h. The reaction mixture was allowed to cool, filtered and then concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-20% EtOAc in hexanes to give the title product (742 mg, 88%).
1H NMR (300 MHz, CDC13) 5 7.39-7.27 (m, 10H), 4.99 (d, J= 1 1.4 Hz, 1H), 4.72 (m, 2H), 4.56 (m, 2H), 4.39 (t, J= 8.1 Hz, 1H), 3.72-3.51 (m, 2H), 2.42-2.25 (m, 2H).
Figure imgf000125_0001
(3R,5S)-2-(4-aminopyrrolo[l,2-fl[l,2,4]triazin-7-yl)-3-(benzyloxy)-5- (benzyloxyniethyl)-tetrahydrofuran-2-oI. The 7-bromopyrrolo[l ,2- f][l,2,4]triazin-4-amine (607 mg, 2.85 mmol) was dissolved in anhydrous THF (10 mL) and stirred under Ar(g) at RT. TMSC1 (1.1 mL, 8.55 mmol) was added dropwise and the mixture stirred for 2h. The reaction was concentrated under reduced pressure and then dried under high vacuum. The residue was suspended in THF (20 mL) and stirred under Ar(g) at -78°C. A 2.5M n-BuLi solution in hexane (2.28 mL, 5.7 mmol) was added dropwise over 10 min. and the resultant mixture stirred for 60 min. The lactone (742 mg, 2.37 mmol) dissolved in anhydrous THF (7 mL) was added to the above mixture over 20 min. The reaction mixture was stirred for 2 h. and then quenched with AcOH until pH was 5-6. The mixture was allowed to warm to RT and then diluted with EtOAc. The solution was washed with saturated NaHC03 solution, saturated NaCl, dried over anhydrous Na2S04 and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-80% EtOAc in hexanes to give the title product (250 mg, 24%).
LCMS m/z 447.2 [M+H], 445.1 [M-H].
Figure imgf000126_0001
(3R,5S)-2-(4-aminopyrrolo| l,2-f] [l,2,4]triazin-7-yl)-3-(benzyIoxy)-5-
(benzyloxymethyl)-tetrahydrofuran-2-carbonitrile. The alcohol (250 mg, 0.56 mmol) was dissolved in anhydrous CH2C12(10 mL) and stirred under Ar(g) at - 15°C. TMSCN (448 μΐ,, 3.36 mmol) was added dropwise and the mixture stirred for 10 min. TMSOTf (466 μΐ,, 2.58 mmol) was added dropwise over 10 min and the resultant mixture stirred for 90 min. at -15°C. Additional TMSCN (224 μΐ,, 3 eq.) and TMSOTf (202 μΕ, 2 eq.) was added and stirring continued for 5 h.
Saturated aqueous NaHC03 solution was added to quench the reaction and the mixture stirred for 10 min. The organic layer was separated and washed with saturated aqueous NaHC03 solution, saturated NaCl solution, dried over anhydrous Na2S04j filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-70% EtOAc in hexanes to give the title product (150 mg, 59%).
LCMS m/z 456.3 [M+H], 454.1 [M-H].
Figure imgf000127_0001
7
(2R,3R,5S)-2-(4-aminopyrrolo[l,2-fj[l,2,4]triazin-7-yl)-3-hydroxy-5- (hydroxymethyl)-tetrahydrofuran-2-carbonitrile (7). The benzyl ether (150 mg, 0.329 mmol) was dissolved in anhydrous CH2C12 (2 mL) and the mixture stirred under Ar(g) at -20°C. A 1M BC13 solution in CH2C12 (724 uL, 0.724 mmol) was added dropwise and the resultant mixture stirred for 2h. Additional 1M BC13 in CH2C12 (724 xL, 0.724 mmol) was added and stirring continued for 2h. The mixture was then cooled to -78°C and slowly treated with a 2:1 mixture of Et3N and MeOH (3 mL). The mixture was stirred for 10 min and then treated with
MeOH (10 mL). The reaction was allowed to warm to RT and then concentrated under reduced pressure. The residue was dissolved in MeOH and concentrated under reduced pressure. The residue was dissolved in MeOH again and treated with solid NaHC03. The mixture was stirred for 5 min and then the solid removed by filtration. The solution was concentrated under reduced pressure and subjected to preparative HPLC to provide the desired product 7 (10 mg, 1 1%).
1H NMR (300 MHz, D20) δ 7.71 (s, 1H), 6.75 (d, J= 4.5 Hz, 1H), 6.65 (d, J= 4.8 Hz, 1H), 4.91 (t, J= 6.3 Hz, 1H), 4.57 (m, 1H), 3.67-3.47 (m, 2H), 2.18 (m, 2H). LCMS m/z 276 A [M+H], 274.0 [M-H].
(2S)-isopropyl 2-((r(2R,3S,4R,5R)-5-(4-aminopyrrolo[l,2-fi ri,2,41triazin-7- vI)-5-c\ ano-3,4-dihydroxvtetrahvdrofuran-2-\l)mcthoxv)(phciioxv)- phosphorylamino)propanoate (Compound 8)
Figure imgf000128_0001
8
The nucleoside 1 (45mg, 0.15mmol) was dissolved in anhydrous trimethyl phosphate (0.5 mL) and the solution stirred under N2(g) at 0°C. Methyl imidazole (36 μί, 0.45 mmol) was added to the solution. Chlorophosphoramidate C (69 mg, 0.225 mmol) was dissolved in anhydrous THF (0.25 mL) and added dropwise to the nucleoside mixture. When the reaction was complete by LCMS, the reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHC03 solution, saturated NaCl, dried over anhydrous Na2S04> filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0-5% MeOH in CH2C12 followed by preparative HPLC to give the product (20.9 mg, 25%).
1H NMR (300 MHz, CD3OD) 5 7.95 (m, 1H), 7.31-6.97 (m, 7H), 4.94 (m, 1H), 4.78 (m, 1H), 4.43 (m, 3H), 4.20 (m, 1H), 3.80 (d, 1H), 1.30-1.18 (m, 9H);
31P NMR (121.4 MHz, CD3OD) δ 3.8.
LCMS m/z 561.0 [M+H], 559.0 [M-H].
(2S)-2-ethvlbutvl 2-((((2R.3S.4R.5R)-5-(4-aniinop\ rrolo| 1.2-fl | 1.2.4|ti ia/in-7- vl)-5-cvano-3.4-dihydroxvtctrahvdrofuraii-2- yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound 9)
Figure imgf000129_0001
Prepared from Compound 1 and chloridate B according to the same method as for the preparation of compound 8.
Ή NMR (300 MHz, CD3OD) δ 7.87 (m, IH), 7.31-7.16 (m, 5H), 6.92-6.89 (m 2H), 4.78 (m, IH), 4.50-3.80 (m, 7H), 1.45-1.24 (m, 8H), 0.95-0.84 (m, 6H). 31P NMR (121.4 MHz, CD3OD) δ 3.7.
LCMS m/z 603.1 [M+H], 601.0 [M-H]. qSVcthvl 2-((((2R S<4R<5R)-5-(4-aminopvri olo[ 1.2-fll K2.4|tria/in-7-vn-5- cyano-3,4-dihydroxytetrahydrofuran-2- yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound 10)
Figure imgf000129_0002
10
Prepared from Compound 1 and chloridate A using same method as for the preparation of compound 8.
1H NMR (300 MHz, CD3OD) δ 7.95 (m, IH), 7.32-6.97 (m, 7H), 4.78 (m, IH), 4.43-4.08 (m, 6H), 3.83 (m, IH), 1.31-1.18 (m, 6H).
31P NMR (121.4 MHz, CD3OD) δ 3.7.
LCMS m/z 547.0 [M+H], 545.0 [M-H]. (2S)-ethvl 2-((((2R.3R<4R<5R)-5-(4-aniinop\ ri olo[ 1.2-fl H<2,4|triazin-7-vl)-5- evano-4-fluoro-3-hvdroxytetrahvdrofuran-2- yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound 11)
Figure imgf000130_0001
11
Compound 11 was prepared from Compound 2 and chloridate A using same method as for the preparation of compound 8.
1H NMR (300 MHz, CD3OD) δ 7.91 (m, IH), 7.33-7.16 (m, 5H), 6.98-6.90 (m, 2H), 5.59 (m, IH), 4.50-4.15 (m, 4H), 4.12-3.90 (m, 3H), 1.33-1.18 (m, 6H). 31P NMR (121.4 MHz, CD3OD) δ 3.8.
LCMS m/z 549.0 [M+H], 547.1 [M-H]. f2S,2'S)-diethyl 2-2,-((((2R<3S.4R.5R)-5-(4-aminopvrrolo| 1.2-f| | K2.4|lriazin- 7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2- yI)methoxy)phosphoryl)bis(azanediyl)dipropanoate (Compound 12)
Figure imgf000130_0002
The nucleoside 1 (14.6 mg, 0.05 mmol) was dissolved in anhydrous trimethyl phosphate (0.5 mL) and stirred under N2(g) at RT. POCl3 (9.2 μΐ,, 0.1 mmol) was added and the mixture stirred for 60 min. Alanine ethyl ester hydrochloride (61 mg, 0.4 mmol) and then Et3N (70 μί, 0.5 mmol) was added. The resultant mixture was stirred for 15 min. and then additional Et3N (70 μΐ, 0.5 mmol) was added to give a solution pH of 9-10. The mixture was stirred for 2 h. and then diluted with EtOAc, washed with saturated aqueous NaHC03 solution followed by saturated aqueous NaCl solution. The organic layer was dried over anhydrous Na2S04 and concentrated under reduced pressure. The residue was subjected to preparative HPLC (C18 column) to yield the product 12 (5.5 mg, 16%).
1H NMR (400 MHz, CD3OD) δ 8.13 (s, 1H), 7.41 (d, J = 4.8 Hz, 1H), 7.18 (d, J = 4.8 Hz, 1H), 4.78 (d, J= 5.6 Hz, 1H), 4.36 (m, 1H), 4.25-4.08 (m, 7H), 3.83 (m, 2H), 1.33-1.23 (m, 12H).
31P NMR (121.4 MHz, CD3OD) δ 13.8.
LCMS m/z 570.0 [M+H], 568.0 [M-H]. (2S^R<4S.5R)-2-(4-aminopvrrolo| l<2-f| | 1.2.4)tria¾in-7-vl)-2-cthvnvl-5-
(hvdroxymethyl)tetrahydrofuran-3,4-diol (Compound 13)
Figure imgf000131_0001
The nucleoside alcohol (0.6 g, 1.08 mmol) (prepared as described in
Compound 1 synthesis) was dissolved in anhydrous THF (8mL) and placed under N2(g). The reaction mixture was stirred and cooled to 0°C and then treated with a 0.5N solution of ethynyl magnesium bromide in THF (17.2 mL, 17.2 mmol). The reaction mixture was stirred overnight at RT. AcOH (1.5 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure and the residue redissolved in CH2CI2. The solution subjected to a plug of silca gel eluting with 0 to 80% EtOAc in Hexanes to provide the title product as a crude mixture.
LCMS m/z 579 [M+H].
Figure imgf000132_0001
The crude ethynyl alcohol (0.624 g, 1.08 mmol) was dissolved in anhydrous CH2CI2 (10 mL) and placed under N2(g). The mixture was stirred and sulfonic acid (0.2 mL, 2.74 mmol) was added. The reaction mixture was stirred for 12 h. at RT. When complete by LCMS, Et3N (0.56 mL) was added to quench the reaction. The reaction was concentrated under reduced pressure and the residue subjected to silica gel chromatography eluting with 0 to 75% EtOAc in Hexanes to yield the ethynyl nucleoside as a mixture of anomers (0.200 g, 33% over 2 steps).
LCMS m/z 561 [M+H].
Figure imgf000132_0002
13
The tribenzyl nucleoside (0.650 g, 1.16 mmol) was dissolved in anhydrous CH2CI2 (30 mL) and cooled to -78°C under N2(g). A solution of boron tribromide (1 N in CH2CI2, 5.5 mL) was added and the reaction mixture stirred for 1 h. at - 78°C. A solution of MeOH (10 mL) and pyridine (2 mL) was added to quench the reaction and the mixture was allowed to rise to RT. The mixture was concentrated under reduced pressure and subjected to preparative HPLC to provide the a- anomer (20 mg) and β-anomer 13 (110 mg)
(β -anomer) 1H NMR (300 MHz, DMSO) δ 7,81 (s, 1H), 7.76 (br s, 2H), 6.80- 6.85 (m, 2H), 5.1 1 (d, J = 7.2 Hz, IH), 4.90 (d, J = 6.0 Hz, 1H), 4.82 (dd, J = 7.2, 4.8 Hz, IH), 4.62 (t, J = 6.3 Hz, IH), 3.95-3.99 (m, IH), 3.85-3.91 (dd, J = 11.4, 5.7 Hz, IH), 3.61-3.67 (m, IH), 3.47-3.55 (m, IH), 3.52 (d, J = 0.9 Hz, IH). (a -anomer) 1H NMR (300 MHz, DMSO) δ 7.80 (s, IH), 7.59 (bs, 2H), 6.80 (d, J = 4.5 Hz, IH), 6.54 (d, J = 4.2 Hz, IH), 5.00 (d, J = 7.2 Hz, IH), 4.89 (d, J = 4.8 Hz, IH), 4.74 (t, J = 5.7 Hz, IH), 4.58 (t, J = 4.5 Hz, IH), 4.27 (m, IH), 3.88 (m, IH), 3.64-3.72 (m, IH), 3.51-3.59 (m, IH), 3.48 (d, J = 0.6 Hz, IH)
LCMS m/z 291 [M+H].
(2R-3R,4R)-5-(4-aminopyrroloil,2-fi ri,2,41triazin-7-vi)-1.3.4- tris(benzyIoxy)hexane-2,5-diol (Compound 14)
Figure imgf000133_0001
The tribenzyl alcohol from Compound 1 synthesis (0.250 g, 0.453 mmol) was dissolved in anhydrous THF (25 mL) and stirred under N2(g). The reaction mixture was cooled to 0°C and then a 3.0 N solution of methyl magnesium chloride in THF(1.2 mL, 3.62 mmol) was added. The reaction mixture was stirred overnight at RT. Acetic acid (1.5 mL) was added to quench the reaction and then the mixture was concentrated under reduced pressure. The residue was redissoved in CH2C12 and subjected to a plug of silca gel eluting with 0 to 80% EtOAc in hexanes. The crude product (0.452 g) was then used in the next reaction without further purification.
LCMS m/z 569 [M+H].
Figure imgf000134_0001
The crude methyl nucleoside (0.452 g, 0.796 mmol) was dissolved in anhydrous CH2C12 (20 mL) and stirred under N2(g). Methanesulfonic acid (0.2 mL, 2.78 mmol) was added and the reaction stirred for 12 hr at T. Et3N (0.56 mL) was added to quench the reaction and then the mixture concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0 to 75% EtOAc in Hexanes to yield the product as a mixture of anomers (0.20 g, 46% over 2 steps).
LCMS m/ 551 [M+H].
Figure imgf000134_0002
The tribenzyl nucleoside (0.20 g, 0.364 mmol) was dissolved in AcOH (30 mL). and charged with Pd/C (Degussa) (400 mg). The stirred mixture was flushed with N2(g) three times and then H2 (g) was introduced, The reaction was stirred under H2 (g) for 2 h. and then the catalyst removed by filtration. The solution was concentrated under reduced pressure and under the residue was re-dissolved in H20. The solution was subjected to preparative HPLC under neutral conditions to provide the a-anomer and β-anomer 14 in 81% yield. (α-anomer) H NMR (300 MHz, D20) δ 7.81 (s, 1H), 7.22 (d, 1H), 6.75 (d, 1H), 4.47 (d, 1H), 4.25-4.31 (m, 1H), 3.88-4.95 (m, 1H), 3.58-3.86 (dd, 2H), 1.50 (s, 3H).
(β-anomer) lR NMR (300 MHz, D20) 57.91 (s, 1H), 7.26 (d, 1H), 6.90 (d, 1H), 4.61 (d, 1H), 4.00-4.09 (m, 2H), 3.63-3.82 (dd, 2H), 1.67 (s, 3H).
LCMS m/z 281 [M+H].
S.S'-l^'-fffflRJS^R^R^-S- -aminopyrroloil^-flfl^^ltriazin-T-vn-S- cyano-3,4-dihydroxytetrahydrofuran-2- yl)methoxy)phosphoryl)bis(oxy)bis(ethane-2 -diyl) bis(2,2- dimethylpropanethioate) (Compound 15)
Figure imgf000135_0001
The nucleoside 1 (0.028 g, 0.096 mmol) was dissolved in trimethylphosphate (1 niL). The reaction was stirred under N2(g) and then treated with lH-tetrazole (0.021 g, 0.29 mmol). The reaction mixture was cooled to 0°C and the phosphane (Nucleoside Nucleotides, Nucleic acids; 14; 3-5; 1995; 763 - 766. Lefebvre, Isabelle; Pompon, Alain; Perigaud, Christian; Girardet, Jean-Luc; Gosselin, Gilles; et al.) (87 mg, 0.192 mmol) was added. The reaction was stirred for 2 h. and then quenched with 30% hydrogen peroxide (0.120 mL). The mixture was stirred for 30 min at RT and then treated with saturated aqueous sodium thiosulfate (1 mL). The mixture was stirred for 10 min. and then concentrated under reduced pressure. The residue was subjected to preparative HPLC to isolate the title product 15. Ή NMR (300 MHz, CD3CN) δ 7.98 (s, IH), 6.92 (d, IH), 6.81 (d, IH), 6.44 (bs, 2H), 4.82 (m, 2H), 4.47 (m, IH), 4.24 (m, 2H), 4.00 (m, 4H), 3.80 (bs, IH), 3.11 (m, 4H), 1.24 (s, 9H).
31P NMR (121.4 MHz, CD3CN) δ -1.85 (s).
LCMS m/z 661 [M+H].
S.S'-2.2'-((((2R. 3S. 4R, 5S)-5-(4-aminopyrrolofl,2-f|fl,2,41triazin-7-yl)-5- ethvnvl-3,4-dihvdroxvtctrahydrofuran-2- yl)methoxy)phosphoryl)bis(oxy)bis(ethane-2,l-diyl) bis(2,2- dimethvlpropanethioate) (Compound 16)
Figure imgf000136_0001
Compound 16 was prepared using the same method as compound 15 except substituting compound 13 as the starting nucleoside.
1H NMR (300 MHz, CD3CN) δ 7.91 (s, IH), 6.86 (d, J = 4,8 Hz, IH), 6.76 (d, J = 4.5 Hz, IH), 6.29 (bs, 2H), 4.69 (t, J = 2.7 Hz, IH), 4.58 (d, J = 5.7 Hz, IH), 4.14- 4.33 (m, 5H), 3.99-4.07 (m, 4H), 3.53 (d, J = 5.4 Hz, IH), 3.11 (q, J = 5.7 Hz, 4H), 1.22 (s, 18H).
LCMS m/z 658.9 [M+]. Tr=2.31
((2R, 3S, 4R, 5R)-5-(4-amiiiopvrrolo| 1.2-f| 11.2.4|triazin-7-vl)-5-cvano-3.4- dihvdroxvtetrahydrofuran-2-vl)methvl tetrahydrogen triphosphate
(Compound 17)
Figure imgf000137_0001
17
Compound 17 was prepared from compound 1 using a similar procedure to the preparation of compound 6. The product was isolated as the sodium salt.
Ή NMR (400 MHz, D20) 5 7.76 (s, 1H), 6.88 (d, J = 4.8 Hz, 1H), 6.73 (d, J = 4.4 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.43 (m, 1H), 4.39 (m, 1H), 4.05 (m, 1H), 3.94 (m, 1H)
31P NMR (121.4 MHz, D20) 5 -5.4 (d, IP), -10.8 (d, IP), -21.1 (t, IP).
LCMS m/z 530 [M-H], 531.9 [M+H] Tr = 0.22 min
HPLC ion exchange Tr=9.95 min
((2R, 3S, 4R, 5S)-5-(4-aminop\ rrolol 1.2-fl 1 1.2<4|tria/in-7-vI)-5-cthvn\l-3<4- dihydroxytetrahvdrofuran-2-vl)methvl tetrahydrogen triphosphate
(Compound 18)
Figure imgf000137_0002
18
Compound 18 was prepared from compound 13 using a similar procedure to the preparation of compound 6. The product was isolated as the TEA salt. 1H NMR (300 MHz, D20) δ 7.85 (s, 1H), 7.09 (d, J = 4.6 Hz, 1H), 6.95 (d, J Hz, 1H), 4.23 (m, 2H), 4.08 (m, 2H), 3.06 (q, J = 7.4 Hz, 20H), 1.14 (t, J = 7 3 OH)
31P NMR (121.4 MHz, D20) δ -10.8 (d, IP), -11.2 (d, IP), -23.2 (t, IP).
LCMS m/z 530.8 [M+H], Tr = 0.46
HPLC ion exchange Tr = 9.40 min
((2R, 3S. 4R, 5SV5-(4-aminopyrrolotl,2-fi ri,2,41triazin-7-vD-3,4-dihvdroxy-5- methyItetrahydrofuran-2-yl)methyI tetrahydrogen triphosphate (Compound 19}
Figure imgf000138_0001
Compound 19 was prepared from compound 14 using a similar procedure to the preparation of compound 6.
Ή NMR (400 MHz, D20) δ 7.78 (s, 1H), 6.98 (m, 1H), 6.84 (m, 1H), 4.45 (m, 1H), 4.04 (m, 4H), 1.54 (s, 3H).
31P NMR (161 MHz, D20) 5 -10.6 (m), -23.0 (m).
LCMS m/z 521.0 [M+H].
((2R,3R,4R,5R)-5-(4-aminopyrrolo[l,2-fl[l,2,4]triazin-7-yl)-5-cyano-4-fluoro- 3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate
(Compound 20)
Figure imgf000139_0001
20
Compound 20 was prepared from compound 2 using a similar procedure to the preparation of compound 6.
1H NMR (400 MHz, D20) δ 7.78 (s, 1H), 6.93 (d, J = 4.4 Hz, 1H), 6.78 (d, J Hz, 1H), 5.45 (dd, J = 53, 4.4 Hz, 1H), 4.38-4.50 (m, 2H), 4.13-4.20 (m, 2H). 31P NMR (161 MHz, D20) δ -5.7 (d, IP), -1 1.0 (d, IP), -21.5 (t, IP).
LCMS m/z 533.9.0 [M+H], 532.0 [M-H] Tr = 1.25 min.
HPLC ion exchange Tr=l 1.0 min
Antiviral Activity
Another aspect of the invention relates to methods of inhibiting viral infections, comprising the step of treating a sample or subject suspected of needing such inhibition with a composition of the invention.
Within the context of the invention samples suspected of containing a virus include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired
glycoprotein; and the like. Typically the sample will be suspected of containing an organism which induces a viral infection, frequently a pathogenic organism such as a tumor virus. Samples can be contained in any medium including water and organic solventWater mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures. If desired, the anti-virus activity of a compound of the invention after application of the composition can be observed by any method including direct and indirect methods of detecting such activity. Quantitative, qualitative, and semiquantitative methods of determining such activity are all contemplated.
Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.
The antiviral activity of a compound of the invention can be measured using standard screening protocols that are known. For example, the antiviral activity of a compound can be measured using the following general protocols.
Respiratory syncytial virus (RSV) antiviral activity and cytotoxicity assays Anti-RSV activity
Antiviral activity against RSV is determined using an in vitro
cytoprotection assay in Hep2 cells. In this assay, compounds inhibiting the virus replication exhibit cytoprotective effect against the virus-induced cell killing that can be quantified using a cell viability reagent. The method used is similar to methods previously described in published literature (Chapman et al., Antimicrob Agents Chemother. 2007, 57(9):3346-53.)
Hep2 cells are obtained from ATCC (Manassas, VI) and maintained in MEM media supplemented with 10% fetal bovine serum and
penicillin/streptomycin. Cells are passaged twice a week and kept at subconfiuent stage. Commercial stock of RSV strain A2 (Advanced Biotechnologies,
Columbia, MD) is titered before compound testing to determine the appropriate dilution of the virus stock that generates desirable cytopathic effect in Hep2 cells.
For antiviral tests, Hep2 cells are seeded into 96-well plates 24 hours before the assay at a density of 3,000 cells/well. On a separete 96well plate, compounds to be tested are serially diluted in cell culture media. Eight concentrations in 3 -fold serial dilution increments are prepared for each tested compound and 100 uL/well of each dilution is transferred in duplicate onto plates with seeded Hep2 cells. Subsequently, appropriate dilution of virus stock previously determined by titration is prepared in cell culture media and 100 uL/well is added to test plates containing cells and serially diluted compounds. Each plate includes three wells of infected untreated cells and three wells of uninfected cells that served as 0% and 100% virus inhibition control, respectively. Following the infection with RSV, testing plates are incubated for 4 days in a tissue culture incubator. After the incubation, RSV-induced cytopathic effect is determined using a Cell TiterGlo reagent (Promega, Madison, WI) followed by a luminescence read-out. The percentage inhibition is calculated for each tested concentration relative to the 0% and 100% inhibition controls and the EC50 value for each compound is determined by non-linear regression as a concentration inhibiting the RSV-induced cytopathic effect by 50%. Ribavirin (purchased from Sigma, St. Louis, MO) is used as a positive control for antiviral activity.
Cytotoxicity
Cytotoxicity of tested compounds is determined in uninfected Hep2 cells in parallel with the antiviral activity using the cell viability reagent in a similar fashion as described before for other cell types (Cihlar et al., Antimicrob Agents Chemother. 2008,52(2):655-65.). The same protocol as for the determination of antiviral activity is used for the measurement of compound cytotoxicity except that the cells are not infected with RSV. Instead, fresh cell culture media (100 uL/well) without the virus is added to tested plates with cells and prediluted compounds. Cells are then incubated for 4 days followed by a cell viability test using CellTiter Glo reagent and a luminescence read-out. Untreated cell and cells treated with 50 ug/mL puromycin (Sigma, St. Louis, MO) are used as 100% and 0% cell viability control, respectively. The percent of cell viability is calculated for each tested compound concentration relative to the 0%> and 100% controls and the CC50 value is determined by non-linear regression as a compound
concentration reducing the cell viability by 50%.
Figure imgf000142_0001
RSV RNP Preparation
RSV ribonucleoprotein (RNP) complexes were prepared from a method modified from Mason et al (1). HEp-2 cells were plated at a density of 7.1 x 104 cells/cm2 in MEM + 10% fetal bovine serum (FBS) and allowed to attach overnight at 37°C (5% C02). Following attachment, the cells were infected with RSV A2 (MOI=5) in 35 mL MEM + 2% FBS. At 20 hours post-infection, the media was replaced with MEM + 2% FBS supplemented with 2 μg/mL
actinomycin D and returned to 37°C for one hour. The cells were then washed once with PBS and treated with 35 mL of PBS + 250 μg mL lyso-lecithin for one minute, after which all liquid was aspirated. The cells were harvested by scrapping them into 1.2 mL of buffer A [50 mM TRIS acetate (pH 8.0), 100 mM potassium acetate, 1 mM DTT and 2 μg/mL actinomycin D] and lysed by repeated passage through an 18 gauge needle (10 times). The cell lysate was placed in ice for 10 minutes and then centrifuged at 2400g for 10 minutes at 4°C. The supernatant (SI) was removed and the pellet (PI) was disrupted in 600 uL of Buffer B [10 mM TRIS acetate (pH 8.0), lOmM potassium acetate and 1.5 mM MgCl2]
supplemented with 1% Triton X-100 by repeated passage through an 18 gauge needle (10 times). The resuspended pellet was placed in ice for 10 minutes and then centrifuged at 2400g for 10 minutes at 4°C. The supernatant (S2) was removed and the pellet (P2) was disrupted in 600 uL of Buffer B supplemented with 0.5% deoxycholate and 0.1% Tween 40. The resuspended pellet was placed in ice for 10 minutes and then centrifuged at 2400g for 10 minutes at 4°C. The supernatant (S3) fraction, containing the enriched RSV RNP complexes, was collected and the protein concentration determined by UV absorbance at 280 nm. Aliquoted RSV RNP S3 fractions were stored at -80°C.
RSV RNP Assay
Transcription reactions contained 25μg of crude RSV RNP complexes in 30 μΐ, of reaction buffer [50 mM TRIS-acetate (pH 8.0), 120 mM potassium acetate, 5% glycerol, 4.5 mM MgCl2, 3 mM DTT, 2 mM ethyleneglycol-bis(2- aminoethylether)-tetraacetic acid (EGTA), 50 μg/mL BSA, 2.5 U RNasin
(Promega), ATP, GTP, UTP, CTP and 1.5 uCi [a-32P] NTP (3000 Ci/mmol)]. The radiolabled nucleotide used in the transcription assay was selected to match the nucleotide analog being evaluated for inhibition of RSV RNP transcription. Cold, competitive NTP was added at a final concentration of one-half its Km (ATP= 20 μΜ, GTP= 12.5 μΜ, UTP= 6 μΜ and CTP= 2 μΜ). The three remaining nucleotides were added at a final concentration of 100 μΜ.
To determine whether nucleotide analogs inhibited RSV RNP
transcription, compounds were added using a 6 step serial dilution in 5 -fold increments. Following a 90 minute incubation at 30°C, the RNP reactions were stopped with 350 μΐ, of Qiagen RLT lysis buffer and the RNA was purified using a Qiagen RNeasy 96 kit. Purified RNA was denatured in RNA sample loading buffer (Sigma) at 65°C for 10 minutes and run on a 1.2% agarose/MOPS gel containing 2M formaldehyde. The agarose gel was dried and exposed to a Storm phosphorimager screen and developed using a Storm phosphorimager (GE Healthcare). The concentration of compound that reduced total radiolabled transcripts by 50% (IC50) was calculated by non-linear regression analysis of two replicates.
1) Mason, S., Lawetz, C, Gaudette, Y., Do, F., Scouten, E., Lagace, L., Simoneau, B. and Liuzzi, M. (2004) Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Research, 32, 4758-4767.
Figure imgf000144_0001
Description of the Parainfluenza Cytoprotection Assay
The Parainfluenza Cytoprotection assay uses Vero cells and Parainfluenza 3 strain C 243. Briefly virus and cells are mixed in the presence of test compound and incubated for 7 days. The virus is pre-titered such that control wells exhibit 85 to 95% loss of cell viability due to virus replication. Therefore, antiviral effect or cytoprotection is observed when compounds prevent virus replication. Each assay plate contains cell control wells (cells only), virus control wells (cells plus virus), compound toxicity control wells (cells plus compound only), compound colorimetric control wells (compound only), as well as experimental wells (compound plus cells plus virus). Cytoprotection and compound cytotoxicity are assessed by MTS (CellTiter®96 Reagent, Promega, Madison WI) dye reduction. The % reduction in viral cytopathic effects (CPE) is determined and reported; IC50 (concentration inhibiting virus replication by 50%), TC50 (concentration resulting in 50% cell death) and a calculated TI (therapeutic index TC50/ IC50) are provided along with a graphical representation of the antiviral activity and compound cytotoxicity when compounds are tested in dose-response. Each assay includes ribavirin as a positive control.
Cell Preparation
Vero cells (Kidney, African green monkey, Cercopithecus aethiops) were obtained from the American Type Culture Collection (ATCC, Rockville,
Maryland) and are grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2.0 mM L-Glutamine, 100 units/ml Penicillin and 100 ug/ml Streptomycin ("growth medium"). Cells are sub-cultured twice a week at a split ratio of 1 : 10 using standard cell culture techniques. Total cell number and percent viability determinations are performed using a hemacytometer and trypan blue exclusion. Cell viability must be greater than 95% for the cells to be utilized in the assay. The cells are seeded in 96-well tissue culture plates the day before the assay at a concentration of 1 x 104 cells/well. Virus Preparation
The virus used for this assay is Parainfluenza 3 strain C 243. This virus was obtained from the American Type Culture Collection (ATCC) and was grown in Vero cells for the production of stock virus pools. For each assay, a pre-titered aliquot of virus is removed from the freezer (-80°C) and allowed to thaw slowly to room temperature in a biological safety cabinet. The virus is resuspended and diluted into tissue culture medium such that the amount of virus added to each well is the amount determined to give between 85 to 95% cell killing at 6-7 days post-infection. MTS Staining for Cell Viability
At assay termination (7 days post-infection), the assay plates are stained with the soluble tetrazolium-based dye MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; CellTiter®96 Reagent, Promega) to determine cell viability and quantify compound toxicity. MTS is metabolized by the mitochondrial enzymes of metabolically active cells to yield a soluble formazan product, allowing the rapid quantitative analysis of cell viability and compound cytotoxicity. This reagent is a stable, single solution that does not require preparation before use. At termination of the assay, 20-25 μί of MTS reagent is added per well and the microtiter plates are then incubated for 4-6 hrs at 37°C, 5% C02 to assess cell viability. Adhesive plate sealers are used in place of the lids, the sealed plate is inverted several times to mix the soluble formazan product and the plate is read spectrophotometrically at 490/650 nm with a Molecular Devices Vmax or SpectraMax Plus plate reader.
Data Analysis
Using an in-house computer program % Cytopathic Effect (CPE)
Reduction, %Cell Viability, IC25, IC50, IC95, TC25, TC50, and TC95 and other indices are calculated and the graphical results summary is displayed. Raw data for both antiviral activity and toxicity with a graphical representation of the data are provided in a printout summarizing the individual compound activity. The Table below shows the activity of selected compounds against Parainfluenza 3 virus.
Figure imgf000146_0001
The specific pharmacological and biochemical responses observed in the assays described may vary according to and depending on the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present invention.
All publications, patents, and patent documents cited herein above are incorporated by reference herein, as though individually incorporated by reference.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, one skilled in the art will understand that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

What is claimed is
Figure imgf000147_0001
Formula I
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen;
each R2, R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (C1-C8)alkyl, (C4-C8)carbocyclylalkyl, (C1-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl, (C2-C8)alkynyl or (C2-C8)substituted alkynyl;
2 3 5
or any two R , R or R on adjacent carbon atoms when taken together are -0(CO)0- or when taken together with the ring carbon atoms to which they are attached form a double bond;
R6 is ORa, N(Ra)2, N3, CN, N02, S(0)nRa, -C(=0)Rn, -C(=0)ORu, - C(=0)NRnR12, -C(=0)SRn, -S(0)RH, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, halogen, (d-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl,
(C2-C8)alkynyl, (C2-C8)substituted alkynyl, or aryl(Ci-C8)alkyl;
each n is independently 0, 1, or 2; each Ra is independently H, (Ci-Cg)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(Ci-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, - C(=0)NRuR12, -C(=0)SRH, -S(0)Ru, -S(0)2R1 !, -S(0)(ORn), -S(0)2(ORu), or -S02NRuR12;
R7 is H, -C(=0)Rn, -C(=0)ORn, -C(=0)NRuR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, or
Figure imgf000148_0001
each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2;
W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R 3 or R 4 is -Y 3 - and the other of W 1 or W2 is Formula la; or W1 and W2 are each, independently, a group of the Formula la:
Figure imgf000148_0002
Formula la
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR),
N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is independently Ry or the formula:
Figure imgf000149_0001
wherein:
each Mia, Ml c, and Mid is independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each Ry is independently H, F, CI, Br, I, OH, R, -C^Y^R, -C(=Y1)OR, - C(=Y1)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC(=Y1)R, -OC(=Y])OR, -OC(=Y])(N(R)2), -SC(=Y])R, -SC(=Y,)OR, - SC(=Y!)(N(R)2), -N(R)G(=Y1)R, -N(R)C(=YI)OR, -N(R)C(=Y1)N(R)2,
-SO2NR2, -CN, -N3, -NO2, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (Q-Cg) alkyl, (Ci-Cg) substituted alkyl, (C2- Cs)alkenyl, (C2-Cg) substituted alkenyl, (C2-C8) alkynyl, (C2-C8) substituted alkynyl, Q,-C2o aryl, C6-C2o substituted aryl, C2-C2o heterocyclyl, C2-C20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -QY1^, -C(Yl)W5, -S02Ry, or -S02W5; and W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRnR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(-NRn), -CH=NNHRn, -CH=N(ORn), -CH(ORn)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- Cg)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl,
Figure imgf000149_0002
-S(0)n(Ci-C8)alkyl, aryl(Ci-C8)alkyl, OR11 or SR11;
each R9 or R10 is independently H, halogen, NRnR12, N(R )ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRH), -CH=NHNRn, -CH=N(ORu), -CH(ORn)2, -C(=0)NRuR12, -C(=S)NRnR12, -C(=0)ORu, R11, OR1 1 or SR11; and
each R11 or R12 is independently H, (Ci-Cg)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(Ci-C8)alkyl, -S(0)n(C1-C8)alkyl or aryl(Q-
1 1 1 ^
C8)alkyl; or R and R " taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or aryl(Cj- C8)alkyl of each R , R , R , R , R or R ~ is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa; and wherein one or more of the non-terminal carbon atoms of each said (Ci-C )alkyl may be optionally replaced with -0-, -S- or -NRa-.
2. The compound for use according to claim 1 wherein the compound of Formula I is represented by Formula II:
Figure imgf000150_0001
R3 R2
Formula II
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen;
each R2 is ORa or halogen;
each R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (Ci-C )alkyl, (C4-C8)carbocyclylalkyl, (Ci-C8)substituted alkyl, (C2-Cg)alkenyl, (C2-C8)substituted alkenyl, (C2--Cs)alkynyl or (C2-C8)substituted alkynyl;
or any two R , R" or R 5 on adjacent carbon atoms when taken together are -0(CO)0- or when taken together with the ring carbon atoms to which they are attached form a double bond; and
R6 is ORa, N(Ra)2, N3, CN, S(0)nRa, -C(=0)Rn, -C(=0)ORu, - C(=0)NRuR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORu), -S(0)2(ORu), -S02NRnR12, halogen, (C1-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-C8)substituted alkyl, (C2-C8) alkenyl, (C2-C8)substituted alkenyl,
(C2-C8)alkynyl, or (C2-C8)substituted alkynyl.
3. The compound for use according to claims 1 or 2 wherein the compound of Formula I or II is represented by Formula III:
Figure imgf000151_0001
Formula III
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R2 is ORa or F;
each R3 is ORa; and
R6 is ORa, N(Ra)2, N3, CN, S(0)nRa, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Ru, -S(0)(ORn), -S(0)2(ORH), -S02NRnR12, halogen, (C]-C8)alkyl, (C4-C8)carbocyclylalkyl, (Ci-C8)substituted alkyl, (C2-Cs)alkenyl, (C2-Cg)substituted alkenyl,
(C2-Cg)alkynyl, or (C2-Cg)substituted alkynyl.
4. The compound for use according to any one of claims 1-3 wherein R6 is CN, methyl, ethenyl, or ethynyl.
5. The compound for use according to any one of claims 1-4 wherein R2 is ORa.
6. The compound for use according to any one of claims 1-5 wherein R3 is OH, -OC(=0)Ru, or -OC(=0)ORn.
7. The compound for use according to any one of claims 1-6 wherein R8 is NRnR12 or OR11.
8. The compound for use according to any one of claims 1 -7 wherein R8 is N¾.
9. The compound for use according to any one of claims 1-7 wherein R8 is OH.
10. The compound for use according to any one of claims 1-9 wherein
R9 is H.
11. The compound for use according to any one of claims 1-9 wherein R9 is NH2.
12. The compound for use according to any one of claims 1-11 wherein R7 is H.
Figure imgf000153_0001
Figure imgf000154_0001
153 or a pharmaceutically acceptable salt or ester thereof.
14. The compound for use according to any one of claims 1-13 further comprising a pharmaceutically acceptable carrier or excipient.
15. The compound for use according to any one of claims 1-14 further comprising administering a therapeutically effective amount of at least one other thereapeutic agent or composition thereof selected from the group consisting of a corticosteroid, an anti-inflammatory signal transduction modulator, a β2- adrenoreceptor agonist bronchodilator, an anticholinergic, a mucolytic agent, hypertonic saline and other drugs for treating Paramyxoviridae virus infections; or mixtures thereof.
16. The compound for use according to claim 15 wherein the at least one other thereapeutic agent is ribavirin, palivizumab, motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637 or BMS-433771 or mixtures thereof.
17. The compound for use according to any one of claims 1-16 wherein at least one therapeutic agent or mixtures thereof is administered by inhalation.
18. The compound for use according to claim 17 wherein at least one therapeutic agent or mixtures thereof is administered by nebulization.
19. The compound for use according to any one of claims 1-18 wherein the Paramyxoviridae infection is caused by a Paramyxovirina virus.
20. The compound for use according to any one of claims 1-18 wherein the Paramyxoviridae infection is caused by a Respirovirus virus.
21. The compound for use according to any one of claims 1-18 wherein the Paramyxoviridae infection is caused by a type 1 or 3 Human parainfluenza virus.
22. The compound for use according to any one of claims 1-18 wherein the Paramyxoviridae infection is caused by a Pneumovirinae virus.
23. The compound for use according to any one of claims 1-18 or 22 wherein the Paramyxoviridae infection is caused by a Human respiratory syncytial virus.
24. The compound for use according to any one of claims 1-23 wherein a Paramyxoviridae polymerase is inhibited.
A compound of Formula I that
Figure imgf000156_0001
Figure imgf000157_0001
or a pharmaceutically acceptable salt or ester thereof.
A compound of Formula I represented by Formula IV:
Figure imgf000157_0002
Formula IV
or a pharmaceutically acceptable salt or ester, thereof;
wherein:
each R1 is H or halogen; each R3 or R5 is independently H, ORa, N(Ra)2, N3, CN, N02, S(0)nRa, halogen, (Ci-Cg)alkyl, (C4-C8)carbocyclylalkyl, (C]-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl, (C2-C8)alkynyl or (C2-C8)substituted alkynyl;
R6 is ORa, N(Ra)2, N3, CN, S(0)nRa, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(=0)SRH, -S(0)Rn, -S(0)2Ru, -S(0)(ORn), -S(0)2(ORn), -SOsNR^R12, halogen, (C,-C8)alkyl, (C4-C8)carbocyclylalkyl,
(Ci-C8)substituted alkyl, (C2-C8)alkenyl, (C2-C8)substituted alkenyl,
(C2-C8)alkynyl, or (C2-C8)substituted alkynyl;
each n is independently 0, 1, or 2;
each Ra is independently H, (C1-Cg)alkyl, (C2-C8)alkenyl, (C2-Cg)alkynyl, aryl(Ci-C8)alkyl, (C4-C8)carbocyclylalkyl, -C(=0)Rn, -C(=0)ORn, - C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), or -S02NRnR12;
R7 is H, -C(=0)Rn, -C(=0)OR! 1, -C(=0)NRnR12, -C(=0)SRn, -S(0)Rn, -S(0)2Rn, -S(0)(ORn), -S(0)2(ORn), -S02NRnR12, or
Figure imgf000158_0001
each Y or Y1 is, independently, O, S, NR, +N(0)(R), N(OR), +N(0)(OR), or N-NR2;
W1 and W2, when taken together, are -Y3(C(Ry)2)3Y3-; or one of W1 or W2 together with either R3 or R4 is -Y3- and the other of W1 or W2 is Formula la; or
W 11 and W 2 are each, independently, a group of the Formula la:
Figure imgf000159_0001
Formula la
wherein:
each Y2 is independently a bond, O, CR2, NR, +N(0)(R), N(OR), +N(0)(OR), N-NR2, S, S-S, S(O), or S(0)2;
each Y is independently O, S, or NR;
M2 is 0, 1 or 2;
each Rx is inde endently Ry or the formula:
Figure imgf000159_0002
wherein:
each Mia, Ml c, and Mid is independently 0 or 1 ;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12;
each Ry is independently H, F, CI, Br, I, OH, R, -C(=Y')R, -C(=Y')0R, - C(=Y1)N(R)2, -N(R)2, -+N(R)3, -SR, -S(0)R, -S(0)2R, -S(0)(OR), -S(0)2(OR), - OC(=Y,)R, -OC(=Y')OR, -OC(=Y1)(N(R)2), -SC(=Y!)R, -SC(=Y1)OR, - SC(=Y')(N(R)2), -N(R)C(=Y!)R, -N(R)C(=Y1)OR, -N(R)C(=Y1)N(R)2, -S02NR2, -CN, -N3, -N02, -OR, or W3; or when taken together, two Ry on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (Ci-C8) alkyl, (Ci-Cg) substituted alkyl, (C2- C8)alkenyl, (C2-C8) substituted alkenyl, (C2-Cg) alkynyl, (C2-Cg) substituted alkynyl, C6-C2o aryl, 06-Ο2ο substituted aryl, C2-C2o heterocyclyl, C2-C20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W3 is W4 or W5; W4 is R, -C(Y1)Ry, -QY^W5, -S02Ry, or -S02W5; and W5 is a carbocycle or a heterocycle wherein W5 is independently substituted with 0 to 3 Ry groups;
each R8 is halogen, NRUR12, N(Rn)ORu, NRHNR1 !R12, N3, NO, N02, CHO, CN, -CH(=NRn), -CH=NNHRU, -CH=N(ORu), -CH(ORu)2,
-C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(Ci-C8)alkyl, -S(0)n(Ci-C8)alkyl, aryl(Ci-C8)alkyl, OR1 1 or SR11;
each R9 is independently H, halogen, NRnR12, N(Rn)ORn, NRnNRnR12, N3, NO, N02, CHO, CN, -CH(=NRU), -CH=NHNRn, -CH=N(ORn),
-CH(ORn)2, -C(=0)NRnR12, -C(=S)NRnR12, -C(=0)ORn, R11, OR11 or SR11; each Rn or R12 is independently H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C4-C8)carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=0)(Ci-C8)alkyl, -S(0)n(Ci-C8)alkyl or aryl(Ci-
C8)alkyl; or R 1 1 and R 12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with -0-, -S- or -NRa-; and wherein each (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or aryl(Ci-
3 5 6 1 1 12
C8)alkyl of each R , R , R , R or R is, independently, optionally substituted with one or more halo, hydroxy, CN, N3, N(Ra)2 or ORa; and wherein one or more of the non-tenninal carbon atoms of each said (Ci-C8)alkyl may be optionally replaced with -0-, -S- or -NRa-.
27. The compound of claim 26 wherein each R 1 , R5 , and R 7 is H and R3 is ORa.
28. The compound of claim 26 or 27 wherein R6 is is CN, methyl, ethenyl, or ethynyl. The compound of any one of claims 26-28 wherein R is NH2 and nd of claim 26 that is
Figure imgf000161_0001
ester thereof.
31. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 25-30 and a
pharmaceutically acceptable carrier.
32. The composition of claim 31 further comprising administering a therapeutically effective amount of at least one other thereapeutic agent or composition thereof selected from the group consisting of a corticosteroid, an antiinflammatory signal transduction modulator, a p2-adrenoreceptor agonist bronchodilator, an anticholinergic, a mucolytic agent, hypertonic saline and other drugs for treating Paramyxoviridae virus infections; or mixtures thereof.
33. The composition of claim 32 wherein the at least one other thereapeutic agent is ribavirin, palivizumab, motavizumab, RSV-IGIV
(RespiGam®), MEDI-557, A-60444, MDT-637 or BMS-433771 or mixtures thereof.
PCT/US2011/045102 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections WO2012012776A1 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
MEP-2014-148A ME01924B (en) 2010-07-22 2011-07-22 Methods and compounds for treating Paramyxoviridae virus infections
BR122020020745A BR122020020745B8 (en) 2010-07-22 2011-07-22 Antiviral compound for the treatment of paramyxoviridae infections and pharmaceutical composition comprising it
AU2011280910A AU2011280910B2 (en) 2010-07-22 2011-07-22 Methods and compounds for treating Paramyxoviridae virus infections
SG2012095683A SG186830A1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
BR112013001553-5A BR112013001553B1 (en) 2010-07-22 2011-07-22 antiviral compounds for the treatment of paramyxoviridae infections and pharmaceutical compositions comprising them
JP2013520895A JP5969471B2 (en) 2010-07-22 2011-07-22 Methods and compounds for treating Paramyxoviridae viral infections
KR1020137004005A KR101821680B1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
NZ606156A NZ606156A (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
SI201130275T SI2595980T1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
PL11743709T PL2595980T3 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
CN201180035776.1A CN103052631B (en) 2010-07-22 2011-07-22 Be used for the treatment of method and the compound of the infection of paramyxovirus coe virus
EA201390152A EA025252B1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
EP11743709.5A EP2595980B1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
AP2013006680A AP3269A (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridaevirus infections
MA35665A MA34470B1 (en) 2010-07-22 2011-07-22 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS
KR1020187001641A KR101924765B1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
MX2013000744A MX2013000744A (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections.
UAA201302207A UA111163C2 (en) 2010-07-22 2011-07-22 METHODS AND COMPOUNDS FOR THE TREATMENT OF Viral Infections of PARAMYXOVIRIDAE
CR20170278A CR20170278A (en) 2010-07-22 2011-07-22 METHODS AND COMPOUNDS TO TREAT VIRAL INFECTIONS BY PARAMYXOVIRIDAE
CA2804840A CA2804840C (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections
ES11743709.5T ES2524356T3 (en) 2010-07-22 2011-07-22 Methods and compounds to treat infections caused by Paramyxoviridae virus
IL224043A IL224043A (en) 2010-07-22 2012-12-31 Compounds for treating paramyxoviridae virus infections
HK13110926.3A HK1183487A1 (en) 2010-07-22 2013-09-25 Methods and compounds for treating paramyxoviridae virus infections
IL245348A IL245348B (en) 2010-07-22 2016-05-01 Methods and compounds for treating paramyxoviridae virus infections
NO2020047C NO2020047I1 (en) 2010-07-22 2020-12-23 Beltsivir or a pharmaceutically acceptable salt or ester thereof
NL301084C NL301084I2 (en) 2010-07-22 2020-12-23 remdesivir or a pharmaceutically acceptable salt or ester thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36660910P 2010-07-22 2010-07-22
US61/366,609 2010-07-22

Publications (1)

Publication Number Publication Date
WO2012012776A1 true WO2012012776A1 (en) 2012-01-26

Family

ID=44534635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045102 WO2012012776A1 (en) 2010-07-22 2011-07-22 Methods and compounds for treating paramyxoviridae virus infections

Country Status (30)

Country Link
US (6) US20120027752A1 (en)
EP (1) EP2595980B1 (en)
JP (2) JP5969471B2 (en)
KR (2) KR101821680B1 (en)
CN (2) CN103052631B (en)
AP (1) AP3269A (en)
AU (4) AU2011280910B2 (en)
BR (2) BR112013001553B1 (en)
CA (1) CA2804840C (en)
CL (1) CL2013000077A1 (en)
CO (1) CO6690740A2 (en)
CR (2) CR20170278A (en)
EA (2) EA025252B1 (en)
EC (1) ECSP13012458A (en)
ES (1) ES2524356T3 (en)
HK (2) HK1183487A1 (en)
IL (2) IL224043A (en)
MA (1) MA34470B1 (en)
ME (1) ME01924B (en)
MX (1) MX2013000744A (en)
NL (1) NL301084I2 (en)
NO (1) NO2020047I1 (en)
NZ (1) NZ606156A (en)
PE (2) PE20130400A1 (en)
PL (1) PL2595980T3 (en)
PT (1) PT2595980E (en)
SG (1) SG186830A1 (en)
SI (1) SI2595980T1 (en)
UA (1) UA111163C2 (en)
WO (1) WO2012012776A1 (en)

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103232507A (en) * 2012-04-27 2013-08-07 北京大学 Modified nucleoside monomers, and synthesizing methods and application thereof
WO2013158776A1 (en) * 2012-04-17 2013-10-24 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
US8809330B2 (en) 2010-06-24 2014-08-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US8853171B2 (en) 2008-04-23 2014-10-07 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
KR20140135820A (en) * 2012-03-13 2014-11-26 길리애드 사이언시즈, 인코포레이티드 2'- substituted carba-nucleoside analogs for antiviral treatment
CN104203253A (en) * 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
WO2015069939A1 (en) * 2013-11-11 2015-05-14 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2016018697A1 (en) 2014-07-28 2016-02-04 Gilead Sciences, Inc. Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections
WO2016069825A1 (en) * 2014-10-29 2016-05-06 Gilead Sciences, Inc. Methods for the preparation of ribosides
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9777035B2 (en) 2014-03-28 2017-10-03 Merck Sharp & Dohme Corp. 4′-substituted nucleoside reverse transcriptase inhibitors
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
US10065958B2 (en) 2010-07-22 2018-09-04 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
WO2018169946A1 (en) 2017-03-14 2018-09-20 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2019053696A1 (en) 2017-09-18 2019-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10251904B2 (en) 2015-09-16 2019-04-09 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10464965B2 (en) 2011-12-22 2019-11-05 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3738969A1 (en) 2014-08-21 2020-11-18 Gilead Sciences, Inc. 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides for use in treating pneumovirinae virus infections
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
CN112675143A (en) * 2020-02-25 2021-04-20 顾世海 Rudesiwei tablets and preparation method thereof
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN113214263A (en) * 2020-02-06 2021-08-06 北京桦冠医药科技有限公司 Synthetic method of Rudesiwei key intermediate
WO2021168004A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
WO2021167882A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
WO2021168038A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
WO2021175296A1 (en) * 2020-03-04 2021-09-10 中国科学院上海药物研究所 Intermediate of remdesivir and preparation method therefor
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021222807A1 (en) * 2020-04-30 2021-11-04 Ajk Pharmaceutical Llc Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
WO2022029704A1 (en) 2020-08-06 2022-02-10 Richter Gedeon Nyrt. Remdesivir intermediates
EA039561B1 (en) * 2015-01-20 2022-02-10 Джилид Сайэнс, Инк. Compounds for treating filoviridae virus infections
WO2021262826A3 (en) * 2020-06-24 2022-02-17 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022047065A3 (en) * 2020-08-27 2022-04-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022107463A1 (en) 2020-11-18 2022-05-27 株式会社トクヤマ Method for producing ketone derivative
US11377456B2 (en) 2020-06-11 2022-07-05 Apotex Inc. Crystalline form of Remdesivir
WO2022142477A1 (en) * 2020-12-30 2022-07-07 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
RU2790376C1 (en) * 2021-12-28 2023-02-17 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" DIMETHYL 7-METHYL-2-(PYRROLIDINE-1-yl)-4-PHENYLPYRROLO[2,1-ƒ][1,2,4]TRIAZINE-5,6-DICARBOXYLATE AND DIMETHYL 7-METHYL-2-(4-R1-PHENYL)-4-(4-R2-PHENYL)PYRROLO[2,1-ƒ][1,2,4]TRIAZINE-5,6-DICARBOXYLATES EXHIBITING ANTIVIRAL ACTIVITY
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11628181B2 (en) 2014-12-26 2023-04-18 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2023102472A1 (en) * 2021-12-01 2023-06-08 The Scripps Research Institute Antiviral prodrugs and formulations thereof
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy
WO2023168194A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2024006376A1 (en) * 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024006461A1 (en) * 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US11912695B2 (en) 2019-03-18 2024-02-27 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11952389B2 (en) 2015-07-22 2024-04-09 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US12006326B2 (en) 2019-10-04 2024-06-11 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US12054507B2 (en) 2020-02-18 2024-08-06 Gilead Sciences, Inc. Antiviral compounds
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016117622A1 (en) * 2015-01-22 2016-07-28 国立大学法人岐阜大学 Tetrazole derivative and antiviral agent
TWI753892B (en) 2016-03-28 2022-02-01 美商英塞特公司 Pyrrolotriazine compounds as tam inhibitors
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN106083962B (en) * 2016-06-08 2018-12-18 成都倍特药业有限公司 A kind of compound and preparation method thereof with cyclophosphamide structure
BR112020006334A2 (en) * 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combination of pharmaceutical agents such as rsv inhibitors
CN110776512A (en) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 Preparation method of nucleoside analogue
CN113214262B (en) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 Compound containing guanidine group, and preparation method and application thereof
US20210252027A1 (en) * 2020-02-07 2021-08-19 Cai Gu Huang Pharmaceutical formulation containing remdesivir
CN113292565B (en) * 2020-02-24 2023-01-31 浙江森科建设有限公司 Nucleoside compound and preparation method and application thereof
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN113493480A (en) * 2020-04-03 2021-10-12 南京正大天晴制药有限公司 Preparation and analysis method of Reidesciclovir isomer
WO2021208910A1 (en) * 2020-04-13 2021-10-21 山东华铂凯盛生物科技有限公司 Polymer preparation for treating virus infection, and preparation method therefor and use thereof
WO2021211997A1 (en) * 2020-04-16 2021-10-21 The General Hospital Corporation B cell immunomodulatory therapy for acute respiratory distress syndrome
CN111494349A (en) * 2020-04-30 2020-08-07 中国人民解放军空军军医大学 Redecevir oral instant membrane and preparation method thereof
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
CN111961057A (en) * 2020-05-26 2020-11-20 李小冬 Alpha-configuration nucleoside and application thereof in treating feline coronavirus infection
WO2022016073A1 (en) * 2020-07-17 2022-01-20 Board Of Regents, The University Of Texas System Pharmaceutical compositions for delivery of remdesivir by inhalation
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
CN116437958A (en) 2020-11-11 2023-07-14 吉利德科学公司 Method for identifying HIV patients susceptible to therapy with gp120 CD4 binding site directed antibodies
CN114507256A (en) * 2020-11-16 2022-05-17 上海医药集团股份有限公司 Chiral isomer of Rudexiluwei process, preparation method and application thereof
RU2756921C1 (en) * 2020-11-20 2021-10-07 Общество С Ограниченной Ответственностью "Технология Лекарств" Method for obtaining remdesivir and phosphoramidates
WO2022166581A1 (en) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 Nucleotide derivative, pharmaceutical composite thereof and use thereof
CN112843073A (en) * 2021-03-30 2021-05-28 山东省农业科学院畜牧兽医研究所 Application of Reddesivir (Remdesivir) in preparation of anti-bovine parainfluenza virus type 3 medicine
KR20240117588A (en) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Compounds for the treatment of HIV viral infection
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI843506B (en) 2022-04-06 2024-05-21 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202402280A (en) 2022-07-01 2024-01-16 美商基利科學股份有限公司 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
TW202421167A (en) 2022-11-18 2024-06-01 美商基利科學股份有限公司 Methods for treating poxvirus infections

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3906950A (en) 1973-04-04 1975-09-23 Isf Spa Inhaling device for powdered medicaments
US4013075A (en) 1974-07-15 1977-03-22 I.S.F. S.P.A. Inhalers and insufflators having a cutting means
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4668218A (en) 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
US4667668A (en) 1981-07-08 1987-05-26 Aktiebolaget Draco Dosage inhalator
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4995385A (en) 1989-02-23 1991-02-26 Phidea S.P.A. Inhaler with regular complete emptying of the capsule
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5458135A (en) 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5740794A (en) 1994-09-21 1998-04-21 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
WO2000056734A1 (en) 1999-03-20 2000-09-28 Aventis Cropscience Gmbh Bicyclic heterocycles, method for producing them and their use as herbicides and pharmaceutical agents
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO2008089105A2 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003489A (en) 1911-04-10 1911-09-19 Minnie Moritz Barber's reversible hair-cloth.
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
CN1291994A (en) 1998-03-03 2001-04-18 诺沃挪第克公司 New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-2-(methylcarbamoyl)-2-phenylethyl) carbamoyl)-2-(2-naphtyl) ethyl) amide
AU3363499A (en) 1998-03-27 1999-10-18 George W. Griesgraber Nucleosides with antiviral and anticancer activity
AU760688B2 (en) 1998-10-16 2003-05-22 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for GABA receptors
JP2003514766A (en) 1999-06-03 2003-04-22 アボット・ラボラトリーズ Oligonucleotide synthesis using Lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AU7490600A (en) 1999-09-15 2001-04-17 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
WO2001060315A2 (en) 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
AU8294101A (en) 2000-07-21 2002-02-05 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (en) 2000-10-18 2009-08-24 파마셋 인코포레이티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (en) 2001-09-13 2003-04-03 Basf Ag Process for the preparation of meso-zeaxanthin
US20040006002A1 (en) 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (en) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh PROCESS FOR THE PREPARATION OF PROTECTED, ENANTIOMERIC ENRICHED CYANHYDRINES BY IN SITU DERIVATIZATION
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
JP2005524662A (en) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド Nucleoside 5'-monophosphate mimetics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
EP1501850A2 (en) 2002-05-06 2005-02-02 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
WO2003100009A2 (en) 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
KR101153254B1 (en) 2003-06-26 2012-07-02 바이오트론 리미티드 Antiviral compounds and methods
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
NZ550464A (en) 2004-03-16 2010-10-29 Boehringer Ingelheim Int Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CA2584367A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CN101043893A (en) 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
US8133870B2 (en) 2004-10-29 2012-03-13 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
ATE407938T1 (en) 2004-12-16 2008-09-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PRODUCTION METHOD THEREOF
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
AU2006230023A1 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
AR056327A1 (en) 2005-04-25 2007-10-03 Genelabs Tech Inc NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
NZ596107A (en) 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
US8067391B2 (en) 2005-10-03 2011-11-29 University Health Network ODCase inhibitors for the treatment of malaria
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
PL1954264T3 (en) 2005-12-01 2010-02-26 Basilea Pharmaceutica Ag Process for the manufacture of epoxybutanol intermediates
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
EP1957485B1 (en) 2005-12-02 2013-02-13 Bayer HealthCare, LLC Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007065289A2 (en) 2005-12-09 2007-06-14 Basilea Pharmaceutica Ag 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
JP2009526850A (en) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Nucleoside aryl phosphoramidates for treating RNA-dependent RNA viral infections
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (en) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Preparation of organometallic compound, useful e.g. in electrophilic substitution reactions, comprises reacting an organic compound with an metal-containing compound in the presence of a lithium compound and a metal
CL2007001427A1 (en) 2006-05-22 2008-05-16 Novartis Ag 5-AMINO-3- MALEATE SALT (2 ', 3'-DI-O-ACETYL-BETA-D-RIBOFURANOSIL) -3H-TIAZOLO [4,5-D] PIRIMIDIN-2-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF A PO INFECTION
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
EP2079753A1 (en) 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2672613A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN100532388C (en) 2007-07-16 2009-08-26 郑州大学 2'-fluorine-4'-substituted-nucleosides analog, preparation method and uses thereof
CN101827589B (en) 2007-08-03 2016-08-17 拜伊特朗有限公司 The compositions of anti-hepatitis c virus and method
KR101502533B1 (en) 2007-11-22 2015-03-13 에스케이케미칼주식회사 Stable pharmaceutical composition containing Taxane derivatives, and method of manufacturing the same
US20090176732A1 (en) * 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2396340B1 (en) 2009-02-10 2013-12-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs
WO2010111381A2 (en) 2009-03-24 2010-09-30 Biocryst Pharmaceuticals, Inc. Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
CN102471327A (en) 2009-07-21 2012-05-23 吉里德科学公司 Inhibitors of flaviviridae viruses
RS55699B1 (en) 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US10023600B2 (en) 2009-09-21 2018-07-17 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
JP5674058B2 (en) 2009-12-28 2015-02-25 ディヴェロップメント センター フォー バイオテクノロジー Novel pyrimidine compounds as mTOR inhibitors and PI3K inhibitors
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
EP2552933A1 (en) 2010-03-31 2013-02-06 Gilead Pharmasset LLC Purine nucleoside phosphoramidate
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (en) 2010-09-13 2013-02-01 Gilead Sciences Inc 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CA2807496C (en) 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EA025341B1 (en) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Substituted nucleotide analogs
RU2599013C2 (en) 2010-10-15 2016-10-10 БАЙОКРИСТ ФАРМАСЬЮТИКАЛЗ, ИНК. (э ЮЭс корпорейшн) Methods and compositions for inhibiting polymerase
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
EP3251692B1 (en) 2011-05-13 2023-09-27 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
DE202012013074U1 (en) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Compositions for the treatment of HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EA031301B1 (en) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-amino acid chemical compounds for treating liver diseases
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
JP2016504284A (en) 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Nucleosides containing antiviral azasugars
EP2919792B1 (en) 2012-11-19 2020-05-20 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
WO2014100505A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014116755A1 (en) 2013-01-22 2014-07-31 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US20140309164A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
UA117375C2 (en) 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
RS61540B1 (en) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
UA119050C2 (en) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
EP3099685B1 (en) 2014-01-30 2018-04-18 F.Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CA2935811C (en) 2014-03-07 2018-09-18 F. Hoffmann-La Roche Ag 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP3143020B1 (en) 2014-05-13 2019-08-21 F. Hoffmann-La Roche AG Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (en) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel pyridazones and triazinones for the treatment and prevention of hepatitis B virus infection
TWI698444B (en) 2014-10-29 2020-07-11 美商基利科學股份有限公司 Methods for the preparation of ribosides
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (en) 2014-12-23 2017-04-26 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF ANALOGS OF 4-PHENYL-5-ALCOXICARBONIL-2-THIAZOL-2-IL-1,4-DIHYDROPIRIMIDINE
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (en) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 HBV cccDNA high flux new method is quantified from cell lysate by real-time PCR
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
CN107208102B (en) 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 Recombinant HBV CCcDNA, method for producing same and use thereof
JP6435054B2 (en) 2015-02-11 2018-12-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 2-oxo-6,7-dihydrobenzo [a] quinolidine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
BR112018005048B8 (en) 2015-09-16 2021-03-23 Gilead Sciences Inc use of an antiviral compound or salt thereof for the treatment of a coronaviridae infection
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
MX2019009443A (en) 2017-02-08 2019-12-16 Biotron Ltd Methods of treating influenza.
AU2018235754B2 (en) 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
ES2938859T3 (en) 2017-05-01 2023-04-17 Gilead Sciences Inc A crystalline form of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4 ]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
CN111093627B (en) 2017-07-11 2024-03-08 吉利德科学公司 Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections
CN111265532A (en) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 Application of substituted aminopropionate compound in treatment of 2019-nCoV infection
CN118766947A (en) 2020-01-27 2024-10-15 吉利德科学公司 Methods for treating SARS CoV-2 infection
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
KR20220164784A (en) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 Inhalation Formulations of 1′-Cyano Substituted Carbanucleoside Analogues
CN115666570A (en) 2020-05-29 2023-01-31 吉利德科学公司 Reidesciclovir treatment method
CA3190702A1 (en) 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3906950A (en) 1973-04-04 1975-09-23 Isf Spa Inhaling device for powdered medicaments
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4013075A (en) 1974-07-15 1977-03-22 I.S.F. S.P.A. Inhalers and insufflators having a cutting means
US4667668A (en) 1981-07-08 1987-05-26 Aktiebolaget Draco Dosage inhalator
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4668218A (en) 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4995385A (en) 1989-02-23 1991-02-26 Phidea S.P.A. Inhaler with regular complete emptying of the capsule
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5792756A (en) 1990-09-14 1998-08-11 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5775320A (en) 1991-07-02 1998-07-07 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5458135A (en) 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5740794A (en) 1994-09-21 1998-04-21 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
WO2000056734A1 (en) 1999-03-20 2000-09-28 Aventis Cropscience Gmbh Bicyclic heterocycles, method for producing them and their use as herbicides and pharmaceutical agents
WO2008089105A2 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 1986
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO
"The Chemistry of Heterocvclic Compounds, A Series of Monographs", vol. 13, 14,, 1950, JOHN WILEY & SONS
BENZARIA ET AL., J. MED. CHEM., vol. 39, 1996, pages 4958
BUNDGAARD, HANS: "Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, article "Design and Application of Prodrugs", pages: 113 - 191
CARBOHYDRATE RESEARCH, vol. 331, no. 1, 2001, pages 77 - 82
CARRYER, JOURNAL OF ALLERGY, vol. 21, 1950, pages 282 - 287
CHAPMAN ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 51, no. 9, 2007, pages 3346 - 53
CIHLAR ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 52, no. 2, 2008, pages 655 - 65
DE BERNARDO, J. ORG. CHEM., vol. 50, 1985, pages 3547
DELAMBERT ET AL., J. MED. CHEM., vol. 37, 1994, pages 498
DENYER, J., AEROSOL MEDICINE PULMONARY DRUG DELIVERY, vol. 23, no. 1, 2010, pages S 1 - S 10
ELIEL, E., WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC.
FARQUHAR ET AL., J. PHARM. SCI., vol. 72, 1983, pages 324
HETEROCYCLES, vol. 34, no. 3, 1992, pages 569 - 74
J CHEM. SOC. PERKIN TRANS. 1, vol. 2, 1984, pages 229 - 38
J. AM. CHEM. SOC., vol. 82, 1960, pages 5566
J. CHEM. SOC. PERKIN TRANS. 1, vol. 20, 1999, pages 2929 - 2936
J. CHEM. SOC. PERKIN TRANS. 1, vol. 3, 1985, pages 621 - 30
J. MED. CHEM., vol. 29, no. 11, 1986, pages 2231 - 5
KHAMNEI, TORRENCE, J. MED. CHEM., vol. 39, 1996, pages 4109 - 4115
KUZIK, J. PEDIATRICS, 2007, pages 266
MASON, S., LAWETZ, C., GAUDETTE, Y., DO, F., SCOUTEN, E., LAGACE, L., SIMONEAU, B., LIUZZI, M.: "Polyadenylation-dcpcndent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor", NUCLEIC ACIDS RESEARCH, vol. 32, 2004, pages 4758 - 4767, XP008070040, DOI: doi:10.1093/nar/gkh809
MITCHELL ET AL., J CHEM. SOC. PERKIN TRANS., 1992, pages 12345
MORRIS, J. ALLERGY CLIN. IMMUNOL., vol. 75, 1985, pages 1 - 13
NUCLEOSIDE NUCLEOTIDES, NUCLEIC ACIDS, vol. 14, no. 3-5, 1995, pages 763 - 766
NUCLEOSIDES & NUCLEOTIDES, vol. 15, no. 1-3, 1996, pages 793 - 807
ORGANIC LETTERS, vol. 3, no. 6, 2001, pages 839 - 842
PAQUETTE, LEO A.: "Principles of Modem Heterocyclic Chemistry", 1968, W.A. BENJAMIN
PUECH ET AL., ANTIVIRAL RES., vol. 22, 1993, pages 155 - 174
SABLE, INFECT. DIS. CLIN. NORTH AM., vol. 9, 1995, pages 987 - 1003
TETRAHEDRON LETTERS, vol. 35, no. 30, 1994, pages 5339 - 42
THEODORA W. GREENE: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY & SONS, INC.

Cited By (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46762E1 (en) 2008-04-23 2018-03-27 Gilead Sciences, Inc 1′-substituted carba-nucleoside analogs for antiviral treatment
US8853171B2 (en) 2008-04-23 2014-10-07 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US9238039B2 (en) 2010-06-24 2016-01-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US9957275B2 (en) 2010-06-24 2018-05-01 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US8809330B2 (en) 2010-06-24 2014-08-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US9487544B2 (en) 2010-07-19 2016-11-08 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US10696679B2 (en) 2010-07-22 2020-06-30 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US10065958B2 (en) 2010-07-22 2018-09-04 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US9278975B2 (en) 2011-12-22 2016-03-08 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
AU2013235220C1 (en) * 2011-12-22 2019-03-28 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013235220B2 (en) * 2011-12-22 2018-03-08 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10464965B2 (en) 2011-12-22 2019-11-05 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US11021509B2 (en) 2011-12-22 2021-06-01 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP2015509983A (en) * 2012-03-13 2015-04-02 ギリアード サイエンシーズ， インコーポレイテッド 2'-substituted carbnucleoside analogues for antiviral treatment
KR102068856B1 (en) 2012-03-13 2020-01-21 길리애드 사이언시즈, 인코포레이티드 2'- substituted carba-nucleoside analogs for antiviral treatment
KR20140135820A (en) * 2012-03-13 2014-11-26 길리애드 사이언시즈, 인코포레이티드 2'- substituted carba-nucleoside analogs for antiviral treatment
JP2017206528A (en) * 2012-03-13 2017-11-24 ギリアード サイエンシーズ， インコーポレイテッド 2'-substituted carba-nucleoside analogs for antiviral treatment
US10485815B2 (en) 2012-03-21 2019-11-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2827875A4 (en) * 2012-03-21 2015-12-02 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104203253A (en) * 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN110917205A (en) * 2012-03-21 2020-03-27 詹森生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
US8980878B2 (en) 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
EA027855B1 (en) * 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Compounds and methods for antiviral treatment
US9504689B2 (en) 2012-04-17 2016-11-29 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
WO2013158776A1 (en) * 2012-04-17 2013-10-24 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US10174038B2 (en) 2012-04-17 2019-01-08 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
CN104583211A (en) * 2012-04-17 2015-04-29 吉里德科学公司 Compounds and methods for antiviral treatment
CN103232507B (en) * 2012-04-27 2016-07-06 北京大学 Modified nucleoside monomer and synthetic method thereof and application
CN103232507A (en) * 2012-04-27 2013-08-07 北京大学 Modified nucleoside monomers, and synthesizing methods and application thereof
US10774106B2 (en) 2012-05-25 2020-09-15 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
US10301347B2 (en) 2012-05-25 2019-05-28 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
US10040814B2 (en) 2012-05-25 2018-08-07 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9845336B2 (en) 2012-05-25 2017-12-19 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US10544184B2 (en) 2012-05-25 2020-01-28 Janssen Sciences Ireland Unlimited Company Uracyl spirooxetane nucleosides
WO2014035140A3 (en) * 2012-08-30 2014-05-01 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014042433A3 (en) * 2012-09-14 2014-05-08 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10487104B2 (en) 2012-12-21 2019-11-26 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10683320B2 (en) 2012-12-21 2020-06-16 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10793591B2 (en) 2012-12-21 2020-10-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10144755B2 (en) 2012-12-21 2018-12-04 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9249174B2 (en) 2012-12-21 2016-02-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10112966B2 (en) 2012-12-21 2018-10-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9388208B2 (en) 2013-11-11 2016-07-12 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
EA029712B1 (en) * 2013-11-11 2018-05-31 Гайлид Сайэнсиз, Инк. PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS
AU2019204381B2 (en) * 2013-11-11 2021-04-01 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
US10059716B2 (en) 2013-11-11 2018-08-28 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
EA039734B1 (en) * 2013-11-11 2022-03-04 Гайлид Сайэнсиз, Инк. PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS
MD20160063A2 (en) * 2013-11-11 2016-11-30 Gilead Sciences, Inc. Pyrrolo[1,2,F][1,2,4]triazines useful for treating respiratory syncytial virus infections
AU2017232039B2 (en) * 2013-11-11 2019-03-28 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
WO2015069939A1 (en) * 2013-11-11 2015-05-14 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
AU2021201554B2 (en) * 2013-11-11 2023-02-02 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
US9701682B2 (en) 2013-11-11 2017-07-11 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
US10377761B2 (en) 2013-11-11 2019-08-13 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
EP4122932A1 (en) 2013-11-11 2023-01-25 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
EP3505173A1 (en) 2013-11-11 2019-07-03 Gilead Sciences, Inc. Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
AU2017232039C1 (en) * 2013-11-11 2019-07-25 Gilead Sciences, Inc. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
US9777035B2 (en) 2014-03-28 2017-10-03 Merck Sharp & Dohme Corp. 4′-substituted nucleoside reverse transcriptase inhibitors
EP3693367A1 (en) 2014-07-28 2020-08-12 Gilead Sciences, Inc. Thieno [3,2-d]pyrimidines, furo [3,2,d]pyrimidines and pyrrolo [3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
WO2016018697A1 (en) 2014-07-28 2016-02-04 Gilead Sciences, Inc. Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections
EP4023650A1 (en) 2014-07-28 2022-07-06 Gilead Sciences, Inc. 4'-substituted-furo[3,2-d]pyrimidine and -pyrrolo[3,2- d]pyrimidine derivatives useful for treating respiratory syncitial virus infections
US10501476B2 (en) 2014-07-28 2019-12-10 Gilead Sciences, Inc. Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections
EP3738969A1 (en) 2014-08-21 2020-11-18 Gilead Sciences, Inc. 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides for use in treating pneumovirinae virus infections
AU2018253483B2 (en) * 2014-10-29 2020-04-16 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
EP3695844A1 (en) 2014-10-29 2020-08-19 Gilead Sciences, Inc. Methods for treating nipah virus infections
US9724360B2 (en) 2014-10-29 2017-08-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
AU2021201474B2 (en) * 2014-10-29 2023-02-02 Gilead Sciences, Inc. Methods for the preparation of ribosides
EP3212175B1 (en) * 2014-10-29 2021-11-24 Gilead Sciences, Inc. Methods for the preparation of ribosides
EA032239B1 (en) * 2014-10-29 2019-04-30 Джилид Сайэнс, Инк. Methods for treating filoviridae virus infections
AU2015339223B2 (en) * 2014-10-29 2018-07-26 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
KR102337664B1 (en) 2014-10-29 2021-12-10 길리애드 사이언시즈, 인코포레이티드 Methods for treating filoviridae virus infections
JP2020097635A (en) * 2014-10-29 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド Methods for preparing ribosides
KR20210152015A (en) * 2014-10-29 2021-12-14 길리애드 사이언시즈, 인코포레이티드 Methods for treating filoviridae virus infections
WO2016069826A1 (en) * 2014-10-29 2016-05-06 Gilead Sciences, Inc. Methods for treating filoviridae virus infections
US10695357B2 (en) 2014-10-29 2020-06-30 Gilead Sciences, Inc. Methods for treating filoviridae virus infections
US10251898B2 (en) 2014-10-29 2019-04-09 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
KR20170066665A (en) * 2014-10-29 2017-06-14 길리애드 사이언시즈, 인코포레이티드 Methods for treating filoviridae virus infections
US9949994B2 (en) 2014-10-29 2018-04-24 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
WO2016069827A1 (en) * 2014-10-29 2016-05-06 Gilead Sciences, Inc. Methods for treating filoviridae virus infections
WO2016069825A1 (en) * 2014-10-29 2016-05-06 Gilead Sciences, Inc. Methods for the preparation of ribosides
AU2015339222B2 (en) * 2014-10-29 2018-11-22 Gilead Sciences, Inc. Methods for the preparation of ribosides
JP7158428B2 (en) 2014-10-29 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Method for preparation of riboside
EP3366295A1 (en) * 2014-10-29 2018-08-29 Gilead Sciences, Inc. Methods for treating filoviridae virus infections
AU2019201232B2 (en) * 2014-10-29 2020-12-10 Gilead Sciences, Inc. Methods for the preparation of ribosides
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11344565B2 (en) 2014-10-29 2022-05-31 Gilead Sciences, Inc. Methods for the preparation of ribosides
KR101822348B1 (en) 2014-10-29 2018-01-25 길리애드 사이언시즈, 인코포레이티드 Methods for treating filoviridae virus infections
KR102453808B1 (en) 2014-10-29 2022-10-12 길리애드 사이언시즈, 인코포레이티드 Methods for treating filoviridae virus infections
TWI767201B (en) * 2014-10-29 2022-06-11 美商基利科學股份有限公司 Methods for treating filoviridae virus infections
US11628181B2 (en) 2014-12-26 2023-04-18 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA039561B1 (en) * 2015-01-20 2022-02-10 Джилид Сайэнс, Инк. Compounds for treating filoviridae virus infections
US11952389B2 (en) 2015-07-22 2024-04-09 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11382926B2 (en) 2015-09-16 2022-07-12 Gilead Sciences, Inc. Methods for treating Arenaviridae and Coronaviridae virus infections
EP3785717A1 (en) * 2015-09-16 2021-03-03 Gilead Sciences, Inc. Methods for treating coronaviridae infections
US10695361B2 (en) 2015-09-16 2020-06-30 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US10251904B2 (en) 2015-09-16 2019-04-09 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018235754B2 (en) * 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CN110869028A (en) * 2017-03-14 2020-03-06 吉利德科学公司 Method of treating feline coronavirus infection
JP2020510070A (en) * 2017-03-14 2020-04-02 ギリアード サイエンシーズ， インコーポレイテッド How to treat feline coronavirus infection
CN110869028B (en) * 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
EP4331677A3 (en) * 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
WO2018169946A1 (en) 2017-03-14 2018-09-20 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
EP4331677A2 (en) 2017-03-14 2024-03-06 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US11597742B2 (en) 2017-05-01 2023-03-07 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US12030906B2 (en) 2017-05-01 2024-07-09 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11975017B2 (en) 2017-07-11 2024-05-07 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
WO2019053696A1 (en) 2017-09-18 2019-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2018332540B2 (en) * 2017-09-18 2023-10-05 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US11149049B2 (en) 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR102696517B1 (en) 2017-09-18 2024-08-21 얀센 바이오파마, 인크. Substituted nucleosides, nucleotides and their analogues
US11773126B2 (en) 2017-09-18 2023-10-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20200098483A (en) * 2017-09-18 2020-08-20 얀센 바이오파마, 인크. Substituted nucleosides, nucleotides and analogs thereof
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11903959B2 (en) 2017-12-07 2024-02-20 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
US11912695B2 (en) 2019-03-18 2024-02-27 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
US12006326B2 (en) 2019-10-04 2024-06-11 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN113214263B (en) * 2020-02-06 2022-09-30 北京桦冠医药科技有限公司 Synthetic method of Rudesiwei key intermediate
CN113214263A (en) * 2020-02-06 2021-08-06 北京桦冠医药科技有限公司 Synthetic method of Rudesiwei key intermediate
US12030903B2 (en) 2020-02-18 2024-07-09 Gilead Sciences, Inc. Antiviral compounds
WO2021168038A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
WO2021168004A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
US12054507B2 (en) 2020-02-18 2024-08-06 Gilead Sciences, Inc. Antiviral compounds
WO2021167882A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
CN112675143A (en) * 2020-02-25 2021-04-20 顾世海 Rudesiwei tablets and preparation method thereof
WO2021175296A1 (en) * 2020-03-04 2021-09-10 中国科学院上海药物研究所 Intermediate of remdesivir and preparation method therefor
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US12012431B2 (en) 2020-03-12 2024-06-18 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
WO2021222807A1 (en) * 2020-04-30 2021-11-04 Ajk Pharmaceutical Llc Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals
US11903953B2 (en) 2020-05-29 2024-02-20 Gilead Sciences, Inc. Remdesivir treatment methods
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
US11377456B2 (en) 2020-06-11 2022-07-05 Apotex Inc. Crystalline form of Remdesivir
WO2021262826A3 (en) * 2020-06-24 2022-02-17 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TWI819321B (en) * 2020-06-24 2023-10-21 美商基利科學股份有限公司 1'-cyano nucleoside analogs and uses thereof
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
WO2022029704A1 (en) 2020-08-06 2022-02-10 Richter Gedeon Nyrt. Remdesivir intermediates
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022047065A3 (en) * 2020-08-27 2022-04-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022107463A1 (en) 2020-11-18 2022-05-27 株式会社トクヤマ Method for producing ketone derivative
WO2022142477A1 (en) * 2020-12-30 2022-07-07 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023102472A1 (en) * 2021-12-01 2023-06-08 The Scripps Research Institute Antiviral prodrugs and formulations thereof
RU2790376C1 (en) * 2021-12-28 2023-02-17 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" DIMETHYL 7-METHYL-2-(PYRROLIDINE-1-yl)-4-PHENYLPYRROLO[2,1-ƒ][1,2,4]TRIAZINE-5,6-DICARBOXYLATE AND DIMETHYL 7-METHYL-2-(4-R1-PHENYL)-4-(4-R2-PHENYL)PYRROLO[2,1-ƒ][1,2,4]TRIAZINE-5,6-DICARBOXYLATES EXHIBITING ANTIVIRAL ACTIVITY
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023168194A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2024006376A1 (en) * 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024006461A1 (en) * 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof

Also Published As

Publication number Publication date
CL2013000077A1 (en) 2013-04-19
PE20171155A1 (en) 2017-08-16
PE20130400A1 (en) 2013-04-10
JP2013535453A (en) 2013-09-12
AU2011280910A1 (en) 2013-02-07
EA201390152A1 (en) 2013-05-30
MA34470B1 (en) 2013-08-01
US20150152116A1 (en) 2015-06-04
UA111163C2 (en) 2016-04-11
EA201691118A1 (en) 2017-01-30
CN105343098B (en) 2018-07-13
PT2595980E (en) 2014-11-27
AU2017201230B2 (en) 2019-05-02
BR112013001553B1 (en) 2021-01-12
KR101924765B1 (en) 2018-12-03
US11492353B2 (en) 2022-11-08
SI2595980T1 (en) 2014-11-28
MX2013000744A (en) 2013-03-07
US10065958B2 (en) 2018-09-04
CA2804840A1 (en) 2012-01-26
CR20130073A (en) 2013-03-25
AU2019208167B2 (en) 2021-05-06
PL2595980T3 (en) 2015-03-31
CN103052631B (en) 2015-11-25
AU2011280910B2 (en) 2015-07-09
EA025252B1 (en) 2016-12-30
US20120027752A1 (en) 2012-02-02
JP2016216480A (en) 2016-12-22
EP2595980A1 (en) 2013-05-29
ECSP13012458A (en) 2013-03-28
AU2015238851A1 (en) 2015-10-29
US20210061806A1 (en) 2021-03-04
IL245348B (en) 2019-07-31
AP3269A (en) 2015-05-31
CA2804840C (en) 2018-09-11
SG186830A1 (en) 2013-02-28
US20230125751A1 (en) 2023-04-27
US20190055251A1 (en) 2019-02-21
CR20170278A (en) 2017-09-29
KR20180012336A (en) 2018-02-05
HK1221657A1 (en) 2017-06-09
IL224043A (en) 2016-05-31
IL245348A0 (en) 2016-06-30
NZ606156A (en) 2015-01-30
AP2013006680A0 (en) 2013-01-31
KR20130091743A (en) 2013-08-19
AU2017201230A1 (en) 2017-03-16
JP5969471B2 (en) 2016-08-17
ME01924B (en) 2015-05-20
HK1183487A1 (en) 2013-12-27
CO6690740A2 (en) 2013-06-17
KR101821680B1 (en) 2018-01-24
NO2020047I1 (en) 2020-12-23
US10696679B2 (en) 2020-06-30
EP2595980B1 (en) 2014-09-03
ES2524356T3 (en) 2014-12-05
CN103052631A (en) 2013-04-17
BR122020020745B8 (en) 2023-10-31
BR122020020745B1 (en) 2023-07-11
NL301084I2 (en) 2021-01-28
BR112013001553A2 (en) 2020-05-26
AU2019208167A1 (en) 2019-08-08
US20150111839A1 (en) 2015-04-23
CN105343098A (en) 2016-02-24

Similar Documents

Publication Publication Date Title
US11492353B2 (en) Methods and compounds for treating Paramyxoviridae virus infections
US20210393659A1 (en) Methods for treating arenaviridae and coronaviridae virus infections
AU2011302310A1 (en) 2&#39; -fluoro substituted carba-nucleoside analogs for antiviral treatment
KR102068856B1 (en) 2&#39;- substituted carba-nucleoside analogs for antiviral treatment
WO2022098371A1 (en) Prodrugs of 1&#39;-substituted carba-nucleoside analogues for antiviral treatment
OA16300A (en) Methods and compounds for treating paramyxoviridae virus infections.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180035776.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743709

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 224043

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12013500035

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2804840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2013000077

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2013520895

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13004212

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/000744

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 000120-2013

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2011743709

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011280910

Country of ref document: AU

Date of ref document: 20110722

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137004005

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CR2013-000073

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: A201302207

Country of ref document: UA

Ref document number: 201390152

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013001553

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 245348

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 001124-2017

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2017278

Country of ref document: CR

Ref document number: CR2017-000278

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 112013001553

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130121